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Abstract 
 
Osteoarthritis (OA) is a debilitating joint disease characterised by pain and progressive 
destruction of elements such as articular cartilage. Autologous chondrocyte implantation is 
a cellular therapy developed to regenerate damaged cartilage and delay or negate the need 
for a total joint replacement. The use of mesenchymal stem cells (MSCs) provides an 
alternative to harvesting healthy cartilage in order to obtain chondrocytes for transplantation. 
In this thesis, the chondrogenic and immunomodulatory properties of human bone marrow 
(BM-MSCs), infrapatellar fat pad (FP-MSCs), subcutaneous fat (SCF-MSCs) and synovial 
fluid (SF-MSCs) derived mesenchymal stem/stomal cells were characterised to determine 
their suitability for cartilage repair. Synovial inflammation and the prevalence of 
macrophage subsets were determined in the synovium and infrapatellar fat pad from patients 
with and without OA. 
 FP-MSCs and SF-MSCs from the same donor differed with regards to in vitro proliferation 
and their response to a proinflammatory stimulus. None of the MSC populations examined 
displayed levels of chondrogenic potency that were akin to their matched chondrocyte 
counterparts, although BM-MSCs and FP-MSCs did show a more enhanced ability to 
undergo chondrogenesis than SCF-MSCs and SF-MSCs. Additionally, the expression of 
certain surface markers commonly associated with chondrogenic potency in chondrocytes, 
such as CD44, were not indicative of the chondrogenic propensity of MSCs. Analyses of the 
phenotype of macrophages in human synovium and FP showed a co-existence of pro- (M1) 
and anti-inflammatory (M2) cells in both tissues. However, cell surface markers employed 
in the study did not permit a clear distinction between M1 and M2 cells. Image analyses 
revealed that the obesity related hypertrophy observed in adipocytes from subcutaneous fat, 
iii 
 
does not occur in adipocytes in the FP. To conclude, the results presented in this thesis adds 
to current knowledge of joint derived stem cells and immune cells.  
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1 Introduction  
Cartilage lesions caused by injury or osteoarthritis (OA) are a serious clinical concern due 
to their limited reparative capacity. Current surgical techniques including debridement, 
mosaicplasty and microfracture, although routinely used, do present some drawbacks. 
Indeed, these methods of treatment can be costly and may not be suitable for certain patients 
depending on certain demographics such as age, body mass index and surgical history1–5.  
As a result, new approaches to treat cartilage defects are being considered in the interests of 
patients, clinicians and health care services. The advent of tissue engineering and cellular 
therapies has provided innovative means of treating cartilage degeneration6,7. Autologous 
chondrocyte implantation (ACI) has emerged as an interesting alternative to traditional 
surgeries for the repair of full thickness chondral lesions. Despite the new hope offered by 
such regenerative techniques, a tremendous amount of research is still required to address 
the many unanswered questions with regard to the basic biology of articular cartilage, the 
characterisation of degenerative joint diseases and the long term clinical benefits of novel 
repair techniques. Clinicians, researchers and bioengineers will need to unite their expertise 
if any meaningful progress is to be made.  
The aim of this thesis introductory chapter is to describe the current scientific knowledge of 
articular cartilage biology and degeneration and to discuss cell based therapies for cartilage 
repair. Special focus will be given to OA as a joint disease, while the future perspectives of 
cell based therapies for cartilage repair will be reviewed. Finally, a brief description of the 
aims of the PhD research project will be provided. 
 
  
 3 
 
1.1 Anatomy of the Knee Joint 
The human knee is comprised of an intricate articulation between three bones: the tibia, 
femur and patella (Figure 1.1). This joint is stabilised by ligaments that attach the bones to 
each other, and is enclosed by a fibrous capsule. The interior of the knee is lined with a single 
layer of cells called the synovium, and is lubricated by the synovial fluid to facilitate joint 
movements. Two crescent-shaped fibrocartilaginous structures (Figure 1.1), called menisci, 
are located between the femur and tibia to help disperse forces within the joint. The structural 
elements in the knee work together to maintain the mechanical stability of the joint, but can 
also be subject to various pathologies. 
1.2 Articular Cartilage: Structure and Function 
Cartilage is a tissue that varies in structure according to its location and function in the body. 
Hyaline cartilage is located at the articulating surface of joints and is structurally adapted to 
its biomechanical functions of load bearing and force distribution. Macroscopically, the 
articular surface in a healthy joint appears smooth and polished 8–10 which contributes to 
free, low friction movements. The thickness of this cartilage ranges from 1-3mm and is 
divided into a superficial zone, a transitional zone, and a deep zone (Figure 1.2), and is 
separated from the calcified cartilage by one or more tidemarks11,12. This calcified region 
attaches cartilage to bone and helps limit the progression of subchondral bone while 
supporting endochondral ossification13–15.  
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Figure 1.1: Anatomy of the human knee joint. 
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Figure 1.2: Schematic representation of articular cartilage. Chondrocytes are arranged 
perpendicular to the joint surface in the deep zone, disorganised in the transitional (middle) 
zone, and aligned parallel to the joint surface in the superficial zone. The orientation of 
collagen fibres mirrors the organisation of chondrocytes in articular cartilage. 
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Together, these stacked layers form a solid yet elastic structure capable of resisting 
compressive and shear forces to allow optimal joint movements. The physical properties of 
articular cartilage are also largely attributed to the complex nature of the extracellular matrix 
(ECM). Chondrocytes are specialised cells that occupy this matrix and are responsible for 
its development and maintenance. Alterations to the function of these cells or degradation of 
the ECM can be the cause of cartilage pathologies. Another key feature of articular cartilage 
is a lack of vascularisation and innervation16,17, the significance of which will be discussed 
later. Additionally, low oxygen levels have been noted in articular cartilage. This hypoxic 
state is often attributed to the lack of blood supply in this tissue and it is believe that the 
chondrocytes adjust to these conditions by adapting their cellular activity through hypoxia 
induced signalling pathways18. Hypoxia inducible factor-1α (HIF-1α) is produced by 
articular chondrocytes and controls the factors involved in cartilage maintenance, in 
particular Sex-Determining Region Y-Box 9 transcription factor (Sox9) and the cartilage 
matrix components under its regulation19. In vivo developmental studies have demonstrated 
that rats lacking expression of HIF-1α show cell death in regions cartilaginous limbs growth 
deprived of oxygen20.  
  
1.3 The Chondrocyte 
Chondrocytes are the lone resident cells of cartilage tissue with a peculiar spatial 
distribution. Early studies by Stockwell indicate an overall low density of cells (as low as 19 
cells per mm3) within mature human cartilage tissue; cell numbers tend to decrease from the 
superficial zone down to the deep zone. There is also a decrease in cell density from infancy 
to adolescence, but a constant cell density during adulthood21,22. Cells in the superficial layer 
appear elongated and lie parallel to the articular surface. In the transitional zone (or middle 
zone), cells appear bigger with a more rounded morphology in either clusters or more 
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frequently as dispersed single cells. Finally, chondrocytes in the deep zone are elliptical in 
morphology and may be arranged in columns perpendicular to the articular surface23. The 
calcified region contains hypertrophic cells (terminally differentiated) that can express 
collagen type-X and alkaline phosphatase24–26. When enzymatically isolated and placed in 
tissue culture flasks chondrocytes adhere to culture plastic, adopt a round/cubical shape in 
early passages and shift to a more elongated fibroblastic morphology as passage number 
increases 27,28.  
The biological activities of chondrocytes are vital to the maintenance of articular cartilage 
structure. The functions of chondrocytes are often detailed as: a) production of the 
components of the ECM, b) remodelling of the ECM and c) detection and response to 
external physical signals through mechanotransduction. Collagens and proteoglycans are 
secreted by chondrocytes16 and  are incorporated into the architecture of the surrounding 
matrix. The pericellular matrix  of mature human chondrocytes incorporates collagens, 
hyaluronan, sulphated proteoglycans, fibronectin and glycoproteins in an encapsulating ring-
like structure29–31.   The chondrocyte together with this pericellular matrix form what is 
known as a chondron, a functional unit believed to have a dual role of resisting compressive 
forces and metabolising matrix components30. In response to a host of stimuli (both 
mechanical and biochemical), chondrocytes secrete a number of enzymes and catabolic 
factors that facilitate the remodelling of the matrix by breaking down its protein 
components32–36. 
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1.4 The Extracellular Matrix  
1.4.1 Collagens 
Collagen is the most abundant protein in articular cartilage accounting for approximately 
60% of its dry mass. These structural proteins occur as triple α-helices coiled around each 
other to form a collagen molecule (Figure 1.3). These in turn organise into collagen fibrils 
and then fibres. To date, 28 collagen proteins have been characterised of which collagen type 
II, IX and XI are the most represented in articular cartilage37,38. In mature articular cartilage 
collagen type II is estimated to comprise ≥ 90% of the total collagen whereas types IX and 
XI are 1% and 3% respectively. The cross-linking of these collagen types is crucial to the 
microarchitecture of cartilage39–41. Collagen fibres form a robust network that helps to 
maintain the general structure of the ECM by resisting the swelling pressure caused by the 
interactions between glycosaminoglycans (GAGs) and water (to be discussed in section 
1.3.2). It is also worth noting the size, distribution and orientation of collagen fibres in the 
different zones of articular cartilage mentioned previously. In the superficial zone, the fibres 
(60-90 nm diameter) appear oriented parallel to the articular surface. A random organisation 
of fibres is observed in the transitional zone, with a smaller variation of fibre diameters (60-
80nm), while bigger fibres (80-100nm) oriented perpendicularly to the articular surface 
appear in the deep zone42,43. This fibrillar organisation mirrors the distribution of 
chondrocytes described earlier, which suggests an interaction between the ECM and the 
phenotypes of the cells residing in each zone.  
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Figure 1.3: Illustration of the progressive assembly of collagen fibres. Image modified 
from Biology (8th Edition)44. 
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1.4.2 Proteoglycans 
Proteoglycans, like collagens, constitute an essential part of articular cartilage by 
contributing to its biomechanical properties. The basic structure of proteoglycans comprises 
of a core protein to which a series of unbranched sulphated GAGs attach45. Chondroitin 
sulphate (CS) and keratan sulphate (KS) are the main GAGs that attached to these proteins 
(Figure 1.4). 
Aggrecan is the most common proteoglycan in articular cartilage (35% of the dry weight of 
cartilage proteins)  and can attach as many as 100 CS chains46. Furthermore, numerous 
aggrecan molecules will bind to link proteins (LP) and “aggregate” on hyaluronan (HA) to 
form a bottlebrush structure (Figure 1.5). 
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Figure 1.4: Schematic of the tetrasaccharide and poly-N-acetyllactosamine bond that exists 
between core proteins and A) chondroitin sulphate or, B) keratan sulphate side chains in 
proteoglycans. Image modified from Essentials of Glycobiology 45. 
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Figure 1.5: Illustration of the aggrecan "bottlebrush" structure (HA =hyaluronan ,LP= link 
protein, IGD= inter-globular domain, G1+G2+G3= globular domains). Image modified 
from Fosang et al47 
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In addition to aggrecan, small leucine-rich proteoglycans (SLRPs) are distributed throughout 
the cartilage matrix. This subfamily of proteoglycans is characterised by multiple protein 
domains linked by a common leucine-rich motif and includes decorin, biglycan, 
fibromodulin and lumican.  An intricate interaction between the core proteins of SLRPs and 
collagen fibres not only contributes to the organisation of the cartilage matrix, but also helps 
to protect collagen from catabolic enzymes48,49.  Studies in SLRP knockout mice revealed a 
lack of, or faulty development of the musculoskeletal system 50–52.  
Lubricin is 345-KDa proteoglycan that occupies the superficial layer of articular cartilage 
and is believed to play a role in joint lubrication by creating low friction conditions for 
articulating surfaces53–55. The proteoglycan 4 gene (PRG4) codes for lubricin and is highly 
expressed by synovial cells and chondrocytes residing in the superficial zone of articular 
cartilage53. 
The negative charge found on the sulphated groups of GAGs causes an attraction of cations 
(such as Na+) which in turn engenders an influx of water molecules into the cartilage matrix 
in an attempt to maintain an electrolytic balance45,56. This water accounts for ~70% of the 
wet weight of cartilage. Swelling caused by this water uptake is restricted by the collagen 
network as discussed previously. The maintenance of physicochemical conditions, such as 
osmolarity and pH within the cartilage tissue, is heavily dependent on these hydrostatic 
events57,58. In addition, the anaerobic conditions in the articular joint promote an acidic 
environment that chondrocytes appear to buffer efficiently with Na+/H+ exchanger 
molecules59.   
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1.4.3 Cell-Matrix Interactions and Mechanotransduction 
Mechanotransduction is the complex process by which cells detect and respond to physical 
stimuli from their surrounding microenvironment. To accomplish this, cells are usually 
attached to their ECM by means of specific binding proteins that form a continuum of 
interconnected structures from the matrix components to the cell nucleus60,61.  Although 
some aspects of these cell-matrix interactions are still being researched, it is clear that cells, 
especially in load bearing tissues, are conditioned by the physical forces that they are 
exposed to. In the case of articular cartilage, integrins play a pivotal role in the connection 
between chondrocytes and their matrix.  Cyclic loading by physical activity deforms the 
matrix which in turn exerts physical forces on the cells themselves; this activates a cascade 
of intracellular reactions catalysed by various enzymes. Focal adhesion proteins such as focal 
adhesion kinases (FAK) are important molecular mediators of these processes. This chain 
reaction ultimately leads to the up or down regulation of specific genes to elaborate a cell 
response. For example, Millard-Sadler et al. demonstrated that signal transduction through 
integrins resulted in the upregulation of aggrecan and metalloproteinases in chondrocytes 
from arthritic patients34. This observation not only confirms the ability of cells to respond to 
mechanical signals, but also highlights the role of physical stimuli in the remodelling of 
cartilage tissue.  
1.5 Cartilage Development and Remodelling 
An understanding of the embryonic events that lead to in vivo chondrogenesis could provide 
important concepts for developing new therapies for cartilage repair. Embryonic formation 
of the skeletal system commences with the early appearance of cartilaginous condensations, 
also called anlage, in specific blastema62. Experiments using chick embryo models revealed 
a highly organised process where mesenchymal cells migrate from the mesoderm and neural 
crest to designated areas, forming condensed structures63,64. This process is thought to be 
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mediated by cell adhesion molecules such as neural-cell adhesion molecule (N-CAM) and 
N-cadherin65–69.  These mesenchymal cells then adopt a chondrocyte phenotype which is 
confirmed by a shift in the composition of the ECM secreted by the cells.  Hence, these 
chondrocytes now produce more collagen type II and proteoglycans while the expression of 
collagen type I is downregulated70–72.  
Cartilaginous condensation is a crucial phase in skeletal development; it serves as a template 
for endochondral ossification which eventually leads to the formation of the majority of 
bones in the axial skeleton and limbs73,74. This process involves the secretion of collagen 
type X by hypertrophic chondrocytes, followed by the invasion of the cartilage template by 
blood vessels, osteoblasts and haematopoietic cells75,76.  In the case of long bone formation, 
the osteoblasts continue to produce more calcified matrix starting from the primary centre 
of ossification (diaphysis), leaving behind only small non-mineralised regions in the 
epiphyses destined to become articular cartilage76,77.  
Pattern formation during embryonic chondrogenesis is controlled by an interplay between a 
host of transcription factors and growth factors76. For example, Sox9 is recognized as a major 
regulator of chondrogenesis during skeletal development by activating the enhancer of the 
collagen type II gene78,79. In fact, anomalies in the expression of Sox9 are known to be the 
main cause of the rare cartilage disease campomelic dysplasia80. Polypeptides of the 
transforming growth factor beta (TGF-β) class, notably TGF-β1 and TGF-β3, have been 
shown to promote the production of GAGs and prevent terminal differentiation of 
chondrocytes81,82. In addition, bone morphogenic proteins, which are also part of the TGF 
superfamily, play an essential role in the initiation of embryonic chondrogenesis83,84. Other 
factors, notably parathyroid hormone-related peptides, Wnt family proteins and fibroblast 
growth factors have been shown to be crucial in skeletal development, but are thought to be 
under the direct or indirect influence of Sox976.  
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Although chondrocytes in mature cartilage have a low proliferative activity, it is generally 
accepted that they remodel their environment in vivo by secreting components of the ECM, 
as well as enzymes which can break down matrix molecules. Like many other tissues, it is 
assumed that a fine balance is maintained between the degradation and production of 
structural entities in articular cartilage. The rate of cartilage matrix turnover is relatively 
slow, with molecules such as aggrecan and collagen having half-lives of 3-24 years and 117 
years respectively85,86. Collagenases or matrix metalloproteinases (MMPs) and aggrecanases 
or disintegrin and metalloproteinases with thrombospondin motifs (ADAMTS), are the main 
enzymes involved in cartilage degradation. Collagenase 3 (MMP-13) for example, is a well-
known zinc dependent proteinase capable of cleaving the helical structure of collagen II 87–
89. Similarly, aggrecanase-1 (ADAMTS-4) and aggrecanase-2 (ADAMTS-5) cleave specific 
motifs between the globular domains, G1 and G2, of aggrecan to release GAGs90,91. To 
counterbalance the degradative effects of these enzymes, particularly MMPs, special tissue 
inhibitors of metalloproteinases (TIMPs) are also produced by chondrocytes and a low or a 
lack of synthesis of these inhibitors has been related to several cartilage pathologies92–94.  
Historically, it was believed that mature articular cartilage, once injured, does not heal8. 
However, a growing body of evidence now suggest that in some cases articular cartilage 
does spontaneously repair without intervention95,96. For instance, in a longitudinal MRI 
based study investigating the factors that predict the progression of OA, the investigators 
observed that certain large cartilage defects had improved over the course of a two year 
period95. It has also been shown that defect in younger patients tend to improve more than 
in patient with OA97. Although the exact cellular mechanisms involved in this natural repair 
remains largely unknown, it is believed that the series of molecular and cellular events occurs 
after and acute joint injury, namely the inflammatory followed by and anabolic/catabolic 
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phase and finally a matrix formation phase98. Understanding these events could offer 
essential insight and open new avenues of research into treating cartilage defects. 
 
1.6 Articular Cartilage Pathologies 
1.6.1 Cartilage injury 
Treating injuries to articular cartilage is one of the major challenges facing clinicians and 
scientists in orthopaedic care and research. Chondral defects can develop as a result of acute 
traumatic impact and normal or abnormal joint loading. It is estimated that 63% of patients 
observed in arthroscopy present some form of cartilage defect99. The International Cartilage 
Repair Society (ICRS) has classified chondral defects into five categories according to the 
depth and size of the injury100 (Table1.1).  
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Table1.1: Classification of cartilage injury according to the International Cartilage 
Research Society. Table adapted from Brittberg and Winalski 100. 
 
Grade Description 
Grade 0 Normal cartilage with no apparent defect 
Grade I Intact cartilage with slight fibrillation and, or 
softening. Lacerations and fissures may be present. 
Grade II Defects extending to ≤50% of the cartilage thickness 
Grade III Defects extending to ≥50% of the cartilage thickness 
but not down to the subchondral bone. 
Grade IV Full thickness cartilage lesion that extends to the 
subchondral bone. 
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In addition to trauma-induced cartilage defects, several osteochondral pathologies also 
present a clinical burden. One such disease is osteochondritis dissecans (OCD), which occurs 
predominantly in young males and is characterised as an initial lesion of the subchondral 
bone, caused by a lack of blood supply, that may progressively lead to the fragmentation and 
or collapse of articular cartilage101–103. OA however is the most prevalent degenerative joint 
disease and will be the focus of the following sub-sections.  
 
1.6.2 Osteoarthritis (OA) 
1.6.2.1 Introduction  
OA is a degenerative joint disease that compromises the integrity of articular cartilage but 
also affects other elements of the joints including the synovium and bone. Although not life 
threatening, OA affects the quality of life of patients causing joint pain, swelling and reduced 
range of motion. Over 8.5 million people suffer from OA in the United Kingdom (the 
majority being over 40 years old), and as such significant financial investment is required 
for its direct and indirect treatment104,105. In 2010, the total cost of arthroscopy, total hip and 
knee replacements for OA in the United Kingdom was estimated at £851.3 million, which 
was increased to £3.2 billion when indirect costs including work days lost and disability 
allowances were factored into the calculation104. 
Women tend to be more frequently affected by OA, while obesity and genetic predisposition 
have also been identified as risk factors106–110. The pathogenesis of this condition remains 
largely unclear, however an imbalance in the homeostatic state of articular cartilage 
combined with the risk factors mentioned above could help to explain the onset risk and 
progression of this disease. 
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1.6.2.2 Articular cartilage in OA 
An understanding of the physiological changes that occur in articular cartilage during OA is 
key to the development of new therapies and targets. Cartilage softening and fibrillation 
(Figure 1.6) are some of the earliest visible events used to characterise the onset of OA. 
Small clefts appear along the surface of the cartilage and progressively increase in depth 
until the degradation of the previously solid structure becomes visible. This process is 
believed to be accentuated with repeated mechanical loading on the joint, leading to further 
ulceration of the articular surface and ultimately contributing to the reduction in cartilage 
thickness111.  
1.6.2.3 Chondrocyte activity in OA 
Injury to articular cartilage affects the architecture of the ECM and the phenotype of resident 
chondrocytes. The loss of the characteristic phenotype of chondrocytes can, in part, be 
accounted for by the downregulation of the transcription factor Sox9, which is the principal 
regulator of chondrogenesis112,113. Studies have shown that chondrocytes from arthritic joints 
enter a hypertrophic state that is defined by increased proliferation and apoptosis, the 
downregulation of factors promoting cartilage matrix formation and the upregulation of 
matrix degrading proteinases and osteogenic factors114,115. Histological observation of 
arthritic cartilage indicates clustering of chondrocytes adjacent to the site of fissure (Figure 
1.6)116,117. It is not clear whether this is due to an increase in chondrocyte proliferation within 
their local pericellular matrix or an aggregation of cells following tissue migration. However, 
mitotic assays appear to support the former118,119.  
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Figure 1.6: Histological observation of cartilage fibrillation and chondrocyte clusters 
(black arrow) in a Grade III cartilage lesion. Image adapted from Pritzker et al.117 
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Although there is an age related decrease in the gene expression of collagen type II, 
chondrocytes from OA patients have been shown to increase the production of the protein 
120–122, possibly in an attempt to restore the disrupted cartilage matrix. Previous immuno-
localisation and gene analysis assays have revealed increased expression of collagen type X 
as an indicator of the change in phenotype of OA chondrocytes123–125, although this is not a 
universally established observation in OA115.  
The abnormal secretion of matrix degrading enzymes by chondrocytes is well documented 
and is an important factor in the progression of OA126,127. Quantitative gene analysis by 
Kevorkian et al. strongly correlated OA progression with the upregulation of MMP13, 
MMP28, MMP9, MMP16, ADAMTS16, ADAMTS2, and ADAMTS14128. The role of 
TIMPs in OA is not fully understood, but the increased expression of TIMP-1 and TIMP-3 
reported by Su et al. does not appear to be sufficient to temper the deleterious effects of 
MMPs129. As mentioned above, another indicator of chondrocyte hypertrophy is the 
production of molecules involved in tissue calcification, notably osteocalcin, osteonectin, 
osteopontin, and alkaline phosphatase130–134 and the expression of the osteogenic 
transcription factor runt-related transcription factor 2 (Runx2)135,136.  In addition, several 
studies have proven that a higher percentage of apoptotic cells reside in OA cartilage 
compared to normal cartilage137,138. These cells show positive expression for the pro-
apoptotic factors, β cell lymphoma-2 (Bcl-2), Fas and annexin V, while a significant amount 
of DNA fragmentation has also been detected137,138. 
 
1.6.2.4 Modifications to the ECM in OA 
Changes that occur in the phenotype of articular chondrocytes will inevitably affect the 
composition and architecture of the cartilage ECM. As a result, proteinases secreted by 
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chondrocytes coupled with the insufficient production of matrix components facilitate the 
overall breakdown of cartilage in OA. The implication of collagenase-mediated denaturation 
of type II collagen fibres has also been demonstrated, while aggrecan degradation is well 
documented in OA subjects91,122,127,139–141. Histological observations indicate a progressive 
loss of GAGs in human cartilage during OA117. 
Furthermore, an age related accumulation of advanced glycation end products (AGEs) 
prompts the excessive crosslinking of collagen fibres in articular cartilage142,143. This process 
leads to increased stiffness of the cartilage matrix, which makes the tissue more brittle and 
prone to breakages and lesions144,145.  
 
1.6.2.5 Involvement of the subchondral bone in OA 
In addition to the changes that occur in the articular cartilage, several studies have 
highlighted the contribution of the subchondral bone in the pathogenesis of OA. Cysts 
present in the subchondral bone are a common radiographic feature that has been correlated 
to OA and eventually knee replacement in a longitudinal study146,147. While there is no 
consensus in the literature regarding the exact mechanism through which these cysts are 
formed, it is believed that they interact with the articular cartilage via small fractures, the 
implications of which remain unclear147. 
Vascular invasion of the calcified zone from the subchondral bone causes the tidemark to 
drift, leading to cartilage thinning and an incorrect dissipation of forces during cyclic joint 
loading14. Radiographic analyses confirm an increase in cortical bone thickness of the 
subchondral plate associated with increased tissue remodelling148. Here again, the 
mechanical properties of the articular unit are altered due to the inefficient mineralisation of 
bone during high turnover rates149,150. Proliferation and terminal hypertrophic differentiation 
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of periosteal cells at the cartilage-bone interface engenders osseous outgrowths on the 
periphery of the joint. These structures are known as osteophytes and represent another key 
feature for the diagnosis of OA151. 
 
1.6.2.6 Influence of Genetics in OA  
The genetics of OA is a subject of much debate. No single gene alteration has been identified 
as solely responsible for the onset and progression of OA. In addition, Mendelian inheritance 
does not support the appearance of OA, which suggests the improbable transmission of the 
disease from parent to child. Genome wide association studies (GWAS) in hip, knee and 
hand arthritic patients have recognised a number of susceptible loci on chromosomes 
2,3,4,6,7,11 and 16. A Single nucleotide polymorphism (SNP) was observed on the 
chromosome 7q22 locus in a  GWAS including 1341 Dutch subjects152. The genes 
implicated in this polymorphism include those coding for G protein-coupled receptor 22 
(GPR22) and HMG-box transcription factor 1 (HBP1). The recent UK based GWAS project, 
arcOGEN, analysed 7410 subjects identifying six OA linked loci153. The authors noted a 
high association linkage on chromosome 3, related to a SNP in guanine nucleotide-binding 
protein-like 3 gene. However these loci do not represent strict OA determinants, but operate 
as predisposing regions that promote the development of the disease. Factors such as 
physical activity tend to be shared within family cohorts and could indirectly influence OA 
clustering by affecting susceptible genes. 
As discussed before, the structural elements of the cartilage ECM are important in 
maintaining the tissue’s integrity. Mutations or alterations in the expression of the genes 
coding for these elements could thus result in the production of defective proteins or no 
proteins at all. The type II collagen α-chain (COL2A1) has been linked to the onset of OA, 
 25 
 
with the arginine to cysteine codon substitution known to be associated with 
chondrodysplasia-induced OA154. There appears to be some contradictory results in the 
literature with regard to the role of the vitamin D receptor (VDR) gene in OA. In one study, 
the investigators used molecular haplotyping in 846 samples to show that an overexpression 
of VDR resulted in a 2.27 fold increase in the risk of knee OA by facilitating the appearance 
of osteophytes155. However, Loughlin et al. were unable to make an association between 
VDR and OA156. In another study, microarray analyses demonstrated a significant over 
representation of the asporin gene in radiographic OA that reduced the expression of 
aggrecan and type II collagen157. Similar associations have been made for other proteins such 
as growth differentiation factor 5 (GDF5)  and frizzled-related protein (FRZB)158–160. To 
conclude, while there is sufficient evidence to support the participation of certain genes in 
the pathogenesis of OA, a definitive hereditary description of the disease is yet to be detailed. 
In addition, it appears that a genetic predisposition to OA is significantly influenced by a 
number of demographic features which further underscores its multifactorial origin. 
 
1.6.3 Inflammation in OA 
As mentioned previously, the destruction of articular cartilage is the primary characteristic 
of OA. An extensive amount of research now points to the secondary involvement of pro-
inflammatory processes in the pathogenesis of OA. Although the historical characterisation 
of inflammation (redness, heat, swelling and pain) may reflect some of the symptoms of OA, 
this definition needs to be extended to integrate the cellular and molecular events that initiate 
and promote the degradation of cartilage161. It must be mentioned that OA-related 
inflammation is not as pronounced as in rheumatoid arthritis (RA) which is an autoimmune 
disease with systemic inflammation162,163.  
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1.6.3.1 Pro-inflammatory molecules in the joint 
The cytokines interleukin-1β (IL-1β) and tumour necrosis factor (TNF) are considered the 
main participants in driving joint inflammation164. Il-1β binds to its specific receptor (IL-1 
receptor type 1)165 and triggers the inhibition of the production of key components of 
articular cartilage matrix, such as collagen type 2 and aggrecan by chondrocytes166,167. TNF-
α has a similar suppressive effect on the synthesis of the link protein of proteoglycans and 
collagen type II by downregulating their respective genes expression in articular 
chondrocytes168,169. Additionally, IL-1-β and TNF-α induce the upregulation of genes of 
catalytic enzymes such as MMP-1, MMP-3, MMP-13 and ADAMTS-4 in 
chondrocytes90,170,171. Studies have also shown that chondrocytes exposed to IL-1β and TNF-
α increase their secretion of other pro-inflammatory molecules, notably IL-6, IL-8 and 
monocyte chemoattractant protein 1172–174. Not only are IL-1-β and TNF-α elevated in the 
synovial fluid (SF) of OA patient, but the expression of the receptors for these cytokines are 
also increased in OA synovial fibroblasts and chondrocytes175,176.  
 
1.6.3.2 Damage-associated inflammation 
The causes of inflammation in the OA joint are continually being revealed. One established 
mechanism is the damage-associated molecular patterns (DAMP) pathway which is initiated 
as a result of tissue and cellular damage in the articular joint. Whether it be through trauma 
or progressive wearing of the joint, small particles and by-products of degeneration are 
released from tissues, such as cartilage and bone. These products represent DAMPs resulting 
in an innate immune response from the host, which in turn generates an increase in local pro-
inflammatory conditions. This process is known as sterile inflammation. HA, cartilage 
oligomeric matrix protein (COMP) and fibronectin are among the molecules derived from 
the breakdown of cartilage ECM known to initiate this immune response177–179.  
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DAMPs are detected by specific cell surface molecules, of which toll-like receptors (TLRs) 
are the best characterised. For example, one study has shown that TLR-4 is necessary for the 
HA induced immune response provoked by sterile inflammation in a mouse model of OA179. 
The activation of the TLR pathways (TLR-2 and TLR-4) leads to the release of catabolic 
factors within the joint by cells such as chondrocytes and macrophages (discussed below in 
section 1.6.3.4)180–182.  
 
1.6.3.3 The role of the synovium and synovitis in joint inflammation 
The synovium can be described as the soft tissue that lines the inside of the articular joint. 
In healthy individuals (no indication of joint pathology), the synovium is comprised of a 
single continuous layer of lining cells (intima) and a fibrous underlying subsynovial stromal 
tissue (subintima) (Figure 1.7)183. The synovial lining cells are divided into macrophages 
(type A cells) and fibroblasts (type B cells or fibroblast-like synoviocytes), which are the 
most abundant of the two cell types. The subsynovial stroma contains fibroblasts and, to a 
lesser extent, immune cells such as macrophages, T cells and mast cells184. Under healthy 
conditions, the synovium maintains the composition of the synovial fluid, secretes lubricin 
which is needed for the lubrication of the joint, and produces nutrients for joint cartilage183.  
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Figure 1.7: Immunohistochemical representation of normal human synovium. Red staining 
indicates CD68 positive macrophages. Image taken from Smith et al.,183. 
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In a diseased joint (OA and RA), the synovium often becomes inflamed; a condition known 
as synovitis. From a histological perspective, synovitis is generally characterised by 
hyperplasia of the synovial lining cells (increase in the number of cells), increased cellularity 
of the subsynovial stroma and infiltration of immune cells from blood vessels185. Synovitis 
can be found in early or late stages of OA, but does not affect the entire synovium (patchy) 
and is not as severe as in RA185,186. Nevertheless, synovitis is believed to play a pivotal role 
in the progression of OA by increasing the inflammatory and catabolic environment in the 
joint. Indeed, immune cells are more abundant in an inflamed synovium and thus the pro-
inflammatory molecules they secrete also becomes elevated187. A longitudinal study has 
correlated an increase in radiographic synovitis with the deterioration of cartilage and 
increased joint pain188.  
The exact mechanism which results in the onset of synovitis is still unknown. The synovial 
tissue appears to be responsive to the presence of fragments of damaged joint tissues and 
chronic haemorrhage. Loose bodies of cartilage and crystal structures, such as those found 
in the bone, are known to induce inflammatory processes in the synovium; a process believed 
to be mediated by IL-1189–191. Taken together, it can be theorised that joint degeneration may 
be one of the initiators of synovitis, which coincides with the general consensus that 
inflammation is a secondary attribute of OA and not the cause of the disease192,193. 
 
1.6.3.4 Macrophages as key mediators of joint immunomodulation 
Originally characterised for their phagocytic activity, macrophages are immune cells 
involved in tissue development and inflammation194. While a pool of tissue resident 
macrophages exist around the human body, monocytes (precursors to macrophages) 
circulating in peripheral blood can be recruited into a given tissue where they become 
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specialised macrophages according the biochemical composition of the local 
microenvironment195. A variety of surface and intracellular receptors and sensors allow 
macrophages to detect signals (DAMP, metabolic and physicochemical changes) in tissues 
to then become activated towards specific phenotypes in order to restore homeostasis195.  
Historically, macrophages were believed to undergo two activation states, classical and 
alternative activation. Macrophages stimulated with any two of interferon- γ  (IFN-γ), 
lipopolysaccharide (LPS) or TNF produce classically activated cells with a pro-
inflammatory phenotype also known as the M1 polarisation state196. These cells are 
characterised by their propensity (when activated) to upregulate genes involved in 
inflammatory cytokine signalling (such as STAT-1), and the secretion of pro-inflammatory 
molecules IL-1, TNF-α, IFN-γ IL-12, IL-23 and nitric oxide (NO)196,197. The alternatively 
activated macrophages, in the M2 polarisation state, are generated following stimulation 
with IL-4 and IL-13, resulting in cells that secret anti-inflammatory molecules such as IL-
10 and IL-1RA (an antagonist of IL-1)196,197. However, a significant number of recent studies 
now suggest that macrophages exist on a spectrum of different phenotypes, as opposed to a 
strict dichotomous model of M1 and M2197,198. This is supported by the discovery of M2 
macrophage subsets that include parasite clearing (M2a), immune regulatory (M2b) and 
wound healing (M2c) macrophages197–199. This tremendous plasticity of macrophages has 
attracted significant research interest, however, the exact functional role of the various 
macrophage subsets in OA still remains unclear. 
In the arthritic joint, much of the available literature is focused on macrophage activity in 
RA. Although studies have investigated the presence of macrophages in the degenerative 
OA joint, few investigations to date have explored the different macrophage subsets and how 
they are potentially involved in the disease200,201. It has been shown that both M1 and M2 
macrophages are present in human synovium and that M1 macrophages were more 
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responsive to alarmins S100 calcium binding protein (S100) A9  and S100A8 (danger signals 
that a functionally similar to DAMPs) by secreting higher amounts of IL-1, IL-6, TNF-α and 
expressing higher levels of MMP-1, MMP-3 and MMP-9 than M2 macrophages 200.  
 
1.6.3.5 Role of the infrapatellar fat pad in joint inflammation 
The infrapatellar fat pad (FP) is a depot of fat tissue located beneath the patellar, forming a 
continuous structure with the patellar tendon. Although the FP is inside the joint capsule, it 
resides outside of the synovial cavity. The precise mechanical function of this adipose tissue 
remains elusive, but recent evidence points to a possible contribution to the inflammatory 
environment in the knee joint. Explant cultures of FP generated significantly higher 
quantities of IL-6 compared to subcutaneous fat202, and conditioned media from FP tissues 
was able to induce fibrosis (measured by the production of total collagen)  in synoviocytes, 
which is a common observation in OA synovium203. FP derived cells secrete a host of other 
molecules (both pro- and anti-inflammatory) in vitro, however it is still unknown whether 
these molecules are produced and to what extent in vivo204,205, or to what degree this affects 
the joint at the various stages of OA. 
 
1.6.4 Risk factors in OA progression: age, gender, previous trauma obesity 
1.6.4.1 Age 
Often referred to as an age-related disease, OA is significantly prevalent in individuals over 
the age of 50 years206. The natural course of aging and loading leads to progressive wearing 
of the joint, which is characteristic of OA. On a cellular level, the hallmarks of aging include 
telomere shortening (engendering genetic instability), reduced anabolism and intracellular 
trafficking, senescence and the depletion of stem cell populations207. These processes have 
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been extensively studied in chondrocytes but are believed to also affect the cells in other 
joint tissues. In addition, these cellular modifications contribute to an age-related 
inflammation, or inflammaging, that accelerates joint destruction192,207–209. 
 
1.6.4.2 Gender 
Radiographic studies of OA patients, have revealed that women have significantly reduced 
joint space width in comparison to men210. It appears that this gender effect is also dependent 
on age, in that women show a quicker reduction in joint space width and a higher incidence 
of OA over the age of 50 years compared to men210,211. Investigations have shown the 
protective effect of the female hormone oestrogen on cartilage explants against degradative 
molecules, such as TNF-α and reactive oxygen species, as well as its ability to enhance the 
production of GAGs in rabbit chondrocytes in vitro212,213. The levels of estrogen in women 
plummet as they get older due to menopause, which could in part account for the onset of 
OA in women after the age of 50 year214.  
 
1.6.4.3 Previous trauma 
Cross-sectional and longitudinal investigations have shown that previous trauma to the knee 
joint is a significant risk factor for the occurrence of degenerative knee disease215–217. Joint 
instability, muscular weakness and tendon malalignment have all been proposed as effects 
of trauma that progressively lead to OA215. High levels of physical activity (>20 miles 
running per week), but not moderate levels, have also been correlated with the high risk of 
developing OA218.  
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1.6.4.4 Obesity 
A strong association has made between obesity and the incidence of OA219,220. Obese women 
are 4 times more likely to develop OA than healthy women, while obese men are 5 times 
more likely to develop  the disease than healthy men221. It was traditionally thought that 
overloading of joints was the link between obesity and OA, considering that increased 
loading has been shown to augment expression of pro-inflammatory molecules and catabolic 
factors in cultured human articular chondrocytes222,223. However, this mechanism does not 
explain the high prevalence of OA in low or nonloading joints, such as the hand, in obese 
individuals224. Moreover, a loss of weight provides symptomatic relief for patients with hand 
OA, suggesting that mechanical overloading is not the only cause of obesity-related OA225.  
Recent evidence now points to the metabolic and inflammatory role of obesity in driving 
joint destruction in subsets of OA patients223,226,227. Obesity is accompanied by low-grade 
systemic inflammation, which is the end product of cytokines and adipokines being released 
into the circulatory system from inflamed fat tissues228. Factors including (but not limited 
to) IL-1, IL-6, leptin and insulin-like growth factor 1 have all been associated with obesity 
related systemic inflammation, of which leptin is the most extensively linked to OA229–231. 
The concentrations of leptin in the synovial fluid of OA patients have been significantly 
correlated to body mass index (BMI), formation of osteophytes and cartilage degradation231.  
The emergence of systemic inflammation and metabolic syndrome as facets of certain OA 
groups opens new avenues for patient screening and adapting treatments.  
 
1.7 General management of OA 
Adequate treatment is vital for the symptomatic relief and improvement in the quality of life 
of OA patients. Patient education and physical therapy are important treatment modalities, 
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but are insufficient effective treatments, alone, in advanced joint failure232,233. In this case, 
pharmacological and surgical treatments need to be considered. Intra-articular injections of 
corticosteroids (eg. hydrocortisone tebutate or triamcinolone acetonide) and non-steroidal 
anti-inflammatory drugs suppress joint inflammation and provide short-term pain relief.234–
236 Conditions such as infections and anticoagulant therapy are however contraindications to 
corticosteroids injections. Surgical procedures can be used as alternatives to steroids, which 
may provide relief over the long term.  Osteotomy involves the removal of a wedge of bone 
to realign a movement axis and, or to alter the distribution of load in the joint237,238. This 
procedure is often indicated for younger patients with moderate joint degradation, and some 
healthy cartilage remaining on the articular surface. Debridement is a less invasive procedure 
where the cartilage surface is smoothed and rid of any flaps or loose tissue bodies239, but is 
not considered appropriate for the more advanced stages of OA.  
To harness the bodies’ inherent ability to repair itself, mesenchymal stem cells (MSCs) can 
be recruited from the subchondral bone marrow (easily accessible in full thickness cartilage 
defects) by abrasion or microfracture. However, the fibrocartilage produced by such marrow 
stimulatory methods is not mechanically comparable to hyaline cartilage. Surgeons also have 
the option of harvesting cylindrical osteochondral grafts from low weight bearing regions in 
the knee to then re-implant them into a cartilage defect. This technique, known as 
mosaicplasty, has the advantage of filling large defects with a biologically functional graft, 
but may cause some donor site morbidity240. Arthrodesis is the fusion of bones, and can be 
beneficial in joints such as the spine, ankle or carpus to relieve pain241–243. As 
aforementioned, advanced stages of OA are characterised by significant pain, reduced range 
of motion and the deterioration of joint elements. Partial or full joint replacement is then the 
most effective form of treatment and comprises the substitution of the affected articulating 
elements with artificial metal, ceramic, or plastic prosthetics.  
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Although this procedure is relatively expensive, it offers the most reliable results in terms of 
pain relief and improvements to joint function. Notwithstanding the efficacy of surgical 
management of OA, there are some limitations that include invasiveness, possibility of 
infection, implant failure and high costs243. Joint replacement is not recommended for young 
patients as the finite lifespan of the implant means revision surgery would be required to 
replace the implant. This has a further significant cost implication and could ultimately lead 
to the loss of the limb. 
  
1.8 Autologous Chondrocyte Implantation (ACI) for Cartilage Repair 
1.8.1 Introduction to cell based therapies  
According to Langer and Vacanti, tissue engineering brings together principles of 
engineering and biology to produce constructs that can replace damaged body tissues244. In 
this promising multidisciplinary field, biologically compatible materials are employed to 
either bring structural support to the native tissue or as a means of delivering cells and small 
molecules (for example growth factors) to a specific site. Biomaterials are selected according 
to their physicochemical properties and may take the form of metals, ceramics or 
polymers245–247. Despite the significant promise and hype, few tissue engineered products 
and cell therapies have been applied routinely in the clinic. Skin replacements Apligraf® 
and Epicel® were amongst the first products to be approved by the Food and Drug 
Administration (FDA) 248,249. Since then, the tissue engineering and regenerative medicine 
(TERM) industry has grown significantly being estimated at approximately $3.6 billion 
worldwide in 2012 250. Orthopaedic products represented the highest market impact with 
over $1.7 billion in sales worldwide.  The most important challenge for the TERM and cell 
therapy industry is the translation phase between basic science and preclinical/clinical 
 36 
 
application, despite the remarkable number of clinical trials in progress using stem cells 
(1618 ongoing trials according to www.clinicaltrials.gov). Most of these proposed therapies 
rarely show superior patient benefits compared to gold standard treatments, thus making 
governing bodies hesitant in bringing them to market.  
 
1.8.2 History of ACI 
Grande et al. initially demonstrated the  repair of surgically induced cartilage defects in the 
patellae of rabbits by the transplantation of chondrocytes isolated from cartilage biopsies in 
1989 251. Five years later, the first results for successful cartilage repair using ACI in 23 
human subjects were published6.  Genzyme’s Carticel® was the first cell therapy procedure 
for the repair of cartilage defects to be approved by the United States (US) Food and Drug 
Administration (FDA) and is the result of a series of investigations by a group in Gothenburg 
(Sweden). The basic principle of ACI involves the harvesting of small cartilage biopsies 
from minor load-bearing areas of the joint during arthroscopy (from the upper medial 
femoral condyle in the original study), from which chondrocytes are isolated by enzymic 
digestion. Chondrocytes are then grown in vitro in Good Manufacturing Practice (GMP)-
compliant conditions for 2-3 weeks. During a second surgical procedure, the chondrocytes 
are injected as a suspension into the defect, which is then covered with a periosteal flap or 
some form of collagen membrane such as Chondro-Gide® (1st generation ACI). A 
retrospective observation of the first patients to receive ACI treatment reported an 
improvement in joint function which was correlated with the formation of hyaline-like 
cartilage and in some cases, impressive tissue integration252,253. 
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Advances in material sciences have offered biocompatible scaffolds upon which cells can 
be seeded before transplantation (2nd generation ACI). These structures provide a 3 
dimensional matrix which has the advantage of retaining the cells within the target site, as 
opposed to having cells “swimming” freely in a suspension, these structures also negate the 
possibility of donor site hypertrophy caused by the recovery of a periosteal flap254. This 
procedure is often referred to as matrix assisted chondrocyte implantation or transplantation 
(MACI or MACT). In spite of the overwhelming amount of published research 
demonstrating cartilage regeneration with ACI, the procedure is still not recommended for 
general clinical use. According to the latest Technology Appraisal from the National Institute 
of Health and Care Excellence (NICE) in 2008, ACI is not recommended for the treatment 
of cartilage defects in the knee unless it is part of a research study aimed at proving the 
efficacy of the procedure255. The reviewing committee highlighted the need for more 
comparative studies of ACI against surgical techniques such as mosaicplasty and non-
surgical methods such as intense physiotherapy. Finally, the paucity of data with regards to 
the cost effectiveness of ACI is also a limiting factor to its widespread, mainstream clinical 
translation. The cost of the in vitro manipulation of cells alone varies between £2000 and 
£5000 per patient in the UK, which suggests that efforts will have to be focussed on reducing 
the general cost of ACI to notably improve its accessibility to patients255. 
 
1.8.3 Clinical outcomes of ACI 
Evaluating the efficacy of ACI is normally achieved by assessing joint function, biological 
repair and the quality and integration of the repair cartilage produced (magnetic resonance 
imaging (MRI) scans, arthroscopic probing and histology), as well as general outcome 
measures related to factors such as pain and generic quality of life of the patient256,257. In the 
follow up assessment performed on the first 101 ACI cases in Sweden, 92% of the subjects 
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with femoral condyle defects showed good to excellent clinical outcome according to the 
Brittberg scoring system252. Similar results were obtained for 75% of subjects with femoral 
condylar defects with ligament reconstruction and 89% subjects with osteochondritis 
dissecans. Subjects with multiple chondral lesions and those with patella lesions had the 
lowest scores of 67% and 68%, respectively. Importantly, the presence of hyaline-like 
cartilage was also reported at the repair site.  
A number of other groups have reported varying outcomes in ACI clinical trials. In a 12-24 
months follow-up study of 169 ACI patients, a statistically significant functional 
improvement (Cincinnati score) was reported in cohorts with simple and complex defects 
(4.3 cm2 - 6.75 cm2) post-treatment 254. Subjects with salvage defects (11.66 cm2) showed 
marked improvements in quality of life, based on the Short Form-36 quality of life scoring 
system254. Another study has demonstrated that patients with a history of prior knee surgeries 
also show general clinical improvement after ACI treatment258. However, the authors failed 
to describe the nature of the previous treatment modalities, such that improvements noted 
may have been as a result of the combined effects of multiple treatments. A multicentre study 
in the US involving 50 patients also reported significant functional joint improvement 36 
months following 1st generation ACI 259.  
In a randomised trial comparing the clinical outcome (4 scoring systems and histology of 
repair cartilage) of ACI and microfracture 12 and 24 months postoperatively, the 
investigators reported no significant differences between the two procedures 260. Younger 
and more active patients did however show better improvement in both groups. A 5-year 
follow-up assessment revealed an increase in failures with time for both procedures, but also 
highlighted that patients with predominantly hyaline cartilage at 24 months had no reported 
subsequent failures261. 
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From a histological perspective, both hyaline and fibrocartilage have been reported 
following ACI. Haematoxylin and eosin (H&E) and immunohistochemical staining for 
collagens have been employed to identify areas within the repair site that contain hyaline 
cartilage, fibrocartilage and a mixture of both 262. Less GAG production in the repair sites of 
ACI subjects than in matched cadaver controls has been previously observed, with 
chondroitin sulphate chains being significantly shorter in ACI samples263. Evidence also 
suggests that some matrix remodelling occurs through enzyme degradation and de novo 
synthesis of structural components such as collagen type II264. 
Notwithstanding the relative success of ACI in the majority of reported studies, some 
complications related to the procedure have been identified. In a systematic review, ACI 
failure was summarized according to a number of parameters including: insufficient 
production of regenerative cartilage, symptomatic (pain including joint locking) and/or 
arthroscopic hypertrophy, poor fusion of new cartilage with native tissue (delamination), 
chondromalacia and other events requiring reoperation265. Other studies have indicated that 
male subjects respond significantly better to ACI treatment than women and that age appears 
to be a key factor in the overall clinical outcome266,267. Obesity and smoking are also 
recognised as patient-specific markers that negatively influence clinical results 268. 
The quality of the cells that are transplanted into the patients after in vitro expansion has 
been suggested as a significant factor influencing the efficacy of ACI. One study assessed 
the viability, CD44 expression and the chondrogenic phenotype of freshly isolated 
chondrocytes from the knees of 80 patients who received ACI269. These cell characteristics 
were then correlated against postoperative functional scores. Results showed that cell 
viability, CD44 and collagen type II expression all significantly influenced the improvement 
of knee function in this study. Interestingly, aggrecan did not seem to influence clinical 
outcome. The same research group had previously shown that chondrocytes from young ACI 
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patients (age 20 or less) showed stronger chondrogenic phenotypes after in vitro expansion 
than those chondrocytes isolated from older patients, an observation that could account for 
the superior clinical results in younger subjects270.   
1.9 Optimisation of ACI 
1.9.1 Cell-Matrix combinations 
As mentioned previously, a number of biomaterials have been developed to improve the 
quality of grafts used for ACI. These materials are generally comprised of hyaluronan or 
collagen. Chondro-Gide® is a porous bilayer membrane comprised of porcine type I and III 
collagen developed by Geistlich Biomaterials271. Hyalofast™ (Anika Therapeutics) is a non-
woven pad made of hyaluronan and can operate as a cell scaffold or as a matrix to retain 
reparative elements from marrow stimulation within a specific site272. BioTissue have 
created BioSeed®-C and Chondrotissue®, both comprised of a two compartment structure 
made of a synthetic polymer fleece and either hyaluronan (Chondrotissue®) or a biological 
glue (BioSeed®-C)273. These materials have been used in clinical trials worldwide, there is, 
however, a lack of studies investigating the behaviour of cells within the matrix of these 
materials. 
 
1.9.2 Alternative cell based strategies for cartilage repair and osteoarthritis 
Another strategy for improving the outcome of cell therapies for cartilage repair is by using 
alternative sources of cells, or a combination of cell types. Stem cells have generated 
tremendous hope for treating numerous diseases that are otherwise incurable. Stem cells are 
generally described as having the ability to maintain an undifferentiated state until an 
appropriate external stimulus (chemical or physical) initiates commitment to other cell 
lineages. Although their classification and nomenclature remains a contentious debate, stem 
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cells are commonly categorised according to the origin of the source tissue (embryonic or 
adult) or their differentiation potential (pluripotent or multipotent).   
 
1.9.2.1 BM-MSCs 
Since the discovery of bone marrow derived mesenchymal stem cells (BM-MSCs) in a series 
of work by Friedenstein et al. 274–276, a tremendous amount of research has revealed the 
therapeutic value of these cells 277–279. The International Society for Cell Therapy (ISCT) 
established 3 minimal criteria for the characterisation of BM-MSCs: 1) adherence to tissue 
culture plastic, 2) expression of specific surface antigens, 3) multipotent differentiation 
(Figure 1.8)280. When exposed to specific biochemical stimuli, such as TGF-β and 
dexamethasone, BM-MSCs undergo chondrogenesis in vitro making them a candidate cell 
type for cartilage repair281. 
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Figure 1.8: Illustration of the isolation and multiple cell lineages into which MSCs have 
been shown to differentiate. Image taken from Wright et al 282.  
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Another key attribute of BM-MSCs that later entered the discussions of MSC 
characterisation by the ISCT283, is their ability to modulate the activity of immune cells, 
notably lymphocytes and macrophages. This has been demonstrated by their capability to 
diminish the proliferation of peripheral blood lymphocytes both in vitro and in vivo in a dose 
dependent manner284. This observation is confirmed in both autologous and allogeneic 
scenarios and is thought to be mediated by the secretion of molecules by BM-MSCs 
(paracrine effect) 284–286. Similarly, BM-MSCs have the ability to switch the phenotype of 
macrophages from a pro-inflammatory M1 state to anti-inflammatory M2 state through a 
paracrine effect involving molecules such as IL-10 and IL-1RA287–289.  
The clinical relevance of this immunomodulatory property was revealed when BMSCs were 
used to successfully treat graft versus host disease in 55 patients who had received 
haematopoietic stem cell transplantations290. The use of BMSCs for treating OA is thus an 
attractive option as they may contribute to suppressing the joint inflammation often 
associated with OA35,291. Contradictory results have been published regarding the capacity 
of BM-MSCs (and other stem cells) to retain their immunomodulatory properties after 
differentiation. Some studies showed no difference in the immunomodulatory properties of 
undifferentiated and chondrogenically differentiated BM-MSCs292, whereas other studies 
show that BM-MSCs do not simultaneously portray enhanced chondrogenic ability and 
immunomodulatory properties, but rather display either one or the other293. In fact, one study 
has shown that chondrogenically differentiated allogeneic BM-MSCs have lost their ability 
to inhibit lymphocyte proliferation, but have increased positivity of immunogenic markers 
such as CD80 and CD86294. This concern needs clarification, but also raises the question of 
whether BM-MSCs should be used for the regeneration of cartilage (differentiation) or to 
dampen joint inflammation (paracrine effect). Achieving both functions simultaneously may 
not be possible295. 
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Wakitani et al., were among the first to demonstrate the possible use of BM-MSCs for 
treating full thickness cartilage defects in an animal model296. Numerous human studies have 
assessed the use of MSCs as either culture expanded cells or as a bone marrow concentrate 
to treat OA of the knee 297–299. Histological observations in 2 year follow-ups of cartilage 
defects that were treated with BM-MSCs showed the formation of normal cartilage (or 
almost normal according to the ICRS histological score) for only 24% of treated patients300. 
However, in one comparative study, cultured MSCs were found to be just as effective as 
chondrocytes (1st generation ACI) in terms of overall knee function and the quality of life of 
patients. Donor age has been shown to significantly affect the quality, phenotype and 
differentiation potential of BMSCs and could prove to be a limiting factor in autologous 
therapies for older patients301–303. In addition, retrieving bone marrow aspirate samples can 
be an invasive procedure resulting in some significant patient discomfort.  
 
1.9.2.2 Adipose stem cells 
Adipose tissue derived MSCs (ASCs) have also emerged as an interesting alternative cell 
source, probably because of the relative abundance and ease of access of fat tissue (usually 
lipoaspirate or subcutaneous fat biopsies) in the body304. Adipose tissue yields higher cell 
numbers than bone marrow, with cells having a higher proliferation rate and a comparable 
differentiation potential in vitro305,306. ASCs do not display the same surface marker 
expression profile compared to BM-MSCs, however the two cell populations share similar 
immunomodulatory properties307–309. The FP is easily accessible during arthroscopy and has 
been investigated as a source of ASCs (FP-MSCs) for autologous OA therapies310–312. FP-
MSCs have been shown to have a higher chondrogenic potential than BM-MSCs, however 
their immunomodulatory properties have not yet been explored. A recent clinical trial 
demonstrated the safety (after 6 months) of ASCs from lipoaspirate when injected intra-
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articularly to treat OA313. According to the investigators, patients administered with a low 
dose of ASCs (2x106) showed an improvement in joint function and less pain compared to 
baseline assessments. 
 
1.9.2.3 Synovium and synovial fluid derived stem cells 
In addition to its established function in maintaining the composition of the synovial fluid, 
the knee synovium also harbours a niche of MSCs (SM-MSCs) originally characterised as 
highly proliferative and multipotent314. Three years later, another source of MSCs (SF-
MSCs) were discovered in the synovial fluid of patients with OA, RA and other 
arthropathies315. SF-MSCs are believed to originate from the synovium, but this has not yet 
been proven316. There is evidence to support the theory that SM- and SF-MSCs have the role 
of repairing damaged tissues in the joint notably cartilage, ligament and tendon317–319. A 
subpopulation of SM-MSCs have been identified and isolated using the markers CD73 and 
CD39320. The immunomodulatory properties of SM- and SF-MSCs have not been fully 
explored. To date, SM- and SF-MSCs have not yet been applied in clinically for the 
treatment of OA. 
 
1.9.2.4 Embryonic and induced pluripotent stem cells 
Embryonic stem cells (ESCs) possess the ability to differentiate into any cell type of the 
three primary germ layers: ectoderm, mesoderm and endoderm (pluripotent)321,322. The 
isolation of ESCs from the blastocysts of surplus human embryos intended for in vitro 
fertilisation have initiated some ethical concerns. Furthermore, the ability of ESCs to form 
teratomas after transplantation in animal models has raised safety issues for cell based 
therapies322. However, cell culture and differentiation protocols have been developed to 
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efficiently generate chondrocytes from ESCs either through direct differentiation, or by 
multi-step protocols usually involving an intermediate stage of differentiation (such as 
embryoid bodies or MSCs)323–325.  
In a ground breaking investigation, it was demonstrated that pluripotent stem cells could be 
derived from skin fibroblasts by retroviral transduction of four genes: octamer-binding 
transcription factor 4 (Oct4), (sex determining region Y)-box 2 (Sox2), Myc  (c-Myc) and 
Kruppel-like factor 4  (Klf4) 326. These induced pluripotent stem cells (iPSCs) which have 
provided the ideal platform for the development of patient specific cells without the concern 
of immunological rejection. However, like ESCs, safety concerns soon emerged for iPSCs, 
including the use of viral means of transferring genes into cells, as well as the use of potential 
oncogenes such as c-Myc to induce pluripotency. Chondrocytes can also be derived from 
iPSCs using the same protocols mentioned above for ESCs, with the added benefit of  the 
cells being donor-matched to avoid immune rejection325,327. Although chondrocytes obtained 
from pluripotent stem cells have not yet been tested in humans, these cells provide new 
possibilities for drug screening and discovery in the field of cartilage regeneration and OA. 
 
1.9.3 Combination of chondrocytes and stem cells 
Recent studies have revealed that chondrocyte-MSC co-cultures help to maintain the 
chondrogenic phenotype of culture expanded chondrocytes in vitro; an effect believed to be 
mediated by the secreted molecules from both cell types328–331. Maumus et al. were able to 
demonstrate this paracrine effect after observing an increase in the expression of hepatocyte 
growth factor (HGF) in FP-MSCs that were co-cultured with articular chondrocytes332. 
When anti-HGF antibodies were added to the culture, the authors observed an increased 
fibrotic phenotype in the chondrocytes. In another study, the reciprocal effect was also 
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observed as chondrocytes secreted parathyroid hormone-related protein (PTHrP) to 
presumably inhibit the hypertrophic differentiation of BM-MSCs329. ASCs and SM-MSCs 
were also found to enhance the re-differentiation of chondrocytes333,334. 
Results from one of the first human trials involving the co-transplantation of allogeneic BM-
MSCs together with freshly isolated autologous chondrons, showed a complete fill of the 
cartilage defect with hyalin-like cartilage at 12 months follow-up335. Short tandem repeat 
analysis revealed the absence of BM-MSCs in the repair tissue after 12 months, which was 
attributed to their possible clearance by immune cells. This one-step procedure would indeed 
be less demanding for the patient and would reduce the overall cost of the therapy.  Using 
stem cells and chondrocytes in combination can be advantageous to treat both cartilage 
defects and joint inflammation. 
 
1.9.4 Hypoxic conditions for cell expansion 
Cells in culture are usually incubated at 20% O2 and 5% CO2. However, it is important to 
highlight that these conditions do not recapitulate those found in the native biological tissue 
of cartilage. A number of studies have estimated the oxygen tension at the articular surface 
to be approximately 6% which is reduced to as low as 0.5% at the cartilage-bone interface336–
338. Consequently, hypoxic (or physiological normoxic) incubation platforms have been 
developed as a means of maintaining the original cell phenotype in vitro. Several studies 
have shown that BM-MSCs proliferated quicker, produced higher cell yields (30-fold) and 
upregulate HIF-2α after 6 weeks culture in 2% O2 as compared to 20% O2339.  More recent 
studies have also showed that hypoxic conditions do not affect the differentiation potential 
of BM-MSCs340. Oxygen tensions of 2% not only supress the hypertrophic differentiation of 
articular chondrocytes, but also induce the re-differentiation of osteoarthritic chondrocytes 
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by the upregulation of key chondrogenic genes (collagen type II and aggrecan) and the 
downregulation of collagen type 1 and genes for MMP1, MMP2, MMP3 and MMP13341,342. 
Chondrocytes and BMSCs co-cultured on electrospun poly(ε-caprolactone) scaffolds at 5% 
and 20% O2 produced more GAG and collagen type II at 5% O2 343. 
 
1.10 Aims of PhD Project 
The purpose of this thesis was to explore MSCs derived from the articular joint as 
alternatives to chondrocytes for the treatment of cartilage defects and OA. This would be 
accomplished by in vitro experiments to characterise the chondrogenic and 
immunomodulatory of these MSCs, as follows: 
 To characterise donor-matched FP- and SF-MSCs a battery of tests was used to 
compare the growth kinetics, multipotency and immunoprofile of surface markers in 
the two cell populations. Investigations were also conducted to determine the 
immunogenic and immunomodulatory properties of FP- and SF-MSCs in response 
to an inflammatory stimulus (Chapter 3).  
 
 To determine the chondrogenic ability of MSCs and chondrocytes that were culture 
expanded in normoxia, in hypoxia (Chapter 4). 
 
 To establish a hierarchy of chondrogenic potency among donor-matched BM-MSCs, 
FP-MSCs subcutaneous fat (SCF-MSCs) and chondrocytes. To identify surface and 
genetic markers that predict chondrogenesis in matched MSCs and chondrocytes 
(Chapter 4). 
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 To characterise the polarisation status of macrophage subsets from the synovium and 
FP of patients with various arthropathies, and to determine if they can be modulated 
in vitro (Chapter 5).  
 
 To determine whether adipocyte hypertrophy occurs in the FP of obese patients as it 
does in subcutaneous fat. (Chapter 5). 
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Chapter 2 
Material and Methods 
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2.1 Cell isolation, culture and maintenance techniques. 
2.1.1 Isolation of BM-MSCs 
Bone marrow aspirates and bone chips were obtained from the tibial plateau of patients 
undergoing total knee replacement (TKR). Bone marrow was first diluted with an equal 
volume of phosphate buffered saline (PBS, Life Technologies Paisley, UK) then layered 
onto 20 ml of LymphoprepTM (Alere Technologies AS, Oslo, Norway) split between two 50 
ml tubes (Sarstedt, Nümbrecht, Germany) and centrifuged at 900g for 20 minutes (Figure 
2.1). The buffy coat, containing mononuclear cells was aspirated and added to complete 
culture medium and centrifuged at 750g for 10 minutes. The resulting cell pellet was re-
suspended in complete culture medium comprised of Dulbecco’s Modified Eagle’s 
Medium/F-12 (DMEM/F-12, Life Technologies) with 1% (v/v) penicillin/streptomycin (P/S, 
Life Technologies) and 10% (v/v) foetal calf serum (FCS, Life Technologies) and cells were 
seeded at 20 million cells per 75 cm2 tissue culture flask (Sarstedt). After 24 hours 
incubation, the medium was changed and the non-adherent cells washed off.  
Bone chips (5-10cm2) were perfused with complete medium and the wash out was seeded 
into a 75 cm2 tissue culture flask. The bone chips were then placed in a 175 cm2 culture flask 
with 30 ml of complete medium for 7 days to allow the plastic adherent cells to migrate out 
of the bone chips. All cultures were maintained in a humidified incubator set at 37°C and 
5% CO2. 
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Figure 2.1: Isolation of mononuclear cells from bone marrow. Lymphoprep allows the 
separation of the bone marrow by density gradient after centrifugation. The BM-MSCs of 
interests are found in the layer labelled as buffy coat. 
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2.1.2 Isolation of MSCs from adipose tissues  
Human FP and subcutaneous fat (SCF) samples were obtained from patients undergoing 
either ACI or TKR. FP was assessed macroscopically under sterile conditions using a Nikon 
SMZ800 dissecting microscope (Nikon, Surrey, UK) and any remaining synovium was 
removed with a sterile scalpel. The synovium, which is often inflamed in end stage OA, 
appears red in contrast to the yellow adipose tissue in the deeper layers (Figure 2.2). After 
dissection, the remaining fat tissue was weighed and transferred to a 25 ml tube (Sarstedt) 
and washed with PBS to remove blood cells. The FP or SCF samples were then transferred 
to a dissection dish, minced thoroughly using a sterile scalpel, and placed in a 15 ml tube 
containing a solution of 1 mg/ml collagenase type I (>125 digesting units/mg, Sigma, Poole, 
UK) in DMEM/F12 with P/S. This suspension was incubated at 37°C, 5% CO2 for 1 hour 
and given a gentle shake every 20 minutes. The resulting digest was strained through a 40 
µm nylon cell strainer and centrifuged (350g for 10 minutes), and the supernatant was 
discarded. The resulting cell pellet was resuspended in complete culture medium and seeded 
at 5000 cells per cm2 in a 25 cm2 tissue culture flask (Sarstedt). After 24 hours incubation, 
the medium was changed and non-adherent cells were washed off. 
2.1.3 Isolation of SF-MSCs 
A surgeon obtained SF from the knees of patients undergoing ACI by injecting 20 ml of 
0.9% saline solution into the joint, followed by flexing of the knee to mix with the SF, after 
which a needle was used to aspirate the fluid344. SF was also obtained from patients 
undergoing TKR by inserting a needle into the joint cavity and aspirating the fluid. 
SF was centrifuged at 800g for 15 minutes, the resulting pellet was resuspended in complete 
medium and seeded into a 25 cm2 tissue culture flask. Non-adherent cells were washed off 
after 24 hours and cultures maintained as stated before.  
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Figure 2.2: Representative images of synovium and FP tissues from an end-stage OA donor. 
A) The inflamed synovium attached the FP appears red. B) The deep regions of the FP 
containing predominantly adipose tissue appears yellow. C) Histological representation of 
synovium (black arrow) attached to FP. D) Histological representation of adipose tissue from 
deep regions of the FP. 
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2.1.4 Isolation of chondrocytes 
Articular cartilage was excised from the femoral condyles of patients undergoing TKR. 
Cartilage tissue was weighed, minced into small pieces with a sterile scalpel and digested in 
collagenase type 2 (≥125 units/mg, Worthington, New Jersey, USA) for 16 hours at 37°C. 
The suspension was passed through a 40 µm strainer and centrifuged (350g for 10 minutes) 
to produce a cell pellet that was resuspended in complete medium and seeded at a density of 
5x103 cells/cm3.  
 
2.1.5 Passaging of cells in monolayer culture 
After reaching 70-80% confluence, cells were harvested by removal of the spent culture 
medium, washing once with PBS and incubating with pre-warmed 0.05% trypsin/0.53 mM 
EDTA (Gibco) at 37°C for 5 minutes. Cells were observed using an inverted light 
microscope (Nikon) and gentle tapping was applied to help cell detachment from the culture 
plastic. The activity of the trypsin was neutralised using an equal volume of complete 
medium and the cell suspension was centrifuged for 10 minutes at 350g. The supernatant 
was discarded and the resulting cell pellet resuspended in 1 ml of complete medium. 10 µl 
of the cell suspension was diluted in an equal volume of trypan blue (Sigma) in a 
microcentrifuge tube; 10 µl of this solution was pipetted under a coverslip on a 
haemocytometer. Trypan blue was used to assess the viability of the harvested cells; dead 
cells appeared blue, while live cells excluded the dye and appeared bright. Using an inverted 
light microscope, at least 200 cells were counted within a certain number of grids on the 
haemocytometer, to give an estimate of the cell number in the suspension using the following 
calculation: 
ܰݑܾ݉݁ݎ	݋݂	݈݈ܿ݁ݏ	݄ܽݎݒ݁ݏݐ݁݀ ൌ ܰൈ2	ሺݐݎݕ݌ܽ݊	ܾ݈ݑ݁	݈݀݅ݑݐ݅݋݊	݂ܽܿݐ݋ݎሻൈ10000ൈܸ 
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where N is the total number of cells harvested and V is the volume (in millilitres) in which 
the cells were resuspended. Cells were reseeded at a density of 5x103/cm2 in tissue culture 
flasks, which corresponds to a split ratio of 1:3. The process of trypsinising, counting and 
reseeding cells will be referred to as a passage throughout this thesis. 
 
2.1.6 Mycoplasma testing of cells 
Mycoplasma are a common source of bacterial infection in cell culture that can alter the in 
vitro phenotype of cells including morphology gene expression and viability.345 Routine tests 
to probe for specific gene sequences using polymerase chain reaction (PCR) were routinely 
conducted to detect the presence/absence of mycoplasma in cultures. 
Firstly, 1 ml of cell culture medium was collected in a sterile microcentrifuge tube and 
centrifuged at 500g for 5 minutes to pellet any cellular debris. The supernatant was collected 
and placed in a sterile microcentrifuge tube and centrifuged at 14,000g for 15 minutes to 
pellet any mycoplasma present. After discarding the supernatant, the pellet was resuspended 
in 100 μl DNAase /RNAase free water (Sigma). A reaction mix was then prepared according 
to manufacturer’s instructions (Promokine, Heidelberg, Germany).  
For each sample, including positive and negative controls, a reaction mix containing 22 µl 
of rehydration buffer and 1 µl of TAQ polymerase was prepared in a sterile microcentrifuge 
tube. The contents of each PCR tube provided in the kit were resuspended in 23 μl reaction 
mix, to which 2 μl of test sample was added (2 µl DNAase /RNAase free water was added 
for negative controls). Tubes containing positive control templates were prepared with 23 µl 
reaction mix and 2 µl DNAase/RNAase free water. The contents of each tube was mixed 
well by agitation, and a thermocycler (Thermo Hybaid, Middlesex, UK) was used to run the 
following program: 3 minutes at 94°C, followed by 36 cycles of denaturation for 30 seconds 
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at 94°C, annealing for 2 minutes at 60°C, elongation for 1 minute at 72°C and a final holding 
step for 5 minutes at 72°C. A 1% (v/v) agarose gel containing SYBR safe DNA stain (1 in 
10,000 dilution, Life Technologies) was prepared and loaded into a gel tank with a well 
comb appropriately positioned. The comb was removed when the gel was set and the tank 
filled with 89 mM TRIS-borate, 2.5 mM ethylenediaminetetraacetic acid (EDTA) (TBE) 
buffer. Test samples (7 µl), controls (7 µl) and a DNA ladder (4 µl, Sigma) were loaded into 
wells within the gel and run at 100V until the PCR products had run at least 2-3 cm. A Gel 
Doc EZ Imager (BIO-RAD, California, USA) was used to visualise bands under ultra violet 
light (an example of a whole gel is given in Appendix 1).  
 
2.1.7 Cryopreservation and thawing of cells 
Cells were banked for future experiments by cryopreservation using a mixture of dimethyl 
sulfoxide (DMSO) and FCS. Cells were harvested by trypsinisation, counted as explained in 
2.1.5 and resuspended in a solution of 10% (v/v) DMSO in FBS to obtain a final suspension 
of 1x106 cells/ml. This suspension was then slowly pipetted into labelled cryovials (1 ml per 
tube) and placed into a cryofreezing container (Nalgene, New York, USA), filled with 100% 
isopropanol at room temperature. The container was then placed in a freezer at -80°C for 24 
hours, after which, the cryovials were transferred to liquid N2 at -196°C for long term 
storage. 
To thaw cells, cryovials were defrosted rapidly in a water bath at 30°C, until a small piece 
of ice remained. The thawed cell suspension was then transferred in a drop-wise manner to 
a 25 ml tube containing 10 ml of ice cold complete medium and then centrifuged at 350g for 
10 minutes. The supernatant was removed and the cell pellet resuspended in complete 
medium. At this stage, the cells were counted and reseeded at a density of 5x103/cm3. 
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2.2 Phenotyping of cells  
2.2.1 Growth Kinetics 
The proliferation rate of cells was assessed by calculating the doubling time (DT) at every 
passage. Cells were seeded in T25 cm2 flasks at a density of 5x103/cm2 until 80% confluence 
prior to trypsinisation, counting and reseeding into a T25 (1:3 split). The following formula 
was used to calculate DT at a given passage: 
ܦ݋ݑܾ݈݅݊݃	ܶ݅݉݁ ൌ ሺݐ2 െ ݐ1ሻൈ lnሺ2ሻlnሺ݊2/݊1ሻ 
where, t2-t1 represents the number of days in culture (between passages), n2 is the number 
of cells harvested and n1 is the number of cell seeded initially. 
To determine the number of population doublings (PDs) produced by cells at each passage, 
the following formula was used: 
ܲܦݏ ൌ 3.32	ሺlog ுܰ െ log ூܰሻ 
Where NH is the number of cells harvested and NI is the initial number of cells seeded. 
2.2.2 Trilineage Differentiation of MSCs  
To assess their multipotency, MSCs at passage 3 were differentiated along osteogenic, 
adipogenic and chondrogenic lineages. Osteogenic and adipogenic differentiation was 
conducted on confluent monolayer cells in 24-well plates (Sarstedt), while a 3D pellet 
culture model was used for chondrogenesis. Cells were fed with their respective 
differentiation medium every 2-3 days for 21 days as explained below. Chondrogenesis was 
also conducted for 28 days for specific experiments, which will be discussed later. 
 
 59 
 
2.2.2.1 Osteogenic differentiation 
Cultures were differentiated using osteogenic medium composed of DMEM/F12, FCS (10% 
v/v), β-glycerophosphate (10 mM, Sigma), dexamethasone (10 nM, Sigma) and L-ascorbic-
acid (50 µM, Sigma)346.  Control cells were fed with complete medium for the same period 
of time. 
2.2.2.2 Adipogenic differentiation 
Cultures were induced with adipogenic medium containing DMEM F12, FCS (10% v/v), 
Insulin-transferrin-selenium-X (ITS, 1% v/v) (ThermoFisher, Massachusetts, USA), 3-
isobutyl-1-methylxanthine (0.5 µM) (Sigma), dexamethasone (1 µM) and indomethacin 
(100 µM, Sigma)347. 
 
2.2.2.3 Chondrogenic differentiation 
A 3D pellet culture system was used to assess the chondrogenic capacity of cultured cells. 
Cells were trypsinised, counted and 2x105 cells were placed into a sterile 1.5 ml 
microcentrifuge tube containing chondrogenic medium which consisted of DMEM F12, 
FBS (10% v/v), P/S (1% v/v), ITS (1% v/v), ascorbic-acid (0.1 mM) (Sigma), 
dexamethasone (10nM) and TGF-β1 (PeproTech, London, UK) (10ng/ml)281. The 
microcentrifuge tubes were centrifuged at 350g for 8 minutes to obtain cell pellets. 
 
2.2.2.4 Staining for alkaline phosphatase activity 
After 21 days of differentiation, osteogenic potential was evaluated by assessing the activity 
of the enzyme alkaline phosphatase. A staining solution was prepared by adding 25 mg 
napthol AS-BI phosphate (Sigma) dissolved in 500 µl of dimethyl formamide (Sigma) to 50 
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mg of Fast Red TR (Sigma) dissolved in 50 ml TrisHCl buffer (Sigma) at pH9. The solution 
was filtered before use. 
Culture medium was removed from the wells and cells were washed with PBS and fixed 
with 500 µl of methanol for 10 minutes. The cells were then washed with PBS and 500 µl 
of the stain solution was added to each well for 1 hour at room temperature. The wells were 
then washed 3 times with distilled water and imaged using an inverted light microscope. 
 
2.2.2.5 Oil Red O staining for lipid formation  
Adipogenic potential was assessed by the presence of lipid droplets using the Oil red O stain. 
A stock solution was prepared by dissolving 500mg of Oil Red O (Sigma) in 100 ml of 
isopropanol (IPA). A working solution was then prepared by adding 6 ml of the stock 
solution to 4 ml of distilled water and filtered using filter paper (Whatman, Kent, UK). 
Cultures were washed with PBS, fixed for 10 minutes with methanol and incubated with 500 
µl of the working solution of Oil red O for 1 hour at room temperature. The wells were then 
washed with distilled water and imaged with an inverted light microscope. 
 
2.2.2.6 Lysine coating of slides  
Poly-L-lysine was used to coat glass slides to allow tissues to adhere to the slides after 
cryosectioning. The slides (CellPath, Newtown, UK) were submerged in 100% IPA, wiped 
clean with tissue paper and then submerged in a solution of 10% v/v poly-L-lysine (Sigma) 
in distilled water for 5 minutes. The slides were then drained and dried in an oven at 37°C 
overnight before use. 
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2.2.2.7 Snap freezing and cryosectioning of chondrogenic pellets 
After 21 days in chondrogenic medium, pellets were carefully removed from culture medium 
and placed on filter paper before being immersed for 10 seconds in liquid N2 cooled hexane. 
Frozen pellets were stored at -80°C until needed. All cryosectioning steps were performed 
between -20°C and -30°C. TissueTek® (Sakura Finetek, Zoeterwoude, Netherlands) was 
placed on a cold chuck, the frozen pellets were submerged in the TissueTek® and frozen 
using cryospray (CellPath). The chuck was then mounted onto a cryostat where pellets were 
sectioned at 7 µm and collected on poly-L-lysine coated slides and stored at -20°C until 
further use. 
 
2.2.2.8 Toluidine blue staining and scoring of chondrogenic pellets for GAGs 
Toluidine blue is a metachromatic stain generally used to reveal the presence of GAGs 
samples348. Frozen slides containing cryosectioned chondrogenic pellets were thawed at 
room temperature and allowed to air dry. Slides were then flooded with a 1% (w/v) toluidine 
blue (pH 2.5) (BDH Lab Supplies, Poole, UK) for 30 seconds and briefly immersed in a 
staining trough filled with tap water to remove excess toluidine blue. The stained slides were 
air dried and mounted with Pertex (HistoLab, Gothenburg, Sweden) and a coverslip before 
imaging. 
A modified version of the Bern Score349 was used to assess three histological features of 
chondrogenically differentiated cells in pellet culture: 1) Uniformity and intensity of 
toluidine blue staining, 2) Distance between cells (amount of matrix produced), 3) 
morphology of cells (Table 2.1) . Each of the three features is given a score between 0-3 and 
the total some of the scores is calculated to give one overall histological score (0-9). This 
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scoring method was modified in that it was performed on pellet sections stained with 
toluidine blue, as opposed to Safranin O–fast green349.  
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Table 2.1: Modified Bern Score used to assess chondrogenic pellets stained with toluidine 
blue349. 
Scoring categories Score 
Uniformity and intensity of toluidine blue stain
No stain 0
Weak staining of poorly formed matrix 1
Moderately even staining 2
Even dark stain 
 
3
Distance between cells/amount of matrix accumulated
High cell densities with no matrix in between (no spacing between cells) 0
High cell densities with little matrix in between (cells <1 cell-size apart) 1
Moderate cell density with matrix (cells approx. 1 cell-size apart) 2
Low cell density with moderate distance between cells (>1 cell) and an 
extensive matrix 
 
3
Cell morphologies represented
Condensed/necrotic bodies 0
Spindle/fibrous cells 1
Mixed spindle/fibrous with rounded chondrogenic morphology 2
Majority rounded/chondrogenic 3
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2.2.2.9 Papain digestion of chondrogenic pellets 
Chondrogenic pellets were digested with the enzyme papain to release GAGs and DNA. A 
digestion buffer consisting of 50 mM sodium phosphate (BDH), 2mM EDTA (Sigma) and 
20mM N-acetyl cysteine (BDH) was prepared and the pH adjusted to 6. Papain (Sigma) was 
added to the digestion buffer to reach a final concentration of 125 µg/ml.  The solution was 
then aliquoted and stored at -20°C. Each chondrogenic pellet was placed in a microcentrifuge 
tube with 200 µl of papain digest and placed in an oven at 60°C for 3 hours. The digest 
suspension was mixed vigorously every 30 minutes by tapping the tubes. Samples were 
centrifuged at 1000g for 5 minutes, aliquoted and stored at -20°C until analysed. 
 
2.2.2.10 Dimethylmethylene Blue Assay (DMMB) 
The DMMB assay is commonly used to measure the quantity of GAGs in tissues or fluids 
350,351. The staining solution was prepared by adding 0.59 g NaCl (Sigma), 0.7 6g of glycine 
(Sigma) and 0.4 g of 1, 9-dimethylmethylene-blue (Serva Electrophoresis, Heidelberg, 
Germany) in 225 ml of distilled water. The pH was adjusted to pH 3.0 using 2M HCl and 
the volume made up to 250 ml with distilled water. The solution was then filtered using filter 
paper and protected from light in aluminium foil and stored at room temperature for later 
use.  
Standards were prepared by dissolving chondroitin sulphate (Sigma, C9819) from bovine 
trachea in PBS to create solutions of 0, 0.05, 0.1, 0.15, 0.2 µg/µL in microcentrifuge tubes. 
50 µl of samples or standards were added to the wells of a 96-well plate in triplicate and 200 
µl of the DMMB staining solution was added to each well. The absorbance was immediately 
read at A530nm and A590nm.  Each sample and standard were processed as follows:   
(A530 nm/A590nm)-(A530nmblank/A590nmblank) 
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where A530nm=absorbance of samples (or standards) at 530 nm, A590nm= absorbance at 
590 nm, A530nmblank= absorbance of 0 µg/µl standard at 530 nm and A590nmblank= absorbance 
of 0 µg/µl standard at 590 nm. A standard curve was plotted from which the total GAG 
content in each sample was calculated using the equation of the curve. 
 
2.2.2.11 DNA Assay 
Results obtained from the quantification of GAGs using the DMMB assay requires 
normalisation to DNA content due to the variability observed in the cellularity of the pellets. 
The PicoGreen® flourescence assay (Invitrogen, Paisley, UK) allows for the quantitation of 
double stranded DNA in solution and was conducted according to the manufacturer’s 
instructions. A 1:200 dilution of the PicoGreen reagent was made in 10 mM Tris-HCl, 1 mM 
EDTA, pH 7.5 buffer (TE buffer) and kept in the dark at room temperature. A 1:50 dilution 
of the lambda DNA standard provided in the PicoGreen® kit was prepared and further 
diluted to 1:40 in TE buffer for a final DNA concentration of 2 µg/mL. This stock solution 
was then used to create standard concentrations of 1 μg/mL, 100 ng/mL, 10 ng/mL, 1 ng/mL 
in TE buffer and TE buffer alone was used as a blank. Experimental samples were diluted 
1:20 in TE buffer. Both the standards and the experimental samples (100 µL) were dispensed 
in triplicate into the wells of a flat-bottomed 96-well plate, and 100 µL of the diluted 
PicoGreen reagent was added to each well. The plate was incubated at room temperature for 
2-5 minutes in the dark after which the fluorescence was read on a plate reader (BMG 
Labtech, Ortenberg, Germany) configured to excitation=480nm and emission=520nm. The 
fluorescence value of the blank was subtracted from each sample/standard and the 
concentration of DNA was determined using the standard curve. The normalisation of GAG 
content in chondrogenic pellets was achieved by dividing the total GAG content of a given 
pellet by the DNA content of that same pellet. 
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2.2.3 Cell surface marker detection by flow cytometry 
2.2.3.1 Introduction 
Flow cytometry is a technology that utilises a combination of fluidics, optics and electronics 
to measure the physical attributes of cells (and other particles). A fluidics system is used to 
channel a stream of cells in single file through lasers resulting in the deviation (or scatter) of 
light depending on the physical properties of a cell (such as size and granularity), and the 
emission of light (fluorescence).  Detectors capture these scattered and emitted lights, which 
are converted into electronic signals by a computer for analysis. Single colour flow 
cytometry involves the use of fluorochrome conjugate monoclonal antibodies to detect the 
presence of a specific antigen from emitted fluorescence at a single wavelength. On the other 
hand, multicolour flow cytometry allows the simultaneous detection of multiple antigens 
produced by a cell using antibodies against these different antigens that are conjugated to 
different fluorochromes.  
 
2.2.3.2 Preparation of cells for flow cytometry 
A panel of cell surface markers were selected based on the ISCT minimum criteria for 
characterising cells as MSCs280,352 (Table 2.2) , in addition to profiling their chondrogenic 
potency269,320,353–358 and immunomodulatory phenotype359, via multi-colour flow cytometry 
(Table 2.2). Experiments were conducted on monolayer cells at P3. For the ISCT MSC 
criteria, 100 000 cells were resuspended in a universal tube containing 1 ml 2% (w/v) bovine 
serum albumin (BSA, Sigma) in PBS and 10% (v/v) of human IgG (Grifols, Barcelona, 
Spain) and incubated at 4°C for 1 hour as a blocking step. The tube was centrifuged at 500g 
for 5 minutes and the pellet was resuspended in 500 µL 2% (w/v) BSA and distributed evenly 
between 5 flow cytometry tubes (100 µl per tube). Fluorochrome conjugated antibodies 
against CD73, CD90, CD105, CD11b, CD14, CD19, CD34, CD45, and Human Leukocyte 
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Antigen-D Related (HLA-DR) (BD Biosciences, Oxford, UK) were added to the tubes 
according to the dilutions and layout given in Table 2.3 and Figure 2.3, respectively.  
The positivity of the following putative chondrogenic potency markers was examined using 
single/multicolour flow cytometry using conjugated antibodies (Table 2.3 and Figure 2.3 B): 
CD44, CD166, CD49c, CD151, CD39, CD271, FGFR3 and αROR2. The presence of the 
immunomodulatory marker CD106 was also determined. Cells were incubated with 
antibodies for 30 minutes at 4°C in the dark and then washed with 1 mL of 2% (w/v) BSA 
per tube, centrifuged at 500g for 5 minutes.  The supernatant was carefully aspirated from 
each tube and the remaining cell pellet resuspended in 300 µL of 2% (w/v) BSA. Samples 
were then acquired on the FACS CantoII cytometer. A FACSCanto II flow cytometer (BD 
Biosciences) was used to acquire data and the FACS Diva version 7.0 or Flowjo version 10 
(Ashland, Oregon, USA) software were used to analyse data. 
 
 
 
 
 
  
 68 
 
 
  
Marker (ref) Cell selection Marker Name 
CD73 (280) MSC (+) 5'-nucleotidase 
CD90 (280) MSC (+) Thy-1 
CD105 (280) MSC (+) Endoglin 
CD14 (280) MSC (-) Monocyte differentiation antigen 
CD11b (280) MSC (-) Integrin alpha M 
CD19  (280) MSC (-) B-lymphocyte antigen 
CD34 (280,352) MSC (-/+) Hematopoietic progenitor cell antigen 
CD45 (280) MSC (-) Protein tyrosine phosphatase receptor type C
HLA-DR (280) MSC (-) Human leukocyte antigens-DR 
CD40283 Immunogenic TNF Receptor Superfamily Member 5 
CD80283 Immunogenic B7-1, costimulatory molecule 
CD86283 Immunogenic CTLA-4 Counter-Receptor B7.2 
HLA-G360,361 Immunomodulatory Human leukocyte antigens-G 
CD44 (269,353) Chondropotency Hyaluronate Receptor 
CD166 (354,355) Chondropotency Activated leukocyte cell adhesion molecule 
CD49c (353) Chondropotency Integrin alpha 3 
CD106 (359) Immunomodulatory Vascular cell adhesion protein 1 
CD151(353) Chondropotency Raph blood group 
CD39 (320) Chondropotency Ectonucleoside triphosphate diphosphohydrolase-1 
CD271(357,358) Chondropotency Low-affinity nerve growth factor receptor 
FGFR3 (356) Chondropotency Fibroblast growth factor receptor 3 
αROR2 (356) Chondropotency Receptor tyrosine kinase-like orphan receptor 2 
Table 2.2: Description of markers used to characterise MSC and chondrogenic potency. 
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Table 2.3: Fluorochrome-conjugated antibodies used to identify MSC and chondrogenic 
potency surface markers. 
Marker (ref) Clone(s) Isotype  control Fluorochrome Dilution
Negative 
cocktail  
ICRF44, 
HIB19, 581, 
HI30, TU36 
IgG1 
IgG2a PE* 1:5 
CD73  AD2 IgG1 BV421* 1:100 
CD90  5E10 IgG1 PE 1:200 
CD105  266 IgG1 APC* 1:100 
CD14  MφP9 IgG2b PercP-Cy5.5* 1:100 
CD11b ICRF44 IgG1 PE 1:100 
CD19  HIB19 IgG1 BV421 1:200 
CD34  581 IgG1 APC 1:20 
CD45 HI30 IgG1 PE 1:20 
HLA-DR TU36 IgG2b APC/PE 1:5 
CD40 5C3 IgG1 PE 1:20 
CD80 L307 IgG1 PE 1:50 
CD86 2331 IgG1 PE 1:50 
HLA-G MEM-G/9 IgG1 FITC 1:20 
CD44 G44-26 IgG2b PercP-Cy5.5 1:100 
CD166 3A6 IgG1 BV421 1:20 
CD49c C3 II.1 IgG1 PE 1:20 
CD106 51-10C9 IgG1 APC 1:2.5 
CD151 14A2.H1 IgG1 PE 1:5 
CD39 TU66 IgG2b APC 1:1.25 
CD271 C40-1457 IgG1 BV421 1:20 
FGFR3 136334 IgG1 APC 1:100 
αROR2 231509 IgG2a APC 1:50 
*PE: Phycoerythrin, BV421: Brilliant Violet 421, APC: Allophycocyanin, PercP-Cy5.5: 
Peridinin-chlorophyll-protein-Cyanine5.5. 
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Figure 2.3: Distribution of fluorochrome conjugated antibodies (Abs) in tubes for flow 
cytometry. A) Abs used to characterise cells for MSC surface markers. B) Abs used to 
identify putative chondrogenic surface markers. Fluorochromes are indicated as purple 
(BV421), red (APC), orange (PercP-Cy5.5), green (PE). 
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2.2.3.3 Analysis of flow cytometry results 
The analysis of flow cytometry data was conducted as illustrated in Figure 2.4. Debris and 
cell doublets (two or more cells attached to each other) were gated from the scatter plots and 
a positivity gate (i.e. 99% of the cells are negative) is established on the singlet population 
of cells stained with the isotype controls. This gate is then applied to test sample containing 
the marker of interest to obtain the percentage of cells that are positive for that marker in the 
population. 
 
2.2.4 Stimulation of MSCs with IFN-γ 
The ISCT have proposed that the assessment of the immunogenic and immunomodulatory 
properties of MSCs be conducted as part of the characterisation process283. It was 
recommended that MSCs be exposed to pro-inflammatory conditions (IFN-γ and or TNFα) 
and tests be performed to evaluate their response by monitoring the levels of specific 
molecules as detailed below.  
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Figure 2.4: Example of flow cytometry analysis to determine the positivity of a surface 
marker. 
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2.2.4.1 Characterisation of co-stimulatory and Major Histocompatibility 
Complex class II markers after stimulation with IFN-γ.  
 
The immunogenic nature of FP-MSCs and SF-MSCs was investigated by assessing the 
presence of the costimulatory markers CD40, CD80, CD86, and the Major 
Histocompatibility Complex (MHC) class II marker, HLA-DR, after stimulation with IFN-γ 
(≥ 2 x 107 units/mg, PeproTech). Cells at P3 were exposed to complete culture medium 
containing either 25 ng/ml (low concentration, ≥500units/ml) or 500 ng/ml (high 
concentration, 1x105 units/ml) of IFN-γ for 48 hours. Untreated cells grown in complete 
medium were used as controls for comparison. After stimulation, cells were prepared for 
single colour flow cytometry as described previously with PE-conjugated antibodies against 
CD40, CD80, CD86 (BD Biosciences) and HLA-DR (Immunotools, Friesoythe, Germany) 
(Table 2.3). 
 
2.2.4.2 Detection of immunomodulatory markers 
Human Leukocyte Antigen- G (HLA-G) was assessed via flow cytometry using antibodies 
against surface and intracellular antigens (Santa-cruz, Texas, USA). Cells at P3 were 
incubated for 20 minutes in a Cytofix/CytopermTM   solution (BD Biosciences) for fixation 
and permeabilisation. The cells were then washed and resuspended in 100 µl of 2% (w/v) 
BSA, stained with unconjugated antibodies against HLA-G for 30 minutes at 4°C (Table 2.3 
for dilution), followed by a wash and resuspension in 100 µl with 2% (w/v) BSA. A 1:20 
dilution of Flourescein isothyocyanate (FITC) conjugated antibodies against the HLA-G 
were used to label the cells for 30 minutes at 4°C. After a final wash in 2% (w/v) BSA, flow 
cytometry data was acquired and analysed as described previously.  
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The production of indoleamine 2,3-dioxygenase (IDO) by cells at P3 was evaluated after 
stimulation with IFN-γ by Western blot. Cells were trypsinised as described previously, 
lysed with cold radioimmunoprecipitation assay buffer (RIPA buffer, 100 µl buffer per 
1x106 cells) containing 25 mM Tris-HCl pH 7.6, 150 mM NaCl, 1% NP-40, 1% sodium 
deoxycholate, 0.1% SDS and protease inhibitors (ThermoFisher) at 4°C, and stored at -20°C 
until further use.  
The bicinchoninic acid (BCA) assay (Life Technologies) was used for the quantification of 
total protein in each sample. Standards were prepared using BSA according to the 
manufacturer’s guidelines for a working range of 20-2000 µg/mL. 25 µL of the standards 
and samples was dispensed into duplicate wells of a round bottomed 96-well microplate 
(Sarstedt) prior to the addition of 200 µL of BCA working reagent to each well and 
incubation at 37°C for 30 minutes. The plate was allowed to cool for 10 minutes and the 
absorbance was read at 562 nm. After quantification of total protein, 20 µg of each sample 
was loaded into pre-cast NuPAGE® 4-12% Bis-Tris gels (Life Technologies). An iBlot and 
transfer stack system (Life Technologies) was used to transfer proteins onto a nitrocellulose 
membrane. Primary and secondary antibodies were added to detect IDO at dilutions of 1:250 
and 1:125, respectively, in antibody diluent (Life Technologies). The primary antibody 
(Abcam, Cambridge, UK), against IDO, was used to probe the membrane for 7 minutes using 
the iBlot system. The secondary antibody (1:125, Life Technologies, conjugated to 
horseradish peroxidase) was applied for 7 minutes. Membranes were washed three times 
with a wash solution (Life Technologies), then twice with autoclaved water on a rocker. A 
chromogenic substrate solution, NovexR Alkaline Phosphatase (Life Technologies), was 
added to the membranes, after which colour development was allowed for no longer than an 
hour protected from light. Membranes were washed again in autoclaved water before being 
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allowed to dry in the dark prior to imaging with a Canon Powershot A490 camera (Canon, 
Tokyo, Japan). 
 
2.2.5 Differentiation of cells in hypoxic conditions 
A SCI-tive Hypoxia workstation (Baker Ruskinn, Bridgend, UK) was used to assess the 
effect of a low oxygen environment on the phenotype and differentiation of chondrocytes 
and MSCs (Figure 2.5 A). In the experiments presented here, 2% O2 in 5% CO2 and 93% air 
was considered as hypoxia whereas standard culture conditions (21% O2 in 5% CO2 and 74% 
air) was considered normoxia. All experiments in hypoxic conditions were performed using 
culture medium that was pre-conditioned at 2% oxygen in the HypoxyCOOLTM system 
(Baker Ruskinn, Figure 2.5 B). To accomplish this, bottles of medium with filtered caps 
were incubated in the HypoxyCOOLTM configured to run for 3 hours at 4°C with agitation 
(usage of the HypoxyCOOLTM was kindly provided by Professor Nick Forsyth). Using a low 
temperature of 4°C with agitation increases the rate of gas exchange and allows the stable 
conditioning of the culture medium. 
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Figure 2.5: HypoxyCOOL™ and Sci-tive. A) Chondrogenic pellets were incubated and fed 
in the closed system of Sci-tive at 2%. B) Culture media was conditioned to 2% O2 in the 
HypoxyCOOL™.  
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2.2.5.1 Measuring oxygen levels in culture medium 
Two dissolved oxygen meters, the Seven2Go Pro (Mettler Toledo, Colombus, USA) and the 
Hanna HI2040 (Hanna Instruments, Rhode Island, USA) (Appendix 2), were used to confirm 
the oxygen levels in the medium that was used to culture cells in hypoxic and normoxic 
conditions. Oxygen levels were measured in the following conditions:  
 Normal medium and pre-conditioned medium measured in ambient conditions (21% 
O2). 
 Normal medium and pre-conditioned medium incubated in the SCI-tive for 24 hours. 
 Medium from cells incubated in a standard incubator (21% O2) or in the SCI-tive 
(2% O2) for 24 hours. 
 Pre-conditioned medium (2% O2) left open in ambient air for 3 hours. Oxygen levels 
were measured every hour. 
For each oxygen meter, measurements were obtained with and without stirring the probe in 
the fluid to ensure that the measurements were representative of the entire fluid and not just 
the areas immediately around the probes. 
 
2.2.5.2 Differentiation of cells in hypoxia 
Chondrocytes and either BM-MSCs, FP-MSCs or SCF-MSCs isolated and grown in 
standard normoxic conditions up to P3. Cells were then trypsinised, counted and centrifuged 
to form 12 chondrogenic pellets for each cell type. Six of the pellets, 3 for GAG/DNA 
analysis and 3 for histology, were then transferred into the SCI-tive hypoxia work station 
and fed with pre-conditioned hypoxic complete medium with supplements to induce 
chondrogenesis (as described previously in section 2.2.2.3). The six other pellets were 
differentiated in normoxic conditions. Chondrogenic differentiation was conducted for 28 
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days after which the pellets were harvested and processed as described previously for further 
analysis. 
 
2.3 Histology of the infrapatellar fat pad and synovium 
2.3.1 Tissue fixation and wax embedding 
FP tissue samples were obtained from TKR or ACI patients in operating theatres and 
observed under a dissecting microscope to localise the attached synovium as described in 
section 2.1.2. Fat and synovium were prepared for embedding as follows. A solution of 4% 
neutral buffered formalin (NBF) was prepared by mixing formaldehyde (1:10 dilution, 
BDH) in distilled water containing 0.03 M sodium dihydrogen orthophosphate (BDH) and 
0.05 M of disodium hydrogen orthophosphate (BDH) at pH 7.4.  After dissection, the tissues 
were fixed in NBF for at least 48 hours at room temperature.  These samples were then 
processed by the pathology laboratory at the RJAH Orthopaedic Hospital as follows.  
Following fixation, tissues were mounted onto labelled cassettes, and samples were then 
placed in the following industrial methylated spirit (IMS, Gent Medical, York, UK) solutions 
for 1 hour each; 70%, 90%, 95%, 100%, 100% and 100%. The samples were successively 
immersed in two xylene solutions for 1 hour each prior to immersing twice in FibrowaxTM 
(VWR, Pennsylvania, USA) at 62°C for 1 hour. The cassettes were mounted onto a mould 
into which hot Fibrowax was dispensed and allowed to cool for 30 minutes or until wax was 
solidified. The mould was then detached from the wax blocks and the tissues sectioned.  
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2.3.2 Sectioning of tissues  
Wax embedded tissues blocks were sectioned at 5 µm thickness on a microtome (Leica, 
Wetzlar, Germany). Serial sections were gently placed in a container of warm water and 
caught onto slides, followed by drying at 37°C for at least 24 hours.  
 
2.3.3 Haematoxylin and Eosin staining 
The H&E stain is commonly used in histology to reveal the general morphology of tissues348. 
Haematoxylin is a basic dye that stains acidic structures (such as the cell nuclei) purple-blue, 
whereas eosin is an acidic dye that stains basic structures such as connective tissues and 
various components of the cytoplasm348. For cryosections, slides were brought to room 
temperature before staining. Wax embedded samples were deparaffinised by successive 
immersions in the following solutions for 5 minutes each: xylene x2, 100 % ethanol x2, 96% 
ethanol and 70% ethanol.  Slides were then rinsed twice each with distilled water for 3 
minutes.  
All slides were placed on a slide rack and flooded with either Gill’s Haematoxylin (Sigma) 
or Harris’s Haematoxylin (ATOM Scientific, Cheshire, UK) for 5 mins, then rinsed with tap 
water for 5 minutes. Slides were then flooded with 1% eosin (v/v in distilled water) for 30 
seconds, dipped quickly in distilled water, then placed in 70% (v/v) IPA for 2 minutes. In 
order to dehydrate the samples, slides were successively submerged in the following ethanol 
solutions in distilled water (v/v) for 1 minute each: 96% ethanol, 100 % ethanol, xylene x2. 
The slides were mounted with Depex (Sigma) while still wet with xylene and allowed to dry 
in a fume hood for at least 1 hour. 
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2.4 RNA extraction and quantitative real-time polymerase chain reaction (RT-
qPCR) 
The PCR assay is used to amplify DNA in order to assess the gene expression fold change. 
PCR involves repeated changes in temperature (cycles) that exponentially produces targeted 
DNA sequences using the DNA polymerase enzyme. In the experiments below, messenger 
RNA (mRNA) was first extracted from cells to produce complementary DNA (cDNA), 
followed by qRT-PCR to evaluate the expression of specific genes. The qRT-PCR method 
allows for the monitoring, recording and quantitative analysis of PCR as it occurs, as 
opposed to an end stage analysis of the PCR product.  
 
2.4.1 Extraction of mRNA from cells 
An RNeasy extraction Kit (Qiagen, Hilden, Germany) was used to obtain mRNA from cells 
according to the manufacturer’s recommendations. After trypsinisation, 200 000 cells were 
counted, centrifuged in a 1.5 mL microcentrifuge tubes, snap frozen in liquid N2 and stored 
at -80°C until further use. Cells were thawed, and resuspended in 350 µL lysis buffer 
(provided with kit) containing a 1:100 dilution of 2-mercaptoethanol (Sigma), ensuring the 
suspension was properly mixed. 350 µL of 70% (v/v) molecular biology grade ethanol in 
RNase free water (Sigma) was added to the tube and the total volume was then pipetted onto 
a spin column placed in a 2 mL collection tube and centrifuged at 8000g for 1.5 minutes. 
The resulting mRNA which was attached to the column was then washed twice by adding 
500 µl of RPE buffer (wash solution provided in kit) and centrifugation at 8000g for 1.5 
minutes. The mRNA was then eluted from the column using 50 µl of RNase-free water, 
collected in a sterile microcentrifuge tubes and stored at -80°C until further use. 
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2.4.2 Generation of cDNA from mRNA 
The QuantiTect Reverse Transcription Kit (Qiagen) was used to generate cDNA according 
to the guidelines provided. This process converts the mRNA previously extracted into 
complementary strands of DNA to be used in the RT-qPCR. All steps of cDNA production 
were performed on ice.  
The mRNA (25 µL) was pipetted into a sterile microcentrifuge tube together with a reaction 
mix containing: 5 µL of reverse transcriptase buffer, 2 µL of dNTP mix, 5 µl random 
primers, 2.5 µL of multiscribe reverse transcriptase enzyme and 10.5 µL of RNAse-free 
water. The tubes were then placed in a thermal cycler (Techne, Cambridge, UK) 
programmed to incubate at 25°C for 10 minutes, then at 37°C for 2 hours, followed by a 
final holding step at 4°C. Samples were stored at -20°C until further use. 
 
2.4.3 Assessing gene expression via RT-qPCR 
The SYBR Green® chemistry, a dye that specifically binds to double stranded DNA as it is 
produced, was used to monitor gene amplification. A reaction mix consisting of: 10 µl of 
SYBR Green Master Mix (Taq DNA polymerase, dNTP and SYBR Green dye), 2 µl of 
primers for the target gene and 6.4 µl RNase free water was prepared for each gene of interest 
and kept on ice. Table 2. 4 gives a description of the target genes that were used. 1.6 µL of 
the previously generated cDNA were pipetted into triplicate wells of a 96-well PCR reaction 
plate together with 18.4 µL of the reaction mix.  
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Table 2. 4: Primers used for qRT-PCR 
Primer name Description 
Reference genes  
PPIA 
Peptidylprolyl isomerase A. An enzyme that catalyses the 
isomerisation of certain peptide bonds. 
TBP 
TATA-binding protein. A protein that binds to DNA and 
forms part of a transcription factor involved in the 
transcription of a wide range of genes. 
Chondrogenic Genes  
SOX978,362 Sex determining region Y-box 9. Master regulator of chondrogenesis and chondrogenic differentiation. 
COL2A1362,363 Collagen type II. Key component of the extracellular matrix of articular cartilage. 
ACAN46,362 Aggrecan. Key component of the extracellular matrix of articular cartilage. 
FRZB362,364 Frizzled-related protein. Intervenes in the developmental formation of cartilage. 
Hypertrophic Genes  
ALK-1362,365 
Activin A receptor type II-like 1. Involved in the 
hypertrophic differentiation of chondrocytes and is 
associated with the increased expression of MMP-13. 
COL10366 Collagen type X. This is produced by terminally differentiated chondrocytes 
All primers were obtained from Qaigen (Hilden, Germany). 
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The plate was then sealed with an optical adhesive film (Applied Biosystems, Foster City, 
USA) and placed in a Quant Studio3 Real-Time PCR System (Applied Biosystems) 
configured to run the following temperature programme: activation (10 minutes at 95°C); 
40 repeated cycles of denaturation (10 seconds at 90°C); annealing (30 seconds at 55°C) and 
extension (34 seconds at 72°C); followed by a final dissociation step (10 seconds at 94°C, 
then 30 seconds at 55°C and 10 seconds at 90°C). 
Preliminary tests were conducted on commonly used reference genes367 Peptidylprolyl 
isomerase A (PPIA), Beta-2 microglobulin (B2M), TATA-binding protein (TBP), 
Glyceraldehyde 3-phosphate dehydrogenase (GAPDH) and hypoxanthine 
phosphoribosyltransferase 1 (HPTR1), to determine which two were the most stable across 
the cells populations tested. PPIA and TBP showed the most favourable results (Appendix 3) 
and were used as the reference genes for all RT-qPCR experiments. 
The relative expression of each gene was determined using the 2-ΔCT method368,369. The 
Quant Studio Design and Analysis Software™ (Applied Biosystems) was used to set the 
baseline (initial cycles with little/no fluorescent signal) and obtain CT values (the cycle 
number at which the fluorescence passes the threshold of baseline fluorescence), as 
illustrated in Figure 2.6.  
The following equation was used to determine the relative gene expression, where the PCR 
signal of the target transcript is compared to the reference gene. 
2ି௱஼் 
Where ΔCT= CT gene of interest – CT reference genes. 
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Figure 2.6: Example of a PCR amplification plot. The baseline corresponds to the cycle 
where no (or little) fluorescence is detected. The threshold, used to determine the Ct value, 
is placed in the linear phase of all the amplification plots.  
 
 
 
 
 
  
 85 
 
 
2.5 Characterisation of macrophages in synovium and fat pad: in situ and freshly 
isolated 
2.5.1 Immunohistochemical characterisation of macrophages in the synovium and 
infrapatellar fat pad 
Immunohistochemistry was used to reveal the presence of cells that were positive for the 
macrophage markers, CD68370, CD86371, CD11c372, CD206373, and Arginase-1374 (Table 
2.5), in donor-matched FP and synovium samples. This technique utilises the specificity of 
antibodies to bind to target antigens in tissues, which can then be visualised by the reaction 
of an enzyme conjugated to the antibody with its chromogenic substrate. All steps of 
immunohistochemistry were performed at room temperature. 
Wax embedded FP and synovium samples were deparaffinised as described in section 2.3.3. 
Heat-induced epitope retrieval was performed by placing the slides in a Coplin jar with a 10 
mM sodium citrate (Sigma) buffer at pH 6, pre-heated in a microwave until the solution 
started to boil, followed by an incubation at 95°C in a water bath for 20 minutes. Samples 
were allowed to cool at room temperature and washed with PBS for 3 minutes. Slides were 
mounted into a Sequenza™ rack (ThermoFisher), rinsed twice with PBS, and incubated with 
a blocking solution consisting of 10% (v/v) normal goat serum (Southern Biotech, Alabama, 
and USA), 1% (v/v) BSA and 1% (w/v) powdered milk (Campina, Rotterdam, Holland) in 
PBS for 30 minutes. 180 µL of diluted primary antibodies (Table 2.5) were added to the 
slides, incubated for 1 hour and washed 3 times with PBS. The biotinylated secondary 
antibody (BioGenix, California, USA) was applied to the slides at a dilution of 1:50 in a 
buffer containing 1% (v/v) BSA and 5% (v/v) human serum in PBS and incubated for 30 
minutes. Three washes with PBS were performed after which an alkaline phosphatase-
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conjugated streptavidin complex was added (1:50 dilution in 1% (v/v) BSA in PBS) for 30 
minutes. Streptavidin is a protein with a high affinity for biotin and thus the streptavidin 
complex would specifically attach to any bound secondary biotinylated antibodies. Slides 
were washed twice with PBS, placed in a Coplin jar and rinsed once with 0.2 M Tris-HCl 
solution at pH 8.5. A solution of 1 g in 25 ml 2 M HCl of New Fuchsin (Chroma, 
Gesellschaft, Kongen, Germany) was mixed with 4% w/v of sodium nitrite (Sigma) in 
distilled water was prepared, together with a second solution of Naphtol AS-MX phosphate 
(18 mg in 2 mL Dimethylformamide). Both solutions were then added to a third solution that 
consisted of 15 mg of levamisole in 60 ml of Tris-HCL and filtered. Slides were immersed 
in this solution (which is the substrate for alkaline phosphatase), for 20 minutes (protected 
from light) and washed 3 times with distilled water. A haematoxylin counterstain was 
performed for 10 seconds followed by a further wash with tap water after which the slides 
were allowed to air dry overnight and mounted with VectaMount™ (Vector Laboratories, 
Peterborough, UK). Slides were imaged using an Olympus SC30 camera (Olympus, 
Zoeterwoude, Netherlands). 
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Table 2.5: Markers used in immunohistochemistry to identify macrophages in synovium 
and FP.  
Marker Macrophage polarisation 
Antibody 
clone 
Source of antibody 
(supplier) Dilution* 
CD68 Pan macrophage marker KP-1 
Mouse anti-human 
Monoclonal (Sigma) Ready to use 
CD11c M1 EP1347Y 
Rabbit anti-human 
Monoclonal 
(Genetex, CA, USA) 
1:200 
CD86 M1 EP1158Y 
Rabbit anti-human 
Monoclonal 
(Genetex) 
1:200 
CD206 M2 - Rabbit anti-human Polyclonal (Abcam) 1:400 
Arginase-1 M2 - Rabbit anti-human Polyclonal (Genetex) 1:1000 
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2.5.2 Ranking the positivity of macrophage markers in stained tissues 
After immunohistochemistry, the positivity of each macrophage marker was ranked 
separately in the synovium, subsynovial stroma, and FP for a total of 11 donors (Figure 2.7). 
All microscopic observations were performed using an X20 objective, unless otherwise 
indicated.  
For this study, the synovium was considered to be the layer (or layers) of cells that line the 
superficial regions of the synovial tissue. Positivity was assessed using three parameters; 1) 
the presence of cells that are stained red, 2) the intensity of the “redness”, 3) the number of 
red cells. Samples were then ranked in order of positivity, for example, from 1 (least positive) 
to 11 (most positive). In the event that two or more samples appeared to have the same level 
of positivity, they were all attributed a mean rank. For instance, if the first 3 samples were 
ranked 1-3, and the following 3 samples were equal in positivity, then these 3 equal samples 
obtain a mean rank of 5 (which is an average of ranks 4+5+6). The next sample would then 
continue with a rank of 7.  
The subsynovial stroma was considered to be the fibrous tissue directly beneath the synovial 
lining (Figure 2.7).  This layer may vary significantly in depth. Positivity was again assessed 
by the presence of cells that are stained red, the intensity of the stain and the number of red 
cells. Samples were ranked following the same method as detailed above. 
To assess the presence of positive cells in the FP, a high power objective (x200) was needed. 
The positivity and ranking of the samples was performed as stated above. Samples were 
ranked by two independent observers using the same ranking method and the mean rank was 
used for statistical analyses. 
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Figure 2.7: Illustration of the different regions that were ranked for each macrophage marker 
following immunohistochemistry. The synovium is a layer(s) cells in contact with the joint 
cavity. The subsynovial stroma is the fibrous layer below the synovium, thus separating it 
from the underlying adipose tissue known as the fat pad. 
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2.5.3 Synovitis score 
The inflammatory status of the synovial tissue was measured based on a previously 
established synovitis grading system185. Synovium tissues were wax embedded, sectioned at 
5 µm and stained for H&E as previously described in section 2.3.2. The synovitis grading 
system was based on three parameters: 1) hyperplasia or enlargement of the synovial lining; 
2) density of cells in the sub-synovial stroma and 3) infiltration of inflammatory cells. Each 
of these features was attributed a score ranging between 0-3 according to Table 2.6 and a 
total grade was determined for each sample by taking the sum of the scores for all three 
features. 
 
2.5.4 Stimulation of fat pad explants with Triamcinolone acetonide (TA) 
Freshly obtained FP samples were dissected to remove any visible synovium as described 
previously and cut into 2-3 cm2 explants that were cultured in an 8-well plate (Sarstedt) with 
DMEM GlutaMAX (ThermoFisher) supplemented with 1% (v/v) ITS, 5% (v/v) fungizone 
(ThermoFisher) and 1% (v/v) gentamycin (ThermoFisher). Sufficient medium was added to 
ensure that the explants were fully submerged (at least 2 mL of medium per well). A 1.4 
mg/mL stock solution of Triamcinolone acetonide (TA) (Bristol-Myers Squibb, Woerden, 
Netherlands) was prepared in DMSO which was added to the explants culture at a 1:100 
dilution. Plates were incubated at 37°C and 5% CO2 for 72 hours.  
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Table 2.6: Criteria for the grading of synovitis. Adapted from Krenn et al185. 
Tissue feature Score Description  
Hyperplasia or 
enlargement of the 
synovial lining 
0 The lining cells form one layer 
1 The lining cells form 2–3 layers 
2 The lining cells form 4–5 layers, few 
multinucleated cells might occur 
3 The lining cells form more than 5 layers, the 
lining might be ulcerated and 
multinucleated cells might occur 
Density of cells in the 
sub-synovial stroma 
0 The synovial stroma shows  
normal cellularity 
1 The cellularity is slightly increased 
2 The cellularity is moderately increased, 
multinucleated cells might occur 
3 The cellularity is greatly increased, 
multinucleated giant cells, pannus 
formation and rheumatoid granulomas 
might occur 
Infiltration of 
inflammatory cells 
0 No inflammatory infiltrate 
1 Few mostly perivascular situated 
lymphocytes or plasma cells 
2 Numerous lymphocytes or plasma cells, 
sometimes forming follicle-like aggregates 
3 Dense band-like inflammatory infiltrate or 
numerous large follicle-like aggregates 
Overall Synovitis grade   
Sum 0 or 1  No synovitis 
Sum 2-4  Low-grade synovitis 
Sum 5-9  High-grade synovitis 
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2.5.5 Extraction of the macrophages from synovium and fat pad tissues or explants 
Enzymatic digestion was used to extract cells from synovium and FP tissues to further 
characterise the phenotype of macrophages via flow cytometry (protocol developed in 
Professor Gerjo van Osch’s lab). After dissection, synovium and FP were weighed and 
incubated at 37°C with shaking for 3 hours with a digestion solution comprised of 2 mg/ml 
collagenase IV (ThermoFisher) and 0.2 mg/ml dispase II (Roche, Basal, Switzerlan) in 
Hanks' balanced salt solution (ThermoFisher). After digestion, FBS was added to the 
suspension (5% v/v) which was then centrifuged at 800g for 8 minutes. The supernatant was 
gently removed with an automatic pipette set to low suction and the pellet was resuspended 
in PBS prior to successive straining through 100 µm and 2x40 µm strainers. The suspension 
was centrifuged again as before and the resulting pellet resuspended in 1 mL of 2% (v/v) 
BSA in PBS in preparation for flow cytometry. At this stage, the cells were counted with a 
1:1 dilution of 3% (v/v) acetic acid with methylene blue (Stem Cell Technologies).  
 
2.5.6 Evaluation of macrophage phenotype by flow cytometry 
Cells were prepared for multicolour flow cytometry as described in section 2.2.3.2. A panel 
of 5 surface markers, CD14375, CD80376, CD86371, CD163377,378 and CD206373, was designed 
to investigate the polarisation status of macrophages (Table 2.7). Cells were equally divided 
into 3 tubes that that were incubated at 4°C for 30 minutes with antibodies as follows; tube 
1) no antibody staining; tube 2) fluorochrome-conjugated antibodies of the isotype controls 
of all 5 markers; tube 3) fluorochrome-conjugated antibodies for all 5 markers. Cells were 
processed as previously described and data was collected using either a FACSCanto II flow 
cytometer or a FACSJazz cell sorter (BD Biosciences).  
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Table 2.7: Panel of surface markers used to investigate macrophage polarisation via 
multicolour flow cytometry 
Marker 
(antibody clone) 
Macrophage 
polarisation 
Conjugated 
fluorochrome 
Dilution of 
antibody 
Isotype 
Control 
CD14 (M5E2) Pan macrophage Marker APC 1:100 IgG2a 
CD80 (L307.4) M1 PE 1:20 IgG1 
CD86 (2331) M1 FITC* 1:20 IgG1 
CD206 (19.2) M2 BV421 1:100 IgG1 
CD163 (GHI/61) M2 PerCP-Cy5.5 1:100 IgG1 
*FITC: fluorescein isothiocynate 
  
 94 
 
Results were then analysed using Flowjo (Figure 2. 8). The CD14 positive population was 
gated, from which the positivity of other markers was determined. Co-positivity of markers 
was obtained by creating a four-quadrant grid on the isotype controls, where 99% of the cell 
population is negative for both markers (lower left quadrant) (Figure 2.8). This grid is then 
applied to the test samples, to reveal cells that are positive for both markers (upper right 
quadrant).  
 
2.5.7 Measuring the size of adipocytes in adipose tissues 
Consent to acquire human tissues was given in accordance with the guidelines of the 
Federation of Biomedical Scientific Societies (Holland) after approval by the local ethical 
committee (MEC 2008-181 and MEC 2012-267). SCF and FP were obtained from obese 
(BMI≥30kg/m2) and non-obese donors (BMI≥29) undergoing TKR. Tissue samples were 
cryosectioned at 7 µm, stained with H&E and imaged using an Olympus SC30 camera. 
Multiple images were acquired of each tissue sample using a x100 objective on an Olympus 
SC30 microscope.  
 
The cross-sectional areas of the imaged adipocytes were calculated using Fiji Is Just ImageJ  
(Fiji) software with the additional Adiposoft plugin379. Three separate sections, with a 
minimum of 25 adipocytes in each section were measured per donor tissue. The Adiposoft 
application was calibrated to identify cells with a diameter between 30-130 µm. A measuring 
scale of 0.33 µm/pixel was also used by the application to determine the cross-sectional area 
(size) of each adipocyte identified in the images. A manual inspection of each output data 
was performed to confirm the correct identification and measurement of adipocytes by the 
program (Figure 2.9). 
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Figure 2. 8: Examples of flow cytometry analyses to determine double positivity of M1 
and M2 markers on macrophages. 
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Figure 2.9: Identification of adipocytes using the Adiposoft plugin in Fiji. A) Original 
image of H&E staining of adipose tissue. B) Output image after being processed in 
Adiposoft. C) Corrected image after manual inspection of processed imaged. The yellow 
contours (B and C) represent the cross-sectional area of an adipocyte. Scale bar= 100µm. 
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2.6 Statistical analysis 
For all analyses, statistical significance was considered at *p<0.05, ** p<0.01 and 
***p<0.001. The distribution of data was determined using the Shapiro-Wilk normality test. 
Parametric statistical tests were used for normally distributed data, whereas nonparametric 
tests were applied for data that was not normally distributed. The statistical tests employed 
for specific experiments are briefly explained in the experimental designs of the results 
section. All statistical analyses were performed in either GraphPad Prism version 6 
(GraphPad Software, California, USA), R version 3.2.1 (The R Foundation, Vienna, Austria) 
or the statistical package for the social sciences (SPSS) version 21 (IBM, New York, USA). 
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Chapter 3: Results 
Characterisation of donor-matched culture 
expanded FP-MSCs and SF-MSCs 
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3.1 Introduction and aim 
Although the FP and SF have been shown to be reservoirs of MSCs in the knee with 
therapeutic benefit, no study has directly compared the phenotype of these cell populations. 
A number of parameters such as tissue source and donor specificity are often overlooked by 
researchers, despite the clear evidence indicating that these features influence the phenotype 
of MSCs. It has been demonstrated that both donor age and gender affect the differentiation 
of BM-MSCs and ASCs; male and young donors generally produce MSCs with a more 
enhanced osteogenic and chondrogenic potency than female and older donors380–382. Further, 
older donors are known to produce MSCs that are less proliferative compared to younger 
donors382. These findings collectively suggest a clear influence of the donor on the 
phenotype of MSCs and support the need for more robust studies that consider tissue origin 
and donor demographics as important parameters when developing cell therapies. 
In addition to the minimum characterisation criteria of MSCs established by the ISCT280, 
which assesses cell surface markers and multipotent ability, understanding the 
immunological properties of MSCs in response to a pro-inflammatory stimulus has also been 
proposed as an important part of their characterisation283. BM-MSCs have been shown to 
increase their production of the immunomodulatory molecule IDO in response to stimulation 
with the pro-inflammatory cytokine IFN-γ383. Like IDO, the human HLA-G is another 
important immunomodulatory molecule produced by BM-MSC and by the trophoblast cells 
in the placenta where it plays a role in maternal tolerance to the foetus361,384. 
HLA-DR interacts with T cell receptors during an immune response, and whilst it is not 
constitutively expressed on BM-MSCs, it is known to be upregulated following a 
pro-inflammatory stimulus385. In contrast, the costimulatory markers CD40, CD80 and 
CD86, which are also involved in T cell mediated immune reactions386, are not produced on 
BM-MSCs even after inflammatory stimulation387. 
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While FP-MSCs and SF-MSCs have been previously characterised in terms of their growth, 
multipotency and CD marker profile310,388, the immunological and immunomodulatory 
properties of these cells have not been thoroughly defined. The purpose of this investigation 
was to assess the influence of tissue sources and donor demographics on the properties of 
MSCs sourced from donor matched FP and SF isolated from human knees. In addition, the 
previously unexplored response of FP- and SF-MSCs to a pro-inflammatory stimulus, such 
as that which may be found in an osteoarthritic joint, was also investigated. 
3.2 Experimental design 
FP and joint SF were obtained with informed consent from 6 patients undergoing either TKR 
or ACI surgery (Table 3.1). FP-MSCs and SF-MSCs were isolated from their respective 
sources and cultured until P10 to assess growth kinetics. Small pieces of the FP were 
processed for histology. At P3, both cell populations were subject to flow cytometry 
according to ISCT criteria, and differentiation to assess multipotency. Cells were also 
stimulated with IFN-γ (0, 25 and 500 ng/mL) before testing for positivity of CD40, CD80, 
CD86 and HLA-G via flow cytometry, and IDO via Western blotting.  
The mean DTs of FP-MSCs and SF-MSCs were compared using a two-way ANOVA with 
Bonferroni’s multiple comparisons tests, while multilevel modelling (or hierarchical 
regression analysis) with Wald’s test was used to determine the effect of donor, cell source 
and passage number on DT. The multilevel level modelling method takes into account the 
hierarchical nature of the data, in this case the fact that experiments were performed on two 
types of cells from individual donors389. The analysis gives simultaneous estimates of 
significant effects that are constant for all donors (known as "fixed effects" or "constant 
effects") and significant effects that vary between individual donors (known as "random 
effects" or "varying effects"). It thus gives a robust framework to disentangle responses that 
are donor-independent and those that differ between donors. A paired Student’s t-test was 
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used to compare means and a Pearson’s test was used to establish correlations where 
appropriate. Graphs are shown as means ± standard error of the mean (SEM). 
 
3.3 Results 
3.3.1 Macroscopic and histological features of the FP 
Donor variability was noted in the apparent level of inflammation of the FP observed by the 
surgeon as indicated by the size of the FP itself and redness of the attached synovium. The 
complex and heterogenous features of the FP tissue were clearly visible in our histological 
preparations showing synovium and adipose regions (Figure 3.1A). Blood vessels appeared 
scattered throughout the synovium (Figure 3.1B) and deeper adipose tissue (Figure 3.1B). 
Mast cells, lymphocytes and numerous blood vessels could also be seen in the subsynovial 
stroma (Figure 3.1C). To avoid contamination of the extracted FP-MSCs with synoviocytes, 
only the deepest areas of the FP were used for digestion, as highlighted in Figure 3.1D. 
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Table 3.1: Demographics of donors from which samples were sourced 
ID Gender Age (years) Condition 
Macroscopic 
observation the 
of FP* Procedure 
Donor 1 Male 35 Chondral defect on lateral 
femoral condyle
Mild 
inflammation ACI 
Donor 2 Female 42 Chondral defect on patella Severe inflammation ACI 
Donor 3 Female 49 Osteochondral defect on patella Hypertrophy ACI 
Donor 4 Female 49 Chondral defect on patella Hypertrophy ACI 
Donor 5 Male 53 OA degeneration of knee with chondral 
defect on trochlea
General 
inflammation ACI 
Donor 6 Male 79 End-stage OA General inflammation Total knee replacement
*Macroscopic observations were made by the surgeon at the time of surgery. 
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Figure 3.1: Histology of a FP. A) Low power view of the fat pad from a patient having a 
knee replacement showing synovium (blue arrow) and adipose tissue (red star). B) The deep 
adipose tissue is indicated by a red star and the adjacent synovium is indicated by a blue 
arrow. C) High magnification view of the synovium with a layer of synoviocytes (blue 
arrow), mast cells (black arrows) and a blood vessel surrounded by a cuff of lymphocytes 
(green arrow). D) Representative region of deep-lying vascularised adipose tissue from 
which FP-MSCs were isolated. Scale bars represent 1 mm (A) and 200 µm (B, C and D). 
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3.3.2 Cell morphology and growth kinetics 
MSCs isolated from both FP and SF were plastic adherent and appeared to consistently have 
a fibroblast-like morphology from early passages (P2) through to the last passage tested 
(P10) (Figure 3.2 A-D). Although some donor variability was observed, the analysis of 
growth kinetics showed that FP-MSCs had a significantly shorter mean DT (p= 0.018) 
compared to SF-MSCs over the 10 passages tested. The proliferation rate of both FP-MSCs 
and SF-MSCs appeared to be progressively reduced with increasing passage number. This 
trend was more noticeable for SF-MSCs than FP-MSCs (Figure 3.3) as they showed a 
significantly longer DT at P9-10 compared to P1-2 (p=0.024) whereas FP-MSCs did not 
(p=0.057).  At P1-P2, FP-MSCs and SF-MSCs had a mean DT of 6.3 ± 2.2 days and 10.3 
± 4.0 days, respectively (p=0.025), compared to 12.9 ± 10 days and 20.9 ± 6.4 days, 
respectively at P9-P10 (p=0.127).  
Multilevel modelling revealed a more complex relationship between cell source, passage 
number and DT. Not only did cell source and passaging significantly influence the DT of 
cells in culture (both p=<0.001), but the increase in cell DT per passage in SF-MSCs 
appeared to be significantly dependant on the donor (p=0.004, Wald’s test, Error! 
Reference source not found.). SF-MSCs had an average increase in DT of 1.4 days at every 
passage, which was not observed for FP-MSCs. In addition, the average doubling time for 
SF-MSCs over the 10 passages was 8.3 days longer than for FP-MSCs and this difference 
was not donor-dependent (p=0.14, ANOVA). FP-MSCs produced more population 
doublings (12.1) over 10 passages than SF-MSCs (8.5), as shown in Figure 3.4. Both cell 
populations generated similar PDs up to passage 3-4 (4 PDs) when they were for 
experiments. However, SF-MSCs started generating fewer PDs than FP-MSCs from passage 
5.  
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Figure 3.2: Microscopic photographs of FP- and SF-MSCs. Representative images were 
taken at A-B) passage 2 and C-D) passage 10. Scale bars represent 100 µm.  
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Figure 3.3: Growth kinetics for FP- and SF-MSCs over 10 passages. Data represents the 
mean doubling time ± standard error of the mean (SEM) for 6 donor-matched FP and SF 
samples. 
 
 
Table 3.2: Results of the Multilevel modelling of the influence of cell source, passage 
number and donor on doubling time of matched FP- and SF-MSCs.  
 
Factor Fixed/Random effect Coefficient or SD (days) p-value
Cell source  
(FP vs SF-MSCs) 
Fixed 8.3 (6.1 – 10.4) <0.001
Passage number  
(SF-MSCs) 
Fixed 1.4 (0.8 – 2.0) <0.001
Passage by donor Random 0.54 (0.19 – 1.1) 0.004 
 
Note: Coefficients and standard deviation (SD) based on a linear mixed effect model. P-
values are from Wald tests (fixed effects) and likelihood ratio tests (random effects).  
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Figure 3.4: Cumulative population doublings (DPs) of for FP- and SF-MSCs. Although both 
cell populations showed an overall increase in DPs during the over 10 passages, FP-MSCs 
(12.1) underwent a higher of cumulative number of PDs than SF-MSCs (8.5). Both cell 
populations displayed similar cumulative PDs profiles between P1-4, but SF-MSCs 
generated less cells from P5. Error bars show standard deviation. 
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3.3.3 MSC immunoprofile 
Flow cytometry analyses (Figure 3.5 A) revealed that both cell populations were over 95% 
positive for the MSC markers CD73 and CD105, but CD90 showed only 92.7% ±11 
positivity in SF-MSCs but 98.3% ± 3.1 in FP-MSCs. Interestingly, some positivity was 
recorded for the cocktail of PE conjugated markers expected to be negative on MSC cultures 
i.e. CD11b, CD19, CD45, CD34 and HLA-DR. FP-MSCs showed significantly (P=0.046) 
greater positivity for the “negative” MSC markers (31.7% ± 24% of cells) compared to cells 
sourced from SF (7.8% ± 6.9% of cells). To explore this further, single PE-conjugated 
antibodies for CD11b, CD19, CD45, CD34 and HLA-DR were used to analyse FP-MSCs. 
FP-MSCs were negative for all of these markers, with the exception of CD34 which was 
30.1% ± 18.6% positive (Figure 3.5 B). The macrophage lineage and inflammation marker 
CD14 was present on both FP-MSCs (30.5% ± 30.3%) and SF-MSCs cells (7.4% ±7.2%, 
P=0.14), with some variability observed between donors (Figure 3.5 C). An increase in 
CD14 positive was associated with donor age for SF-MSCs (n=5, r=0.94, p=0.016), but not 
FP-MSCs (n=5, r=0.66, P=0.23). 
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Figure 3.5: MSC immunoprofile of FP and SF-MSCs (flow cytometry) at passage 3.  A) 
Both cells types were immunopositive for CD73, CD90, CD105; FP-MSCs showed 
significantly higher expression for the cocktail of ISCT defined negative MSC selection 
markers compared to SF-MSCs (p=0.046). B) Single colour cytometric analysis revealed a 
high positivity for CD34 in FP-MSCs (n=3), but no positivity for CD11b, CD19, CD45 and 
HLA-DR. Error bars indicate SEM. C) Cell positivity for CD14 was variable between donors 
and matched cell populations (n=5). 
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3.3.4 Multipotency 
After 21 days of differentiation, all donor matched samples showed multipotent capability 
(Figure 3.6). Histological staining for metachromasia, using toluidine blue, of chondrogenic 
cell pellets after differentiation revealed a similar level of GAG production by both cell 
populations, with no discernible difference in staining intensity between donors. FP-MSCs 
and SF-MSCs in adipogenic medium produced lipids which stained positively with oil red 
O, with those produced by FP-MSCs being more numerous and larger than those produced 
by SF-MSCs. Furthermore, they also showed stronger staining for alkaline phosphatase 
compared to SF-MSCs, which suggests greater osteogenic potential for the FP-MSCs.  
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Figure 3.6: Trilineage differentiation of FP and SF-MSCs at passage 3. The two MSC 
populations demonstrate multilineage differentiation potential when grown in specific 
differentiation media; Chondrogenesis is shown by sulphated GAG production (purple 
metachromasia when stained with toluidine blue), adipogenesis is shown by the formation 
of lipid vesicles (oil red O) and osteogenesis is shown by the activity of alkaline phosphatase 
(red staining). Images are representative of the differentiation potential of all six donor 
matched samples. Scale bars represent 100 µm. 
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3.3.5 Immunogenic and immunomodulatory properties of FP- and SF-MSCs in a 
pro-inflammatory environment 
 
After 48 hours of treatment with either 25 or 500 ng/ml of the pro-inflammatory cytokine, 
IFN-γ, analysis via flow cytometry showed that CD40, CD80 and CD86 were not present on 
either FP-MSCs or SF-MSCs and were similar to the untreated controls (Figure 3.7). In 
contrast, a low concentration (25 ng/ml) of IFN-γ significantly increased the positivity for 
HLA-DR in both cell populations compared to their respective controls (FP-MSCs=39.8% 
±35.1%, SF-MSCs=13.1%±11.7%). FP-MSCs also showed a significantly higher 
percentage of HLA-DR positive cells (46.9%±36.5) compared to SF-MSCs (10.0% ±10.4) 
with 500 ng/ml IFN-γ (P=0.04). Donor variability was noted with regards to the induction 
of HLA-DR by IFN-γ, however MSCs derived from both the FP and SF of donor 2 
consistently produced more HLA-DR in response to IFN-γ stimulation compared to the other 
donors, at both doses tested (Figure 3.7 C-D). After stimulation with 25 ng/ml of IFN-γ, FP-
MSCs showed enhanced production of HLA-DR, which was positively correlated with an 
increase in donor age (n=6, r=0.82, P=0.045); SF-MSCs showed no donor age dependant 
trends (n=6, r=0.72, P=0.105). No correlation between donor age and production of HLA-
DR by FP-MSCs (r=0.69, p=0.16) and SF-MSCs (r=0.66, p=0.14) after stimulation with 500 
ng/ml.  
Both cell populations produced the immunomodulatory marker, HLA-G, regardless of 
inflammatory stimulus and with no significant difference observed between FP-MSCs and 
SF-MSCs (n= 3, Figure 3.8A). Western blots showed that the production of IDO in both cell 
populations was induced by IFN-γ stimulation but was absent in unstimulated controls 
(Figure 3.8B). 
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Figure 3.7: Immunogenic properties of FP and SF-MSCs after stimulation with IFN-γ at 
passage 3. A) The production of co-stimulatory markers (CD40, CD80, and CD86) and the 
MHC class II receptor, HLA-DR, for FP-MSCs is shown after 48 hours of stimulation with 
IFN-γ along with unstimulated controls. Unstimulated and stimulated FP-MSCs do not 
produce co-stimulatory molecules, but show greater HLA-DR positivity at 25 ng/ml 
(39.8%±14.3, p<0.0001) and at 500 ng/mL (46.9%±14.9, p<0.0001) stimulation with IFN-
γ. B) SF-MSCs show no positivity for co-stimulatory markers, even after stimulation, but 
produce significantly higher levels of HLA-DR at 25 ng/ml (13.1 % ± 6.4, P=0.0015) and 
500 ng/mL IFN-γ (9.8% ± 4.3, P=0.025) compared to unstimulated control. C-D) Donor 
variability in the levels of induced HLA-DR on FP-MSCs and SF-MSCs was observed at 
both 25 ng/mL and 500 ng/ml.   However, donor 2 (indicated by the square data points) had 
higher positivity for HLA-DR compared to other donors for both FP-MSCs and SF-MSCs 
and for both IFN-γ doses tested. Error bars indicate SEM 
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Figure 3.8: Immunomodulatory properties of FP and SF-MSCs after stimulation with IFN-γ 
(error bars indicate SEM). A) Both FP and SF-MSCs (n=3) constitutively produce HLA-G 
in control conditions (82.7%±5.1 and 64.0%±3.4 respectively), as well as following 
treatment with 25 ng/ml (73.8%±11.2 and 52.4%±12.5 respectively) and 500 ng/ml IFN-γ 
(79.7%±8.3 and 5.2%±14.9 respectively). B) Image of a representative Western blot 
indicating the production of IDO by FP-MSCs and SF-MSCs after stimulation with IFN-γ, 
but not in untreated controls. 
  
 115 
 
3.4 Discussion 
 The results presented in this chapter have characterised the endogenous population of MSCs 
found in patient matched samples of infrapatellar FP and joint SF and explored the possible 
influence of a pro-inflammatory stimulus on the immunogenic and immunomodulatory 
properties of these cells. Histology of the FP and synovium revealed the presence of immune 
cells, notably mast cells and lymphocytes, in the superficial regions of the tissues. Both of 
these cell types are known to be present in synovial tissues of arthritic patients and produce 
molecules that promote joint inflammation187,390,391. Macroscopic inspection of the FP 
during surgery in the present study revealed some degree of inflammation as indicated by 
the size of the FP itself and the redness of the attached synovium. Data presented in this 
thesis chapter shows that both FP- and SF-MSCs are plastic adherent cells with similar 
fibroblast-like morphologies in vitro.  A significant increase in the doubling time of SF-
MSCs at late passages (compared to FP-MSCs) was noted, which suggests that SF-MSCs 
lose proliferative capacity earlier than FP-MSCs. Reports have indicated that both human 
BM-MSC and ASC DTs increase with passage number392–394; a longer culture period may 
have been required in the current study in order to observe a similar reduction in FP-MSC 
proliferation. The consistent difference in growth rate observed between FP-MSCs and SF-
MSCs, isolated from matched donors, highlights that these cells are biologically different. 
Interestingly, an investigation observing patient-matched SM-MSCs and SF-MSCs revealed 
no significant difference in the proliferation rate of the two cell types between P0 and P2395, 
perhaps providing supportive evidence that these cells share a common origin.  
Donor-matched SF-MSCs and FP-MSCs were positive for MSC cell surface markers CD73, 
CD90, CD105, as well as many of them being positive for the macrophage lineage marker 
CD14375. The positivity of CD90 displayed by SF-MSCs (<95%), and the presence of CD14 
on both cell populations indicates that although joint SF and the stromal fraction of FP 
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contain cells that in part meet the ISCT criteria for MSCs, they may also harbour a sub-
population that do not. CD14 positivity has previously been reported on BM-MSCs396, but 
not FP-MSCs or SF-MSCs to date. Macrophage-like synoviocytes, which are also positive 
for CD14, are a likely contaminant sub-population contributing to the heterogeneity in the 
cultures397,398. SF is known to contain CD14 positive macrophages that secrete pro-
inflammatory cytokines, such as IL-1 and TNF-α, that induce enzyme-mediated cartilage 
degradation399,400. Furthermore, there is increased detectable soluble CD14 in the SF of 
osteoarthritic patients experiencing increased joint pain401. Hence, the positive association 
of CD14 in SF-MSCs and advancing age could be indicative of an increase in pro-
inflammatory conditions in the degenerative joints of older subjects192,402,403. 
No single surface marker that was investigated in this study allowed for a clear distinction 
between FP-MSCs and SF-MSCs, which suggests that a broader panel of markers would be 
required in order to distinguish between these two cell types. Recent guidelines from the 
ISCT and the International Federation for Adipose Therapeutics and Science now accept 
CD34 as being positive on adipose stromal cells352. CD34 positive cells in FP-MSCs and 
other ASCs cultures404,405, are likely to represent subpopulations of either vascular 
endothelial lineages, pericytes or a mixture of the two, as found in cells isolated from 
subcutaneous lipoaspirate. Further work would be required to isolate and phenotypically 
characterise these CD34 positive cells within adipose tissues to assess their function in native 
and transplanted tissues. 
In agreement with previous studies315,406, the results presented here confirm the multipotency 
of both cell populations. FP-MSCs showed enhanced differentiation towards adipogenic and 
osteogenic lineages compared to SF-MSCs; this comparison, to date, has not been previously 
shown. Endothelial cells, that can be found in the enzyme digest of the FP, have been shown 
to promote the osteogenic differentiation of BM-MSCs407,408. This could account for the 
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enhanced osteogenic potential of FP-MSCs. Also, as previously described 388,406, both FP-
MSCs and SF-MSCs populations were shown to possess chondrogenic ability, although no 
discernible difference in the chondrogenic potential of FP-MSCs or SF-MSCs derived from 
the same donor was noted. 
In addition to surface antigens and differentiation characterisation criteria, the need to 
understand the immunological properties of MSCs is becoming crucial to the development 
of cell therapies283,409, particularly in the treatment of conditions which involve 
inflammatory elements as is the case for OA193,410. Antigen presenting cells, such as 
macrophages,   interact with T cells via MHC class II molecules, such as HLA-DR, to trigger 
an alloresponse411. This reaction involves the activation, differentiation and proliferation of 
T cells but is not possible without the expression of costimulatory surface molecules412. The 
results presented here are the first to show an increased positivity of HLA-DR and a lack of 
expression of costimulatory molecules on matched FP-MSCs and SF-MSCs in response to 
an in vitro inflammatory stimulus. BM-MSCs stimulated with IFN-γ have been shown to 
produce levels of HLA-DR that are comparable to the observations in this study with FP-
MSCs387. Conversely, the immunoprofile of IFN-γ induced HLA-DR on SF-MSCs was 
much lower, perhaps indicating that SF-MSCs are less immunogenic following 
inflammatory stimulation and hence display a distinct immunological phenotype compared 
to FP-MSCs and also BM-MSCs. This is the first time that a difference in positivity for 
HLA-DR on stimulated MSCs derived from the same joint has been reported and requires 
further investigation. Inflammation of the knee has been reported to increase with age due 
to elevated levels of  pro-inflammatory molecules 192,413. The results of this thesis chapter 
indicate a trend for increased HLA-DR production with age by FP-MSCs after exposure to 
IFN-γ. It could be hypothesised that the inflammatory nature of the FP is increased with age 
and in turn pre-conditions the endogenous MSC niche to respond to IFN-γ by augmenting 
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HLA-DR positivity. The reason why this correlation was not reproduced in the SF-MSCs 
derived from the same joints remains undetermined, but this observation highlights another 
biological difference between the two cell populations. In vivo investigations evaluating the 
general effects of natural aging and inflammation on MSC pools within the human knee joint 
are needed. Such tests could not only elucidate the cellular pathways involved in the 
pathogenesis of chronic joint diseases, but may also reveal potential therapeutic targets 
(genetic, molecular or cellular) to counter the degenerative processes. Despite the presence 
of HLA-DR on FP- and SF-MSCs in the results presented in this chapter, these cells cannot 
be considered as truly immunogenic without an accompanying increase in the production of 
costimulatory markers 412,414.  
It is perhaps also noteworthy that the only donor included in this study observed in surgery 
to have a ‘severely inflamed’ infrapatellar FP (donor 2) produced FP-MSCs and SF-MSCs 
which showed the most pronounced response to an inflammatory stimulus. This might 
suggest that cells derived from such severely inflamed joints are ‘primed’ to be more 
responsive to inflammatory stimuli, however a larger cohort of donors with better defined 
(macroscopic and histologically quantified) tissues would be required to confirm this 
hypothesis. 
The immunosuppressive properties of SF-MSCs have been demonstrated in mixed 
lymphocyte reactions415, but the constitutive production of HLA-G in FP-MSCs and SF-
MSCs has not been reported previously. IFN-γ stimulation did not significantly influence 
the production of HLA-G in either cell population, however, a larger sample size may be 
required to confirm this result. The levels of HLA-G reported here have also been reported 
in both BM-MSCs and UC-MSCs 361,387. HLA-G positive umbilical cord-MSCs (UC-MSCs) 
have been shown to inhibit the proliferation of pro-inflammatory T helper 1 cells, which are 
present in OA joints416, and to promote the expansion of anti-inflammatory regulatory 
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T cells. The results presented in this thesis chapter demonstrate that the production of IDO 
can be induced in both cell populations by an inflammatory stimulus, comparable to BM-
MSC and ASC cultures417,418. In a collagen induced arthritis mouse model, IDO deficiency 
was associated with a high incidence of arthritis and pronounced T cell infiltration 419. The 
pro-inflammatory conditions within the OA joint could potentially activate the local MSC 
populations to dampen the influence of certain immune cells such as T cells and 
macrophages. The present study suggests that FP-MSCs and SF-MSCs may be considered 
as immunomodulatory cells in inflammatory conditions, due to their ability to produce both 
of the immunomodulatory molecules tested (HLA-G and IDO). However, a more in depth 
in vitro functional testing alongside BM-MSCs will be required to fully assess their 
therapeutic value in this respect. Others have shown that conditioned media derived from 
BM-MSCs, stimulated with IFN-γ and TNF-α, reduced the gene expression of 
pro-inflammatory and cartilage degrading molecules in synovial and cartilage explants in 
vitro420. This trophic feature remains largely undefined in FP- and SF-MSCs but may provide 
insight into the possible mechanism of action that these cells might have in an arthritic joint. 
The use of donor matched samples in the investigations described here has allowed for the 
assessment of donor-specific variability. Tissue source appears to be more influential on the 
proliferative and differentiation properties of joint derived MSCs than the donors themselves 
or related factors. The reasons for this are still unclear. An increase in donor age, for 
example, is known to negatively affect the differentiation potential and growth rate of BM-
MSCs302 and subcutaneous ASCs382, but this does not seem to apply for the FP- and SF-
MSCs observed in our study. 
Donors included in this study were predominantly patients with chondral defects and with 
early signs of OA.  However, one donor was described as having end stage OA and was thus 
undergoing total joint replacement. This heterogeneity in samples may account for some of 
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the variability observed, but also provides insight into the inherent biological differences in 
donors that should be considered in the development of new cartilage repair strategies.  
3.5 Conclusion  
We have characterised the phenotype and have identified biological distinctions between 
MSCs sourced from the FP and SF within the same articular joint. Table 3. 3 gives a 
summary of the results presented in this chapter. We have confirmed that there is potential 
for the use of FP-MSCs or SF-MSCs in the treatment of cartilage defects following ex-vivo 
expansion. However, it may be more advantageous to find a means of recruiting these 
resident MSCs with chondrogenic potency from their respective niches in vivo, as opposed 
to current methods of transplanting culture expanded cells. The advantage of this approach 
would be that the significant costs and regulatory hurdles involved with the in vitro 
manufacturing of cells may be circumvented. 
Further, the results presented in this chapter have shown that the levels of CD14 on SF-
MSCs and the inducibility of HLA-DR on FP-MSCs are potentially related to age-associated 
inflammation. These results confirm for the first time, an immunomodulatory capacity for 
FP- and SF-MSCs which confers further therapeutic value to these cells with regards to 
treating the inflammatory aspect of OA. This also highlights the need to understand the 
physiological inflammatory conditions to which transplanted cells return and how this could 
affect the outcome of a cellular treatment. FP-MSCs and SF-MSCs may not realistically be 
suited for large-scale allogeneic therapies due to limited sample availability and low cell 
numbers, but certainly represent sources of autologous cells for cartilage regeneration in 
addition to sourcing chondrocytes from healthy cartilage, as is used currently. Further 
investigations will seek to understand how these MSCs can be directed to effect repair 
endogenously, either by means of dampening down inflammatory processes, by producing 
repair cartilage themselves or even by encouraging recruitment of reparative cells. 
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Table 3. 3: Summary of the main findings presented in this results chapter comparing the 
phenotype of donor matched FP- and SF-MSCs. 
 FP-MSCs SF-MSCs 
Grow Kinetics 
• Sustained average DT 
over 10 passages 
• Increase in average DT 
over 10 passages 
• Reduced proliferation 
from P4-5 
Surface marker 
profile 
• Positive for: CD73, 
CD90, CD105, 34, 
CD14 
• Negative for: CD19, 
CD45, HLA-DR, 
CD11b 
• Positive for: CD73, 
CD90, CD105, CD14 
• Negative for: CD19, 
CD45, HLA-DR, 
CD11b 
Multipotency 
 Chondrogenic, 
Osteogenic 
Adipogenic 
 Chondrogenic 
Osteogenic  
Adipogenic 
Response to 
inflammatory 
stimulus 
• No CD40, CD80, 
CD86 positivity 
• Increased HLA-DR  
• No change in HLA-G 
• Increased IDO 
• No CD40, CD80, 
CD86 positivity 
• Increased HLA-DR 
• No change in HLA-G 
• Increased IDO 
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Chapter 4: Results  
 
Assessment of the chondrogenic potential of 
donor matched MSCs and chondrocytes. 
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4.1 Introduction and aim 
BM-MSCs have been used in several clinical trials as an alternative cell source for use in 
cell therapies to treat cartilage injuries and OA421–423.  The process of acquiring a sample of 
bone marrow however, results in an additional painful procedure for the patient.  The FP and 
SCF are also accessible alternative sources of MSCs that have been considered for cartilage 
regeneration, however, few studies have directly compared the chondrogenic potency of 
BM-MSCs, FP-MSCs and SCF-MSCs to chondrocytes 311,424–426.  
An important factor to consider when comparing and contrasting the properties of different 
cell types is the “donor impact” as donor demographics, such as age and gender, are factors 
which are known to affect cell proliferation and differentiation capacity 380–382.  The impact 
of donor is particularly critical for autologous treatment regimes, and in deciding whether 
such a cell-based therapy represents the appropriate treatment option for an individual 
patient. Unravelling the impact of tissue and donor source and developing tools to predict 
the efficacy of cell-based treatments will likely result in the refinement of existing treatments 
and may provide valuable additional information for consideration during the decision 
making process of cost benefit versus clinical efficacy.   
Furthermore, low oxygen cell culture conditions have been extensively investigated as a 
means of improving the quality of cells before transplantation for cartilage repair342,427. 
Chondrocytes used for ACI are grown in standard culture conditions at an elevated oxygen 
level compared to the articular joint to which they return338. Since MSCs are currently being 
investigated as a replacement for chondrocytes, it is important to assess the differentiation 
potential of both cell types, preferably from the same donors. 
In this study, the chondrogenic potential of 4 different cell types (chondrocytes, BM-MSCs, 
FP-MSCs and SCF-MSCs) was examined.  Donor-matched cell types were compared in this 
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investigation to establish the impact of tissue source and donor on chondrogenic 
differentiation capacity and to continue the process of establishing a marker panel indicative 
of chondrogenic potency and likely clinical success. Such markers could be screened for and 
used in the selection of a particular cell type and/or sub-population of cells with enhanced 
chondrogenic capability prior to treatment. 
Previous studies assessing the chondrogenic potential of SF-MSCs have focused on cells 
sourced from the SF of end stage OA donors, with only a few studies investigating cells from 
normal or early OA donors388,428. Also, no study to date has applied a panel of markers as 
part of the chondrogenic characterisation of SF-MSCs. 
4.2 Experimental design-1 
Cartilage, BM, FP and SCF were obtained from 5 patients undergoing TKR (Table 4.1 
provides information on the demographics of the patients used in this study). Chondrocytes 
and MSCs were isolated as explained in sections 2.1.4, 2.1.1 and 2.1.2. Cells were 
maintained in standard tissue culture conditions (5% CO2, 21% O2, 37°C) up to P3, after 
which 6 chondrogenic pellets were created (section 2.2.2.3) for each cell population. A set 
of 6 sister pellets were differentiated in the SCI-tive™ hypoxic work station set at 5% CO2, 
2% O2, and 37°C. Measurements were performed to determine the oxygen levels in pre-
conditioned culture media in the SCI-tive™ and standard culture media (section 2.2.5.1). 
Prior to differentiation, cells were prepared for flow cytometry and RNA extraction for PCR 
(sections 2.2.3 and 2.4). After chondrogenic induction for 28 days, pellets were either frozen 
and processed for histology (toluidine blue staining and scoring), or quantitation of GAG via 
the DMMB and PicoGreen® assays (sections 2.2.2.8, 2.2.2.10 and 2.2.2.11).  
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Table 4.1: Demographics of patients used in experimental design 1 
Gender Age (years) Pathology 
Male 71 OA with extensive joint degeneration 
Female 67 OA with loss of joint space 
Female 75 Patello-femoral OA and loss of joint space in medial compartment 
Female 81 OA 
Male 74 OA with joint stiffness 
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A one-way ANOVA was used to compare means of variables across cell populations where 
applicable and multilevel modelling (Section 3.2) was used to correlate the expression of 
genes and the positivity of surface markers to the chondrogenic outcome of the various cell 
populations (histology/GAG quantitation). In these models, cell source, gene expression, and 
cell surface marker positivity were considered as fixed effects, while the donor was 
considered as a random effect. The donor effect was determined using Wald’s tests. A 
correlation matrix was used to determine associations between genes. Figure 4.1 gives an 
illustration of the experimental workflow. 
4.3 Experimental design-2 
SF was obtained from 15 patients undergoing cell therapy, and MSCs were isolated as 
described in section 2.1.3 (Table 4.2 provides information on the demographics of the 
patients used in this study). Cells were cultured until P3, after which flow cytometry and 
RT-qPCR analyses were undertaken prior to chondrogenic induction, which was assessed 
after 28 days via pellet histology and GAG quantification, performed as described in section 
4.2 (chondrogenic differentiation was not performed in hypoxic conditions). Pearson’s and 
Spearman’s correlation analyses were performed to find associations between gene 
expression and the positivity of surface markers prior to differentiation, to production of 
GAG by SF-MSCs after differentiation. 
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Figure 4.1: Workflow of experiments to compare the chondrogenic potential of donor 
matched chondrocytes and MSCs. All cell populations were isolated and expanded in 
normoxia. At passage 3 cells were characterised by flow cytometry and gene analysis and 
chondrogenically differentiated in normoxia and hypoxia. Correlation analyses were used to 
relate chondrogenic outcome with baseline flow cytometry and gene data.  
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Table 4.2: Demographics of patients used in experimental design 2 
Donor number Gender Age BMI 
1 Male 22 35.0 
2 Female 48 29.5 
3 Male 21 37.6 
4 Female 19 34.1 
5 Male 36 23.6 
6 Male 28 30.5 
7 Male 28 27.0 
8 Female 30 27.8 
9 Male 47 26.6 
10 Female 35 23.8 
11 Male 29 19.4 
12 Male 30 36.3 
13 Female 36 21.1 
14 Female 63 23.7 
15 Female 42 25.0 
BMI: body mass index 
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4.4 Results: Comparing the chondrogenic induction of donor matched chondrocytes 
and MSCs 
4.4.1 Measurement of oxygen levels in culture media 
The levels of dissolved oxygen in culture conditions were measured using two different 
probes (HI2040 and Seven2Go). The manufacturers of the HI2040 recommended that 
measurements be made while stirring the probe in the fluid, however, this was not required 
for the Seven2Go. Measurements were conducted with and without stirring for both probes 
for comparison. Dissolved oxygen was measured at 17.3-22.2% in the unconditioned media 
commonly used for tissue culture, whereas media that was preconditioned in the 
HypoxyCOOLTM displayed levels of dissolved oxygen in the 3.6-5.0% range (Figure 4.2 A-
B). These oxygen levels did not vary when monitored in cell cultures growing in hypoxic 
and normoxic conditions (Figure 4.2 C-D).  
 
4.4.2 Comparison of the formation of chondrogenic pellets in hypoxia and normoxia 
Cells that were grown in normoxia were chondrogenically differentiated in hypoxic and 
normoxic conditions. In general, cells failed to develop into 3D spherical pellets in hypoxic 
conditions, but instead formed fragile (disintegrating) structures (Figure 4.3), making them 
difficult to section and analyse. However, in normoxic conditions, as expected, cells 
successfully formed 3D chondrogenic pellets. For this reason, pellets formed in hypoxia 
were discarded and further analysis was only performed on pellets formed in normoxia.  
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Figure 4.2: Measurement of oxygen levels in culture media in various conditions.  
A-B) Dissolved oxygen in unconditioned media and media pre-conditioned in the 
HypoxyCOOL™. C-D) Dissolved oxygen in media from cell cultures in normoxia (21%) 
and hypoxia (2%). Measurements were obtained using the HI2040 and Seven2Go oxygen 
probes with and without stirring of the probes. Error bars represent the standard deviation 
(SD) of triplicate measurements.  
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Figure 4.3: Pellets formed in hypoxic and normoxic conditions. Cells were culture expanded 
in monolayer in normoxic conditions and subsequently differentiated in pellet cultures in 
hypoxic and normoxic conditions at passage 3. Representative images acquired using 
polarised light under a light microscope immediately after chondrogenic differentiation are 
shown. Scale bar represents 200 µm.  
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4.4.3 Immunoprofiling of cells for MSC and chondrogenic markers 
Flow cytometry analyses revealed immunopositivity for the MSC markers CD73, CD90 and 
CD105 for all of the populations of cells examined, but to varying levels (Table 4.3). FP and 
SCF derived MSCs adhered to ISCT280 criteria (i.e. were >95% positive), chondrocytes and 
BM-MSCs also adhered to ISCT criteria for CD90 and CD105 positivity, but were <95% 
positive for CD73 (Table 4.3). All of the cell populations tested were <2% positive for CD19, 
CD45 and HLA-DR, in line with ISCT criteria. Some positivity was recorded in all of the 
cell populations tested for CD34 with the highest levels (62.2-74.4% positivity) seen in the 
adipose derived MSCs, which also adheres to ISCT criteria352 (Table 4.3). CD14 was present 
on all the cell populations tested, ranging on average between 14.8-21.4% positivity for each 
cell type (Figure 4.5). Interestingly, chondrocytes and BM-MSCs displayed significantly 
higher levels of CD106 than FP and SCF-MSCs (p<0.001).  
Differences between cell types for putative chondrogenic potency marker positivity were 
noted for CD49c, CD166 and CD39 (Figure 4.5). Chondrocytes showed significantly greater 
positivity for CD49c compared to SCF-MSCs (p=0.014), whereas the adipose derived MSCs 
showed significantly higher positivity for CD166 compared to chondrocytes or BM-MSCs 
(p=0.0046 and p=0.0002, respectively for FP-MSCs and p=0.021 and p=0.01, respectively 
for SCF-MSCs). No differences were noted for CD44, CD151 or CD271, in that all cell 
types were >95% positive for CD44 and CD151, and <5% positive for CD271. No positivity 
for αROR2 as recorded. 
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Table 4.3: Immunoprofiles for MSC markers on cell culture expanded cells at passage 3 
prior to chondrogenic differentiation (n=6). 
 
 Percentage of positive cells (mean% ±SD) 
Surface  
Markers Chondrocytes  BM-MSCs FP-MSCs SCF-MSCs 
CD73 91.2 (±17.7) 87.1 (±18.0) 99.9 (±0.1) 99.9 (±0.0) 
CD90 98.0 (±3.8) 96.4 (±2.5) 99.9 (±0.0) 99.9 (±0.1) 
CD105 99.4 (±0.7) 96.7 (±4.1) 98.1 (±4.1) 99.9 (±0.1) 
CD34 9.5 (±8.0) 5.1 (±5.4) 74.5 (±15.6) 62.2 (±20.8) 
CD45 1.5 (±0.6) 1.3 (±0.4) 2.4 (1.3) 1.6 (±0.6) 
CD14 20.4 (±27.1) 14.8 (±12.0) 17.9 (±36.5) 21.4 (±39.3) 
CD19 1.3 (±0.8) 2.0 (±1.2) 1.4 (±0.6) 1.6 (±0.5) 
HLA-DR 1.4 (±0.6) 1.3 (±0.8) 1.7 (±0.7) 1.3 (±0.6) 
CD106 71.9 (±39.8) 67.5 (±30.3) 29.9 (±43.3) 31.1 (±45.6) 
  
 134 
 
 
 
 
 
Ch BM FP SCF
0
50
100 ***
***
***
***
CD34
Ch BM FP SCF
Po
sit
ive
 ce
lls
 (%
)
Ch BM FP SCF
Po
sit
ive
 ce
lls
 (%
)
A B
C
 Figure 4.4: Immunoprofile of MSC selection markers that showed significant variability (a 
2-way ANOVA was used to compare marker positivity between cell populations). A) CD34 
was significantly more positive FP and SCF-MSCs compared to chondrocytes and BM-
MSCs (p<0.001). B) No significant difference was noted between the cell populations for 
CD14 positivity. C) Chondrocytes and BM-MSCs were significantly more positive for 
CD106 than FP and SCF-MSCs.  
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Figure 4.5: Immunoprofiles for putative chondrogenic potency markers on culture expanded 
cells prior to chondrogenic induction. Flow cytometry was used to detect the percentage of 
positive cells for each marker on monolayer cell populations of chondrocytes (Ch), bone 
marrow MSC (BM), fat pad MSC (FP) and sub cutaneous fat MSC (SCF) prior to 
chondrogenic differentiation in pellet cultures. A) All cell populations showed high 
positivity for CD44. B) Chondrocytes showed significantly higher levels of CD49c than 
SCF-MSCs. C) FP- and SCF-MSCs had a significantly higher positivity for CD166 than 
chondrocytes and BM-MSCs. D) No significant difference was observed for CD151 which 
was highly expressed in all cell populations. E) The positivity of CD39 was similar for across 
cell populations. F)   Data shown are the means +/- the standard deviation of 5 donors for 
each cell population. One-way ANOVA and post-hoc Bonferroni tests were used to test for 
significant differences in the positivity of cell surface markers between cell types. 
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4.4.4 Gene expression prior to chondrogenic differentiation 
 Of the cell types tested in this study, the chondrogenic potency genes (Sox9, Coll II, 
aggrecan, and FRZB) were expressed at the highest levels in culture expanded chondrocytes 
(Figure 4.6 A, B and D). Further, chondrocytes demonstrated the lowest expression profiles 
for the hypertrophic genes tested (Alk1 and Coll X). Of the MSC cell populations examined, 
BM-MSCs displayed chondrogenic and hypertrophic profiles that most closely resembled 
those of culture expanded chondrocytes. In contrast, the adipose sources of MSCs 
investigated (FP-MSCs and SCF-MSCs) were least like culture expanded chondrocytes and 
demonstrated the lowest chondrogenic potency and the highest hypertrophic gene expression 
profiles. SCF-MSCs expressed Alk1 at significantly higher levels than chondrocytes and 
BM-MSCs (p=0.044 and p=0.034, respectively) (Figure 4.6 F). 
 Gene expression associations for all of the cell types examined in this study were 
tested using Pearson’s correlation coefficient analyses and are presented in a correlation 
matrix (Table 4.4). Significant interactions noted between the chondrogenic potency genes 
were as follows; aggrecan was positively associated with Sox9, Coll II and FRZB, in 
addition, Sox9 was positively associated with Coll II (p=0.026). There was also a significant 
negative association observed between Coll II and Alk-1 expression (p=0.001).  
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Figure 4.6: The expression of chondrogenic and hypertrophic genes in monolayer cell 
populations at passage 3, prior to chondrogenic induction. Gene expression is shown relative 
to the reference genes PPIA and TBP.  Data shown are the means +/- the standard deviation 
of 5 donors for each cell population. One-way ANOVA and post-hoc Bonferroni tests were 
used to test for significant differences in gene expression levels between cell types.  
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Table 4.4: Pearson’s correlation analysis matrix comparing genes that are predictive of 
chondrogenic potential. Significant values are highlighted. 
  Alk-1 Coll X FRZB Aggrecan Coll II 
Sox-9 r=-0.36 p=0.15 
r=0.28 
p= 0.28 
r=0.43 
p= 0.09 
r=0.70 
p= 0.001 
r=0.54 
p= 0.026 
Coll II r=-0.74 p= 0.001 
r=0.30 
p=0.23 
r=0.45 
p= 0.07 
r=0.53 
p= 0.03   
Aggrecan r= -0.44 p= 0.076 
r= 0.25 
p= 0.33 
r= 0.65 
p= 0.005     
FRZB r= -0.33 p= 0.19 
r= 0.26 
p= 0.32       
Coll X r= -0.33 p= 0.20         
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4.4.5 Assessment of GAG production and pellet sizes after chondrogenic 
differentiation 
After 28 days of chondrogenic differentiation, donors demonstrated variability in 
chondrogenic capacity across the cell types tested. When results from individual donors were 
examined, chondrocytes consistently produced superior chondrogenic pellets in terms of 
GAG quantitation (using the DMMB/DNA assays) and histological analyses, but the 
propensity for MSCs to undergo chondrogenic differentiation was variable between 
individuals. Although chondrocytes produced the highest average amount of GAGs 
compared to MSCs, no statistically significant difference was found (Figure 4. 7 A). 
Similarly, significant variability was observed in the amount of DNA produced in pellets 
with no significant difference in between cell types (Figure 4. 7), suggesting that some of 
the cell types continue to proliferate while undergoing chondrogenesis. SF-MSCs produced 
the most average DNA per pellet, whereas chondrocytes produced the least amount of DNA 
per pellet. 
Normalised GAG/DNA analyses appeared to match the histological findings noted for each 
patient, i.e. larger pellets with prominent matrix metachromasia had the highest levels of 
GAG measured (Figure 4.8). Pearson’s correlation analyses across donors confirmed that 
there was a significant association between pellet GAG quantitation and histological score 
(p=0.01). When donors were grouped and chondrogenic analyses were performed comparing 
differentiation between cell types, chondrocytes consistently demonstrated the most 
pronounced chondrogenic differentiation in terms of GAG/DNA analyses; they produced 
significantly more GAG than BM and SCF derived MSCs (p=0.032 and p=0.030, 
respectively, Figure 4.9 A). In terms of chondrogenic score SCF-MSC scores were 
significantly lower than chondrocytes, BM and FP derived MSCs (p<0.0001, p=0.0195 and 
p=0.0082 respectively) and chondrocytes scored significantly higher than BM-MSCs 
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(p=0.013, Figure 4.9 B). Chondrocytes also produced the largest pellets (in terms of 
diameter) compared to any of the MSCs tested (p<0.0001, Figure 4.9 C). 
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Figure 4. 7: Total GAG and DNA produced per pellet after chondrogenic differentiation. A) 
GAG content (µg) in pellets cultures from chondrocytes (Ch), bone marrow MSC (BM), fat 
pad MSC (FP) and subcutaneous fat MSC (SCF) after 28 days of chondrogenic 
differentiation as determined from the DMMB assay. B) DNA content (µg) in pellets after 
28 days of chondrogenic differentiation as determined from the PicoGreen assay. Data is 
shown as individual points for each donor, with the mean and SD. 
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Figure 4.8: Assessments of chondrogenic differentiation in pellet cultures for individual 
donor. Cells were expanded up to 3 passages before chondrogenic differentiation. A) 
Production of GAG/DNA in pellet cultures from chondrocytes (Ch), bone marrow MSC 
(BM), fat pad MSC (FP) and subcutaneous fat MSC (SCF). GAG were measured after 
chondrogenic differentiation using the DMMB assay and normalised to the DNA content of 
pellets, each donor is represented in individual graphs. Data shown are the means +/- the 
standard deviation of triplicate pellets.  B) Chondrogenic pellets from Ch, BM, FP and SCF 
showing representative toluidine blue staining for each donor. Scale bars represent 200 µM. 
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Figure 4.9: Chondrogenic assessments of pellet cultures across cell types for all donors 
combined. A) Production of GAG/DNA in pellet cultures from chondrocytes (Ch), bone 
marrow MSC (BM), fat pad MSC (FP) and subcutaneous fat MSC (SCF).  (B) Chondrogenic 
histology scores for Ch, BM, FP and SCF. (C) Mean chondrogenic pellet diameter (µm) for 
Ch, BM, FP and SCF. Data shown are the means +/- the standard deviation of triplicate 
pellets and 5 donors for each cell population. One-way ANOVA and post-hoc Bonferroni 
tests were used to test for significant differences between cell types. 
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4.4.6 Association between surface markers or gene expression and GAG production 
Multilevel modelling analysis was performed in an effort to identify chondrogenic potency 
predictors prior to chondrogenic differentiation. This analysis demonstrated that Alk1 
expression and CD166 immunopositivity both negatively associated with GAG quantitation 
in pellet cultures (Table 4.5). However, CD49c and CD39 expression positively associated 
with GAG quantitation and histological score respectively, post-chondrogenic 
differentiation (Table 4.5).  Sox9 expression positively associated with chondrogenic 
histological score, whereas expression of the hypertrophic genes Coll X and Alk1 were 
shown to negatively associate (Table 4.5).  
Further multilevel model analysis showed that cell type (but not donor) had a significant 
impact on the predictive aspect of gene expression for both of the chondrogenic assessments 
tested i.e. GAG quantitation (p<0.001) and histological outcome (p<0.001). Similarly, cell 
type (but not donor source) had a significant impact on the predictive aspect of cell surface 
marker positivity with regard to both GAG quantitation (p<0.001) and histological outcome 
(p<0.001). Using an interaction term in a multilevel model consisting only of the cell types 
and one predictive variable. results showed that the relationship between Sox9/Alk1 
expression and the histological outcome varied significantly across cell source (p=0.03 and 
p=0.034 respectively), which was not the case for Coll X (p=0.07). The relationship between 
Alk1 expression and GAG quantitation also did not vary across cell types (p=0.43). In terms 
of immunopositivity, the relationship between CD39 positive cells and histological outcome 
varied significantly between cell types (p<0.001) as did the relationship between CD49c or 
CD166 positive cells and GAG quantitation (p<0.001 for both markers). A Spearman’s 
correlation analysis was also conducted to determine a link between the levels of CD34 and 
CD106 (due to the variability in the and the chondrogenic outcome of the cell types; however 
no significant association was found. 
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Table 4.5: Multilevel modelling of how gene expression and surface markers relate to 
chondrogenic outcome. Significant associations are highlighted. 
                                                                                                                                                                 
  
 GAG/DNA  Histology score 
 Coefficient 95% CI p values  Coefficient 95% CI p values 
Sox-9 -5.6 -11.7, 0.5 0.07  1.01 0.18, 1.84 0.02 
Coll II 22.3 -7.8, 52.4 0.14  3.96 -0.16, 8.08 0.06 
Aggrecan -0.003 -0.2, 0.2 0.97  -0.019 -0.04, 0.004 0.10 
FRZB 33.1 -27.4, 93.6 0.3  0.86 -7.46, 9.18 0.83 
Coll X -0.01 -0.02, 0.003 0.12  -0.002 -0.004, -0.0002 0.03 
Alk-1 -9.5 -12.2, 6.7 <0.001  -0.61 -0.99, -0.23 0.003 
CD49c 0.2 -0.1, 0.5 0.018  -0.04 -0.02, -0.01 0.63 
CD166 -0.3 -0.5, -0.04 0.03  0.01 -0.04, 0.034 0.16 
CD39 -0.02 0.01, 0.4 0.78  0.024 0.01, 0.04 0.002 
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4.5 Results: Predictive analysis of the chondrogenic potential of SF-MSCs 
4.5.1 Immunoprofiling SF-MSCs for MSC and chondropotency markers  
SF-MSCs were negative for CD19, CD45 and HLA-DR (≤2%), but showed positivity for 
CD34 (28.4%±29.0) and CD14 (53.8%±36.0), which does not fit the recommended ISCT 
criteria (Table 4.6). Although CD105 (98.9%±1.0) was consistently positive, CD73 
(89.0%±18.0) and CD90 (89.8±16.0) positivity varied markedly across donors, again not in 
accordance with ISCT criteria. SF-MSCs were positive for CD44 (98.97%±1.0), CD151 
(99.51%±1.0), CD49c (26.74%±18.0), CD39 (26.77±20.0) and CD271 (5.80±5.0). The 
immunomodulatory marker CD106 (87.15%±12.0) was also expressed on SF-MSCs.  
 
4.5.2 Expression of chondrogenic and hypertrophic genes in SF-MSCs 
SF-MSCs showed significant variability between donors with regards to the expression of 
chondrogenic and hypertrophic genes (Table 4.7). SF-MSC expression levels of Sox9 and 
aggrecan relative to reference genes were similar to the levels obtained for SCF-MSCs in 
the previous results section (section 4.4.4), whereas the expression of FRZB and Alk-1 in SF-
MSCs were comparable to FP-MSCs and BM-MSCs, respectively. 
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Table 4.6: The immunoprofile of SF-MSCs for surface markers at passage 3, prior to 
chondrogenic differentiation. 
Marker Mean positivity (±SD) 
CD19 2.1 (±0.30) 
CD34 28.4 (±29.0) 
CD45 2.1 (±0.40) 
HLA-DR 1.3 (±0.7.0) 
CD14 53.8 (±36.0) 
CD73 89.0 (±18.0) 
CD90 89.8 (±16.0) 
CD105 98.9 (±1.0) 
CD39 26.77 (±20.0) 
CD44 98.97 (±1.0) 
CD49c 26.74 (±18.0) 
CD151 99.51 (±1.0)  
CD106 87.15 (±12.0) 
CD166 23.42 (±23.0) 
CD271 5.80 (±5.0) 
 
 
 
Table 4.7: The expression of chondrogenic genes relative to reference genes prior to 
chondrogenic differentiation by SF-MSCs. 
Gene Mean (±SD) 
Sox 9 0.28 (±0.26) 
Coll II 7.0x10-3 (1.3x10-2) 
Aggrecan 15.27 (±8.6) 
FRZB 4.3x10-2 (±3.5x10-2)
Coll X 1.6x10-3 (±1.5x10-3)
Alk-1 0.20 (±0.16) 
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4.5.3 Assessment of GAG production in SF-MSCs after chondrogenic differentiation 
SF-MSCs produced relatively low amounts of GAG with a mean of 3.5 µg (±2.7) of GAG 
for the 15 donors tested. Histology confirmed this low production of GAG in that only weak 
patches of positive staining were observed for toluidine blue through the pellets (Figure 4.10 
A). Donor 4 however produced on average 12.7 µg of GAG, which was markedly higher 
than the average produced by other donors. This increased GAG production was confirmed 
with histological analyses, in that uniform metachromatic staining was observed throughout 
the pellet (Figure 4.10 B). The average diameter of the SF-MSCs pellets after chondrogenic 
differentiation was 800 µm (range 659 µm-954 µm). 
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Figure 4.10: The production of GAG by SF-MSCs at passage 3. A) Quantification of GAG 
from DMMB/DNA assays. Error bars represent the SD of triplicate pellets for the same 
donor. B) Images are of toluidine blue stained pellets. Scale bar=200 µm. 
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4.5.4 Correlation between surface markers, gene expression and donor demographics 
compared to the production of GAG/DNA and histological outcome after 
chondrogenic differentiation. 
The cells from donor 4 produced markedly more GAG/DNA compared to the other donors 
tested, which caused the occurrence of an outlier that significantly influenced statistical 
analyses (Figure 4. 11). For instance, the associations between CD49c positivity and 
GAG/DNA production, showed significantly different trends depending on whether the 
outlier of donor 4 was included in the analyses. When donor 4 was included in the correlation 
analyses, no significant association was found between surface markers and GAG/DNA or 
histological scores. As a result, and for simplicity, data for donor 4 was excluded from all 
statistical analyses. Of the proposed chondrogenic markers, only CD49c showed a 
significant (negative) correlation with the production of GAG/DNA (Table 4.8). Due to their 
unexpected variability for positivity of CD14, CD73 and CD90 across donors, analyses were 
run to determine whether the positivity of these markers was associated with the production 
of GAG/DNA by SF-MSCs. The results showed a negative correlation between CD90 
positivity and GAG/DNA production. No such pattern was observed for CD14 or CD73. No 
significant correlations were established between surface markers and histological scores.  
Correlation analyses revealed that only the expression of CollII in SF-MSCs prior to 
chondrogenic induction was positively associated with the production of GAG (Table 4.8); 
no such trend was observed when correlating gene expression to histological scores. 
Interestingly, the cells from Donor 4, which produced the highest amount of GAG, also 
showed the highest expression of Sox9.  
Neither donor age nor BMI correlated with the chondrogenic potential of SF-MSCs (Table 
4.8). However, it is again noteworthy that donor 4, whose cells showed the highest 
chondrogenic potential, were derived from the youngest donor.  
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Figure 4. 11: Illustration of the impact of donor 4 as an outlier on correlation analyses. A-B) 
Scatterplots show that donor 4 significantly influences the trend of the correlation between 
the positivity of CD49c before differentiation and the production of GAG/DNA after 
differentiation of SF-MSCs. C-D) Scatterplots show that donor 4 significantly influences the 
trend of the correlation between the gene expression of Sox9 before differentiation and the 
production of GAG/DNA after differentiation of SF-MSCs. In this instance, the correlation 
is positive when donor 4 is included in the analysis, whereas the association was negative 
without donor 4. 
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Table 4.8: Correlation between the positivity of surface markers before chondrogenic 
induction with the production of GAG and histological score after chondrogenic 
differentiation of SF-MSCs. 
 GAG/DNA Histology score  r p value r p value 
Surface markers  
CD49c p -0.54 0.047 -0.04 0.92 
CD166 p -0.31 0.28 -0.18 0.64 
CD39 s -0.02 0.95 -0.25 0.52 
CD271s 0.35 0.21 0.08 0.85 
CD73 s -0.16 0.58 -0.14 0.71 
CD90 s -0.6 0.03 -0.11 0.78 
CD14 p -0.45 0.11 -0.37 0.31 
Sox9 s -0.22 0.45 0.59 0.12 
Genes  
CollII s 0.73 0.007 -0.56 0.15 
Aggrecan p -0.12 0.70 -0.15 0.73 
FRZB p 0.11 0.71 0.28 0.50 
CollX s 0.37 0.21 -0.45 0.27 
Alk1
s 0.03 0.93 -0.26 0.54 
Demographics 
Age p 0.05 0.86 -0.62 0.09 
BMI p 0.09 0.7 0.32 0.47 
s =Spearman’s correlation used for non-normally distributed data; p =Pearson’s correlation 
used for normally disturbed data. 
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4.6 Discussion 
Low oxygen conditions have been explored as a method for improving the in vitro expansion 
of cells aimed at cartilage regeneration. However, researchers often fail to measure or report 
the true levels of oxygen present in hypoxic culture platforms, or ensure that oxygen levels 
are sustained throughout the whole culture period, including during media changes. The 
investigations reported here revealed that although culture media was pre-conditioned at 2% 
and the hypoxic work station was programed to incubate at 2%, the true levels of oxygen in 
the culture media were above 2% but less than 5%. 
Oxygen concentrations are essential in maintaining the various stem cell niches in vivo, but 
also in preserving the phenotype of stem cells in vitro429,430. Hypoxic conditions (1-5% O2) 
enhance the isolation, proliferation and differentiation potential of BM-MSCs and adipose 
derived MSCs339,431,432. The failure of cells grown in hypoxia to form 3D pellets in hypoxia 
shown in this chapter requires further investigation, to understand their adaptability to low 
oxygen after being exposed to an oxygen-rich environment during expansion. It is 
challenging to compare the in vitro results obtained in this results chapter to other published 
studies due to the lack of sufficient information on the detailed culture methods used. For 
example, many hypoxia studies fail to report whether or not pellets were removed from 
hypoxic conditions for feeding, or whether preconditioned media was used427,433.  
Although results in the literature appear to be contradictory432,434, one study has shown that 
low oxygen levels (below 5%) were detrimental to the chondrogenic potential of SCF-MSCs 
that were culture expanded in normoxic conditions435. Normoxia expanded chondrocytes, 
BM-MSCs and FP-MSCs have been shown to have enhanced chondrogenic propensity in 
hypoxia341,427,436. When BM-MSCs were expanded in 3% or 21% O2 and differentiated in 
both 3% and 21% O2, it was reported that cells produced more GAG and expressed higher 
levels of chondrogenic genes (Sox9 and Coll II) when differentiated in 3% compared to 21% 
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O2 427. Similar results were obtained when chondrocytes expanded in 21% O2 were 
differentiated in both 2% and 21% O2341. FP-MSCs also displayed superior chondrogenic 
potential in 5% compared to 20% O2 after expansion in 21% O2436. These results do not 
corroborate the findings presented in this chapter; possibly due to the different experimental 
conditions employed such as donor demographics, tissue source (e.g. tibial plateau as 
opposed to iliac crest for BM-MSCs) and cell density of chondrogenic pellets. Importantly, 
these contradictory results call for studies with more controlled hypoxic environments. The 
results presented here were part of a more comprehensive experiment, which included the 
isolation and culture of chondrocytes in hypoxia. Interestingly, chondrocytes isolated and 
expanded in low oxygen conditions displayed a superior chondrogenic phenotype (as shown 
by higher GAG and type II collagen production) compared to the ones isolated and expanded 
in normoxia (Appendix 4). 
While some investigations have compared the in vitro chondrogenic potency of donor 
matched chondrocytes and FP-MSCs (porcine model)437, or matched FP- and SCF-MSCs 
(human)405, no such study has been conducted for matched chondrocytes, BM-, FP- and 
SCF-MSCs together. As expected, FP and SCF-MSCs showed higher levels of CD34 than 
BM-MSCs and chondrocytes, due to their origin from adipose tissues352. Chondrocytes 
appear to exhibit a similar MSC immunoprofile to BM-MSCs, which could be an indication 
of dedifferentiation as chondrocytes perhaps revert to a phenotype that is more like MSCs 
after being culture expanded. Previous research directly comparing matched chondrocytes 
and BM-MSCs has shown that the two cell types displayed multipotency and had similar 
surface marker profiles. In results section 4.4, known immunoprofiles and gene profiles 
believed to be indicative of chondrogenic potential were tested in a predictive model 
comparing chondrocytes, BM, FP and SCF derived MSCs from 5 matched human donors. 
In terms of immunoprofile, the putative chondrogenic markers CD44, CD151 and CD271 
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were excluded from predictive analyses due to their uniform expression levels across cell 
types. CD49c, CD166 and CD39 were also present on all of the cell populations examined 
but to varying degrees and as such were taken forward into chondrogenic potency analysis.   
The expression of the chondrogenic genes, Sox9, CollII, ACAN and FRZB, and the 
hypertrophy associated genes, CollX and Alk1, were determined in the various cell 
populations prior to chondrogenic differentiation. In doing so, it was confirmed that for all 
the cell populations tested, the master regulator of chondrogenesis, Sox9, correlates with the 
expression of Coll II and ACAN and that the hypertrophy associated marker Alk1 is 
negatively associated with Coll II expression. In addition, the data presented in this results 
section shows that there is a positive association between the expression of FRZB and ACAN, 
which has been previously reported in the chondrogenic ATDC5 cell line438.  
Following chondrogenic differentiation in cell pellets, quantitative assessment of GAG 
synthesis demonstrated that chondrocytes generate significantly more GAG compared to 
BM-MSCs and SCF-MSCs but not FP-MSCs, with some notable variation between donors. 
These findings are comparable to previous studies which have shown that chondrocytes and 
FP-MSCs display similar levels of GAG production and that FP-MSCs produce more GAG 
than BM-MSCs 439 and donor matched SCF-MSCs405. Further, assessments for chondrogenic 
differentiation status in terms of GAG quantitation and histological score were significantly 
correlated. Chondrocyte-generated pellets consistently produced the highest scores, which 
were significantly greater than those formed by BM- or SCF-MSC populations, whereas 
SCF-MSCs pellets produced the lowest scores of all the cell populations examined. 
Measurements of the diameter of pellets showed that chondrocytes produced the largest 
pellets compared to BM and SCF derived pellets.  
Interestingly, stem cells appear to generate pellets with a higher cellularity compared to 
chondrocytes based on DNA content and histological observations. This could be due to 
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more cell proliferation in stem cell pellets during differentiation. Taken together, this data 
suggests that, not too surprisingly, culture expanded chondrocytes have the greatest 
propensity for chondrogenic differentiation in vitro, closely followed by FP-MSCs and then 
BM-MSCs, whereas SCF-MSCs consistently produced the worst chondrogenic outcome 
measures, regardless of the assessment used. These findings are corroborated by other 
studies that have reported paired comparisons between these cell types310,405,425,440,441. 
However, this is the first time, to date, that all four of these cell populations have been 
examined in the same study, allowing for a hierarchical chondrogenic potency comparison 
with the impact of donor taken into account by donor matching the samples tested. 
The multilevel modelling analyses performed in this study have allowed the exploration of 
the relationships between putative chondrogenic potency markers (gene expression and 
surface marker profiles) and chondrogenic outcome, whilst simultaneously examining the 
potential influence of donor and cell type. These analyses are derived from a small donor 
sample size, acknowledged as a limitation of the study, and should be interpreted with 
caution.  
Nonetheless, multilevel analysis indicated that CD49c and CD39 immunopositivity positively 
predict GAG production and histological score respectively in cell pellets, with no significant 
difference observed between donors. Other studies have shown that CD49c positivity on 
chondrocytes and CD39 positivity on synovium derived MSCs is associated with increased in 
vitro chondrogenic potential320,353, however, these relationships across matched chondrocytes, 
BM-MSCs and adipose derived MSCs presented here have not been demonstrated before. 
Perhaps surprisingly CD166 positivity did not indicate chondrogenic potential, as has been 
previously shown354; in fact immunopositivity for this marker was negatively associated with 
chondrogenic assessments. One potential explanation for this finding might be that CD166 
was expressed at significantly greater levels on SCF-MSCs compared to chondrocytes and 
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BM-MSCs and that the data shown in results section 4.4 indicates that SCF-MSCs consistently 
demonstrate a poor propensity for chondrogenic differentiation.  Interestingly, in this multi-
cell type, donor matched study, the source of cells significantly influences both GAG 
production in pellet culture and also the histological score of the pellet. In contrast, the donor 
had no demonstrable impact on either of the chondrogenic assessments tested, although these 
results are based on a small cohort of donors and a larger cohort might be required to 
demonstrate a “donor effect”.   
 
In addition, multilevel modelling has revealed that the expression of Alk1 and Coll X are 
negatively associated with chondrogenic potential in terms of histology scores, expression 
of Alk1 and the GAG content of chondrogenically induced pellet cultures. In contrast, Sox9 
expression prior to chondrogenic differentiation positively correlated with histological pellet 
scores. Some of these gene associations match a previous report comparing FP-MSCs and 
SCF-MSCs405. The novelty of this study is that some of these chondrogenic potency gene 
associations hold true across all of the cell types examined. The poor correlation between 
the baseline (pre-differentiation) expression of the chondrogenic genes Coll II and ACAN is 
noteworthy and comparable to findings in other studies 442,443. For example, one study has 
confirmed that the transplanted chondrocyte expression levels of ACAN and Coll II in ACI 
had no bearing on clinical outcome444. Further, it has been demonstrated that the genome-
wide transcription profile of Coll II and ACAN (amongst other genes) did not correlate with 
the production of GAG in a single cell analysis of bovine MSCs and chondrocytes443. The 
authors attribute this finding to the heterogeneity in single cell transcriptional profiles. It is 
extremely likely that the gene analysis presented in results section 4.4, derived from 
heterogenous cell populations and four very different tissue sources will vary to an even 
greater extent. 
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The chondrogenic potency of SF-MSCs was also assessed in results section 4.5, but not from 
donors with end stage OA as in the previous results section (4.4). The immunoprofile of SF-
MSCs indicate that they do not meet the recommended ISCT criteria. As stated previously 
it is possible that a heterogeneous cell population was enriched from the SF of patients 
receiving ACI. Furthermore, these results corroborate observations by another group where 
human SF-MSCs, obtained before and after ligament surgery, did not fully meet the ISCT 
recommended immunoprofile 318. The positivity of CD14 suggests the presence of 
macrophages and other immune cells as explained in section 3.8. The levels of CD34 also 
show the possible presence of perivascular and or endothelial cells404. The heterogeneity of 
these cells is shown by the lower than expected levels of CD73 and CD90, which did not 
meet the 95% positivity recommended by ISCT. Furthermore the low positivity of proposed 
chondrogenic markers CD49c, CD39 and CD271 were also previously reported 315,388,428,445.  
The levels of GAG observed for SF-MSC derived pellets presented in this chapter are 
comparable with previous reports315. The relatively low production of GAG could be 
explained by the heterogenous phenotypes of these cells, as indicated also by the flow 
cytometry results obtained. The patchy metachromatic staining of the chondrogenic pellets 
suggests that there are a subpopulation of SF-MSCs with some chondrogenic potential, 
although the relative abundance of these cells was perhaps insufficient to produce substantial 
detectable quantities of GAG in the experiments described. One possible explanation for this 
observation could be the impact that the degenerative state of the joint could have on the SF-
MSC phenotype. It is believed that SF-MSCs may be recruited from other tissues in the joint, 
such as synovium, bone marrow and ligament318  and it has been shown that the OA joint SF 
contains more SF-MSCs388. It could be hypothesised that the donors in this study did not 
have sufficient joint degeneration to trigger the recruitment of MSCs into the SF. For 
instance, it has been suggested that chemoattractant molecules released from a damaged 
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ligament could be responsible for the increase in SF-MSCs noted after ligament surgery 
(within weeks) 318. 
The negative correlation established between CD49c and GAG production might suggest 
that the influence of this marker as an indicator of chondrogenesis in chondrocytes may not 
be valid for SF-MSCs353. The available literature that reports the use of surface markers as 
possible predictors of chondrogenic potential focuses predominantly on chondrocytes, and 
to a lesser extent, BM-MSCs. CD49c is part of the integrin alpha3 sub-unit, a surface 
receptor that adheres chondrocytes to components of the cartilage ECM such as laminin and 
collagens353,446. The data obtained in results section 4.5 indicates that SF-MSCs are 
composed of a heterogeneous cell population, most of which are likely to originate from 
different microenvironments in vivo which could explain the variability in the expression of 
CD49c observed across SF-MSC donors. Furthermore, the changes in expression that occur 
in response to cell culture expansion may vary in the individual cell types that combine to 
form the SF-MSC cell population. The negative correlation noted between CD90 and GAG 
production was unexpected. Since CD90 is an MSC characterisation marker, it can be 
theorised that the presence of fewer MSCs in the mixed population of SF cells resulted in a 
reduced chondrogenic phenotype.  
When correlating gene expression to GAG production by SF-MSCs, only COLL II showed 
a significant association, a finding that has not been previously reported. Donor 4, which 
showed the highest expression of Sox9 also showed enhanced production of GAGs and a 
high chondrogenic histological score, comparable to the results obtained in section 4.4 for 
other established MSC sources. This might indicate that the MSCs within the SF for this 
donor were more uniform and could have originated from one of these tissue sources. The 
“disconnect" between other known chondrogenic genes and the differentiation capacity of 
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SF-MSCs is akin to the results obtained for donor matched chondrocytes, BM-MSCs, FP-
MSCs and SCF-MSCs in results section 4.4.  
Donor age and BMI did not correlate with the chondrogenic outcome measures examined 
for SF-MSCs. Donor 4 was the youngest donor (19 years old) and perhaps unsurprisingly 
produced SF-MSCs with the best chondrogenic outcome, although cells from a donor only 
2 years older (donor 3) did not follow the same trend. Previous investigations have shown 
that younger donors produce BM-MSCs with superior chondrogenic potential compared to 
cells derived from older donors381. 
4.7 Conclusion 
The main findings of this chapter are illustrated in Figure 4.12. The results presented here 
demonstrate the chondrogenic predictive value of high levels of Sox9 and low levels of 
COLL X or Alk1 expression as well as immunopositivity for CD49c and CD39 in 
chondrocytes, BM-MSCs, FP-MSCs and SCF-MSCs. The expression of COLL II and 
immunopositivity for CD49c and CD90 have also been shown to be predictive of 
chondrogenic potential in SF-MSCs. Using donor-matched samples has shown that, cell type 
significantly influenced the chondrogenic potency of the MSC sources examined in this 
study. MSCs sourced from the infrapatellar FP of the knee or bone marrow provide the ‘next 
best’ alternative to chondrocytes, in terms of in vitro chondrogenic differentiation capacity. 
Further, the results presented in this chapter have consistently shown that SCF-derived 
MSCs and SF-MSCs have the poorest propensity for chondrogenic differentiation. These 
findings have important clinical implications, not only for the understanding of MSC 
chondrogenic differentiation capacity, but also for the development of cell therapy strategies 
to screen for and select potent cell types prior to application in the treatment of cartilage 
injuries. Follow-on studies should be geared towards understanding the molecular 
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mechanisms that account for the differences observed between cell populations and in the 
development of methods to select cells with enhanced chondrogenic potential. 
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Figure 4.12: Summary of the principle findings presented in Chapter 4. A) Chondrocytes 
and MSCs isolated from the knee joint and expanded in normoxic conditions (21%) show 
poor chondrogenic ability in low oxygen (2%), but display enhanced chondrogenesis in 
normoxia. B) The positivity of surface markers CD49c and CD39 and the expression of Sox9 
are positive predictors of the chondrogenic ability of chondrocytes and MSCs. On the 
contrary, the positivity of CD166 and expression of Alk-1 and Coll X are negative predictors 
of chondrogenesis these cells.  
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Chapter 5: Results  
 
Characterisation of joint derived macrophages and 
adipocytes: implications for inflammation in OA. 
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5.1 Introduction and aim 
In an attempt to understated the parameters involved in the progression of OA, recent studies 
have revealed the role played by joint inflammation, and more specifically synovial 
inflammation447. Macrophages, which are located in and along the synovial membrane, are 
one of the cell types responsible for the production of pro-inflammation molecules that 
contribute to the acceleration of joint degeneration. The ability of these cells to switch from 
a pro-inflammatory phenotype (M1) to an anti-inflammatory (M2) has not been investigated 
in the context of OA pathogenesis, and has thus attracted tremendous research interest for 
the development of novel therapies. Although the contribution of the infrapatellar FP to joint 
inflammation still remains undefined, studies have indicated the presence of macrophages 
within this adipose tissue448. In addition, certain regions of the FP are in direct contact with 
the synovium, which has led to the question of whether inflammatory processes occurring 
in the synovium can influence the FP (and vice versa). 
Obesity is considered a risk factor for the development of OA not only with regard to the 
biomechanical disruptions it engenders in load bearing joints, but also for the systemic 
inflammatory and metabolic alterations that occur in obesity as suggested by recent 
studies223. The expansion of fat tissues is triggering by an energy imbalance, increased 
calorie intake coupled with inadequate or low energy expenditure, which intern engenders 
metabolic abnormalities and hypertrophy (and or hyperplasia) of adipocytes449. The size of 
adipocytes has been directly correlated with the production of pro-inflammatory molecules 
(such as IL-6, TNF-α and monocyte chemoattractant protein-1) and is thus considered an 
indicator of adipose tissue inflammation450. However, it is unknown whether these changes 
occur in the FP in a similar way to other well characterised adipose tissues451.  
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5.2 Experimental design-1 
Donor-matched FP and synovium tissues were obtained from 11 patients with various 
arthropathies (Table 5.1). Tissues were wax embedded, sectioned (section 2.3), stained with 
H&E and a synovitis score was performed to determine the degree of synovial inflammation 
(section 2.5.3).  
Immunohistochemistry was used to reveal the presence of cells that were positive for CD68 
(pan macrophage marker), CD86 (M1), CD11c (M1), CD206 (M2) and arginase-1 (Arg-1, 
M2) (section 2.5.1). The synovium, sub-synovial stroma and FP of the 11 donors were 
ranked for each marker (section 2.5.2), and Spearman’s correlation analysis was performed 
to determine potential associations in the positivity of markers between tissues.  
In addition, donor-matched FP and synovium tissues were obtained from 4 patients 
undergoing TKR and were digested to obtain the cellular fraction (section 2.5.4). Flow 
cytometry was used to assess the phenotype of the macrophages, using CD14 (pan 
macrophage marker), CD163 (M2), CD206 (M2), CD80 (M1) and CD86 (M1) (section 
2.5.6). A Friedman’s test with Dunn’s multiple comparison statistical test was used to 
compare the abundance of markers in both tissues. FP explants from 2 donors were treated 
with the corticosteroid, triamcinolone, after which the stromal vascular fraction was 
extracted and flow cytometry was used to assess the phenotype of the macrophages, as 
explained above.  
5.3 Experimental design-2 
 FP (n=19) and SCF (n=12) were obtained from obese and non-obese donors undergoing 
TKR for OA (Table 5.2). Tissue samples were cryosectioned, stained for H&E and image 
analysis was used to determine the size of adipocytes (Section 2.5.7). Correlation analyses 
were used to establish associations between donor BMI and adipocyte size. 
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Table 5.1: Demographics of donors used in the immunohistochemical 
characterisation of macrophages in synovium and FP. 
Donor Gender Age Procedure 
1 Female 68 TKR 
2 Female 72 TKR 
3 Female 46 TKR 
4 Female 50 TKR 
5 Female 44 Cell therapy 
6 Male 57 Amputation, no known joint pathology (normal) 
7 Male 51 Debridement 
8 Female 44 Cell therapy 
9 Female 46 Cell therapy 
10 Male 34 Debridement 
11 Male 35 Cell therapy 
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Table 5.2: Demographic information and categorisation for obese and non-obese 
donors 
Donor  Gender Age BMI 
FP Obese  
1 Male 54 30.4 
2 Male 74 30.0 
4 Female 56 35.4 
5 Female 69 35.8 
6 Female 74 35.8 
7 Male 56 27.3 
8 Female 54 31.8 
9 Female 63 32.8 
10 Female 77 48.5 
11 Female 60 35.9 
FP non-obese  
1 Male 58 21.5 
2 Female 62 24.0 
3 Female 75 23.8 
4 Female 78 23.9 
5 Female 63 22.3 
6 Female 60 22.9 
7 Male 55 25.9 
8 Female 77 25.9 
SCF obese 
1 Female 58 31.9 
2 Female 66 47.2 
3 Male 69 35.8 
4 Female 54 30.1 
5 Female 53 35.0 
6 Male 63 32.2 
7 Female 77 48.5 
8 Female 65 32.4 
SCF non-obese
1 Male 79 26.8 
2 Female 72 25.9 
3 Female 50 26.0 
4 Male 81 24.2 
FP: infrapetallar fat pad, SCF: subcutaneous fat 
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5.4 Results: Characterisation of macrophages from synovium and FP 
5.4.1 General histological features of synovium and FP 
Histological observations of synovium revealed some variability across donors in terms of 
morphological features. For instance, the synovium taken from an amputee showed a single 
layer of synovial cells, whereas all samples from TKR patients displayed hyperplasic 
synovial linings, indicative of inflammation (Figure 5.1 A-B). Blood vessels also appeared 
to be more predominant in synovial samples from TKR patients. Fragments of cartilage and 
bone that were partially or fully embedded in the synovium were common observations in 
tissues from end-stage OA patients (Figure 5.1 C-D). The morphology of the FP itself did 
not appear to differ across donors, i.e. it consisted of compact adipocytes with scattered 
blood vessels and fibrous connective tissues were noted throughout (Figure 5.1 E). 
The Krenn scoring system185, which is an assessment of synovial hyperplasia, cellularity of 
the subsynovial stroma and the presence of immune cell infiltrate, was used to determine the 
degree of synovitis in each of the samples. This scoring system then allowed samples to be 
categorised as no synovitis, low grade synovitis and high grade synovitis (Figure 5.2 A-B 
compares a sample with no synovitis and another with high grade level of synovitis). A range 
of different scores was obtained across donors, the lowest being 0 (normal synovium) and 
the highest being 6 (synovium with severe synovitis) (Figure 5.2 C).  Although no statistical 
significance was established, the mean synovitis score was higher in synovium from TKR 
donors (5) than donors who received cell therapy (3) (Figure 5.2 D).  
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Figure 5.1: General observations of synovium and FP from H&E stain.  
A) Synovium from an amputee (donor 6) comprised of a single layer of lining cells   (black 
arrow, scale bar=50 µm). B) Hyperplasic synovium from a TKR patient (Donor 2) with high 
cellularity in the lining (black arrow). In addition, more numerous and larger blood vessels 
can be seen in the sub-synovial stroma (green arrows, scale bar=50 µm). C) Bone fragments 
being embedded in the synovium from donor 2 (blue arrow), confirmed as birefringent bone 
lamellae striped structures under polarised light (D, scale bar=500 µm). E) Typical FP with 
blood vessel (green arrow) and fibrous connective tissue (yellow arrow, scale bar=500 µm). 
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Figure 5.2: Assessment of synovitis. A) Example of synovial tissue showing no synovitis. 
B) Example of synovial tissue showing high grade synovitis. Follicle-like lymphocyte 
infiltrate is indicated with the red arrow, hyperplasic synovial lining is shown with the blue 
arrow. Scale bar = 500 µm. C) Synovitis score for all donors. D) Comparison of the synovitis 
score of samples obtained from TKR and cell therapy. An unpaired Mann Whitney test 
showed no statistical difference between the two groups. 
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5.4.2 Immunohistochemical characterisation of macrophages in synovium, sub-
synovial stroma and FP 
The pan macrophage marker CD68 was used to localise macrophages in synovium, sub-
synovial stroma and FP. Cells that were CD68+ in the synovial lining and the stroma were 
spherical or elongated (Figure 5.3 C-F), whereas the CD68+ cells appeared compact in 
between neighbouring adipocytes in the FP (Figure 5.3 H) sometimes forming what are 
known as “crown-like structures”. Physiologically, crown-like structures represent the 
clearance of dead (or dying) adipocytes from fat tissue by multiple macrophages452. Samples 
from OA donors generally showed a higher staining intensity for CD68 than non-OA donors. 
Spearman’s correlation analysis showed a strong association between CD68 positivity in the 
synovial lining and the stroma, but no association was found between CD68 positivity in the 
synovium and the FP, or in the stroma and the FP (Figure 5.8 A-C).  
The markers CD86 and CD11c were used to detect M1 macrophages in the tissues observed.  
In terms of staining intensity and the number of positive cells, the immunopositivity of CD86 
(both intracellular and surface) in the synovial lining appeared relatively low in samples 
from donors with little or no signs of OA, compared to donors with OA (Figure 5.4 A-D). 
The sub-synovial stroma and FP of both OA and non-OA donors contained CD86 positive 
cells (Figure 5.4 E-H). No correlation in CD86 positivity was found between the synovial 
lining, stroma and FP (Figure 5.8 D-E). Interestingly, a low incidence of CD11c positive 
cells was observed for synovium, sub-synovial stroma and FP across all donors (with some 
donor samples showing no positive cells). Tissue samples containing follicle-like 
lymphocyte infiltrate did however contain some CD11c cells (Figure 5.5 F). Due to the rarity 
of CD11c positive cells in most of the tissues observed, correlation analyses were not 
performed for this marker. 
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Immunohistochemistry was performed to detect the M2 markers, Arg-1 and CD206, on cells 
in the various tissues. Arg-1 positivity was present in the synovial lining of cells, stroma and 
FP of healthy and OA donors (Figure 5.6 A-H). Cells that were more intensely stained for 
Arg-1 were observed inside or in the periphery of blood vessels in the stroma (Figure 5.6 F). 
A strong positive correlation was found between Arg-1 positivity in the synovial lining and 
the sub-synovial stroma and also between the synovial lining and the FP, however no 
significant correlation was found between the stroma and the FP (Figure 5.8 G-I). An 
abundance of CD206 positive cells was observed in the synovial lining, stroma and FP across 
all donor samples (Figure 5.7 A-F). Here again, a significant positive correlation was found 
between the synovial lining and the stroma and between the stroma and the FP, but not 
between the synovial lining and the FP (Figure 5.8 J-I). 
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Figure 5.3: Immunohistochemical analysis of CD68 in normal and representative OA 
synovium and FP. Green arrows indicate cells that are positively stained. A-B) Staining of 
CD68 in normal and OA synovium (low magnification). C-D) CD68 staining at high 
magnification. E-F) Comparison of CD68 staining in the sub-synovial stroma of a normal 
and an OA donor. G-H) CD68 staining in deep regions of the FP derived from a normal and 
OA donor. Scale bars: A and B= 500 µm, C-H= 50 µm. 
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Figure 5.4: Immunohistochemical analysis of CD86 in normal and representative OA 
synovium and FP. Green arrows indicate examples of synovial cells that are positive, red 
arrows show positive staining around blood vessels. A-B) Staining of normal and OA 
synovium for CD86 (low magnification). C-D) CD86 staining at high magnification in 
normal and OA synovium. E-F) Comparison of CD86 staining in the sub-synovial stroma of 
a normal and OA donor. G-H) Arrow depicts a crown-like structure in the FP. Scale bars: A 
and B= 500 µm, C-H= 50 µm. 
 175 
 
 
Figure 5.5: Immunohistochemical analysis of CD11c in normal and representative OA 
synovium and FP. Green arrows indicate examples of cells that are positive, the blue arrow 
shows indicates a follicle-like lymphocyte infiltrate. A-B) No staining for CD11c in normal 
and OA synovium was visible (low magnification). C-D) Absence of CD11c positive cells 
in the synovial ling of both healthy and OA donors. E-F) CD11c positive cells in lymphocyte 
infiltrate located in the sub-synovial stroma. G-H) Absence of CD11c positivity in the FP. 
Scale bars: A and B= 500 µm, C-H= 50 µm. 
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Figure 5.6: Immunohistochemical analysis of Arginase-1 (Arg-1) in normal and 
representative OA synovium and FP. Green arrows indicate examples of cells that are 
positive. A-B) Staining of normal and OA synovium for Arg-1 (low magnification). C-D) 
Comparison of Arg-1 staining at high magnification in normal and OA synovium. E-F) 
Comparison of Arg-1 staining in the sub-synovial stroma of a normal and OA donor. Yellow 
arrows show cells lining blood vessels that were more intensely stained. G-H) Weak Arg-1 
staining in the deep regions of FP from a normal and OA donor. Scale bars: A and B= 500 
µm, C-H= 50 µm. 
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Figure 5.7: Immunohistochemical analysis of CD206 in normal and representative OA 
synovium and FP. Green arrows indicate cells that are positive. A-B) Staining of normal and 
OA synovium for CD206 (low magnification). C-D) Comparison of CD206 staining at high 
magnification in normal and OA synovial lining. E-F) Comparison of CD206 staining in the 
sub-synovial stroma of a normal and OA donor. G-H) Staining of CD206 in deep regions of 
FP in a normal and OA donor. Scale bars: A and B= 500 µm, C-H= 50 µm. 
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Figure 5.8: Spearman’s rank correlation analysis of macrophage staining between tissue 
layers (red boxes indicate significant correlations). Associations of macrophage positivity 
between synovium (lining) and stroma (left), stroma and FP (middle), synovium and FP 
(right) are shown for A-C)  CD68, D-F) CD86, G-I) Arginase-1 (Arg-1), J-I) CD206. Red 
dots= end-stage OA, blue dots= cell therapy, black dots= arthroscopic debridement, green 
dots=normal donor. 
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5.4.3 Correlation between synovitis score and macrophage score 
Spearman’s correlation tests were performed to evaluate associations between the synovitis 
score and the individual macrophage marker ranks of synovium, stroma and FP of each 
donor examined. A strong positive correlation was found between the synovitis score and 
the macrophage rank of the synovium for CD68, CD86, Arg-1 and CD206 (Table 5.3). A 
similar trend was observed when correlating the synovitis score to the macrophage ranks of 
the stroma, with the exception of CD86 which showed no significant association (Table 5.3). 
Synovitis did not significantly correlate with the FP macrophage rank for any of the markers 
assessed (Table 5.3). 
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Table 5.3: Spearman’s correlation analysis of the association between the synovitis score 
and macrophage rank in the synovium, stroma and FP. Values represent correlation 
coefficients with p values in brackets; significant correlations are highlighted. 
 Synovitis score vs macrophage rank in: 
synovium stroma FP 
CD68 0.73 (p=0.013) 0.70 (p=0.018) 0.42 (p=0.19)
CD86 0.87 (p<0.001) 0.31 (p=0.34) 0.26 (p=0.44)
Arg-1 0.83 (p=0.004) 0.84 (p=0.004) 0.26 (p=0.46)
CD206 0.76 (p=0.009) 0.65 (p=0.034) 0.06 (p=0.86)
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5.4.4 Flow cytometric assessment of macrophages from matched synovium and FP 
The total cell population of 4 donor matched synovium and FP was extracted by enzymatic 
digestion and multicolour flow cytometry was used to further investigate the presence of 
macrophages in donor matched synovium and FP. The pan macrophage marker CD14 was 
used to gate and analyse only the monocyte/macrophage population in the cell extract of 
both tissues. The surface marker profile of the subsets of macrophages (M1/M2) was 
investigated using the markers CD80 (M1), CD86 (M1), CD163 (M2) and CD206 (M2). In 
the four donors investigated, CD14 positive cells represented 20-35.7% (mean=25%) of the 
total cells extracted from the synovium, and 14.3-33% (mean=21.5%) of the cells extracted 
from the FP. Figure 5.9 A illustrates the positivity of CD14 in matched synovium and FP for 
individual donors. In this population of monocyte/macrophages, synovium and FP showed 
comparable levels of CD80 (11.8% and 11% respectively), whereas CD86 positivity in 
macrophages from the synovium was 43.7% compared to 29.5% in the FP derived 
macrophages (Figure 5.9 B-C). No statistical significance was obtained for the comparison 
of CD80 and CD86 positivity between synovium and FP. Interestingly, although no 
statistical difference was obtained, the average positivity of M2 markers CD163 
(synovium=51.4%, FP=64.8%) and CD206 (synovium=23%, FP=33.1%) was higher in 
macrophages from the FP in comparison to those derived from the synovium. However, a 
bigger sample size would be required to confirm this trend. 
Analyses were performed to determine if certain macrophage subsets were more abundant 
than others in synovium and FP (Figure 5.9). The positivity of CD163 was significantly 
higher than CD80 in both the synovium (p=0.03) and FP (p=0.003) ( 
 
 
 
 
Table 5. 4). No other significance differences were observed between macrophage markers. 
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Figure 5.9: Immunopositivity of macrophage markers in cells from donor matched synovium 
and FP. A) Percentage of CD14 positive cells (monocyte/macrophages) present in the cell 
extract of synovium and FP. B-C) Percentage of cells within the CD14 populations that were 
positive for M1 markers CD80 and CD86. D-E) Percentage of cells within the CD14 
population that were positive for M2 markers CD163 and CD206 
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Table 5. 4: Comparison of M1 and M2 markers in CD14 positive macrophages from matched 
synovium and FP (n=4). P values are from Friedman’s test with Dunn’s multiple comparison. 
Significant comparisons are highlighted and the marker with the highest levels indicated in 
brackets. 
Synovium FP
CD80 vs. CD86 p=0.44 p> 0.57 
CD80 vs. CD163 p=0.03 p=0.003 
CD80 vs. CD206 p> 0.99 p=0.25 
CD86 vs. CD163 p> 0.99 p=0.93  
CD86 vs. CD206 p>0.99 p> 0.99 
CD163 vs. CD206 p=0.25 p>0.99 
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To further characterise the subsets of macrophages present in synovium and FP, the co-
expression of M1 and M2 markers was investigated.  On average, macrophages from the 
synovium showed co-expressions for, CD86 and CD163 (26.3%), CD86 and 206 (6.3%) and 
CD163 and CD206 (9.4%) (Figure 5.9). In FP macrophages, only co-expression of CD163 
and CD206 (6.9%) was revealed. CD80 showed no co-expression with any of the other 
macrophage markers investigated.  
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Figure 5.10: Flow cytometry analysis of the co-positivity of M1 and M2 markers. 
Representative scatter-plots showing the co-positivity of M1 and M2 markers observed in 
macrophages isolated from donor matched synovium and FP. Comparisons are shown for 
A) CD163 vs CD86, B) CD206 vs CD86, C) CD206 vs CD163. Values shown in the 
quadrants represent a percentage of the CD14 positive macrophage population extracted 
from synovium and FP. The position of the quadrants was determined from isotype controls 
using a 99% confidence level (not shown). 
 
  
 186 
 
5.4.5 The influence of anti-inflammatory stimuli on the polarisation of macrophages 
from FP explant cultures 
In order to determine whether the phenotype of the macrophages studied can be modulated, 
FP explants from two donors were stimulated with the anti-inflammatory drug triamcinolone 
for 72 hours (compared to an untreated control). Multicolour flow cytometry was used to 
measure M1 and M2 markers in CD14 positive macrophages extracted from these explants. 
Results revealed that the M2 markers, CD163 and CD206, were increased in both FP explant 
macrophages tested after triamcinolone treatment, while the M1 marker CD80 decreased 
(Figure 5.11). CD86 was unchanged in donor 2 but increased in donor 1 after triamcinolone 
treatment. Here again, CD86 was co-expressed with CD163; this co-expression was also 
increased after triamcinolone treatment (Figure 5.12).  
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Figure 5.11: The effect of triamcinolone on explant cultured macrophages from the FPs. 
Multicolour flow cytometry was used assess the positivity of M1 and M2 markers on CD14 
positive macrophages in FP explants after treatment with the anti-inflammatory drug 
triamcinolone for 72 hours. Results are shown for two donors. 
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Figure 5.12: Scatter plots illustrating the influence of triamcinolone (72 hours treatment) on 
the co-expression of CD86 and CD163 markers on macrophages from FP explant cultures. 
A) Donor 2, B) Donor 2. Triamcinolone induced an increase in the macrophage expression 
of both CD86 and CD163. The position of the quadrants was determined from isotype 
controls using a 99% confidence level. 
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5.4.6 Association between donor BMI and adipocyte size. 
Microscopic observation of H&E stained adipose tissues showed no distinct difference 
between adipocytes in terms of general morphology and distribution when comparing the 
FP and subcutaneous fat from obese and non-obese donors. However larger adipocytes were 
noticeable in the subcutaneous fat of obese donors compared to other donor groups (Figure 
5.13). The size of adipocytes in subcutaneous adipose tissue was correlated to donor BMI 
(r=0.63, p=0.028), which was not the case in the FP (r= -0.06, p=0.82) (Figure 5.14). For 
non-obese donors (BMI < 30), FP adipocyte size (1765 μm2 ± 163.5) was not significantly 
different to subcutaneous adipocyte size (2157 μm2 ± 835.6, p >0.99). However the size of 
adipocytes from the FP of obese (1732 μm2 ± 292.4) and non-obese donors (1765 μm2 ± 
163.5) were significantly smaller than subcutaneous adipocytes from obese donors (3195 
μm2 ± 833.9, p=0.03 and p=0.04 respectively) (Figure 5.14C). 
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Figure 5.13: Representative images of H&E stained cryosections of adipose tissue derived 
from the FP and SCF of non-obese and obese donors. Adipocytes in the SCF of obese donor 
were larger (cross sectional area) than the adipocytes in the FP and of obese donor and the 
SCF/FP of non-obese donors. Scale bar= 100 µm. 
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Figure 5.14: Relationship between BMI and adipocyte size. Spearman's test for correlation 
between donor BMI and adipocyte size in A) the FP and SCF. C) Comparison of the median 
size of adipocytes in the FP and SCF in obese and non-obese donors. 
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5.5 Discussion 
Joint inflammation, albeit a secondary feature of OA, is considered to be a promotor of joint 
degeneration193. An inflamed synovium (synovitis) is an important player in joint 
inflammation due to the increased secretion of pro-degradative molecules by synovial 
cells447.  The synovial tissues of OA patients examined in this chapter showed typical signs 
of synovitis, i.e. hyperplasia, immune cell infiltrate and increased cellularity of the stroma. 
Additionally, an increased number of blood vessels was noted in the synovial tissues of OA 
donors which corroborates with previous studies showing the histological association 
between indicators of neovascularisation, such as the proliferation of endothelial cells, and 
increased synovitis grade in OA patients453. The presence of bone and cartilage fragments in 
synovial tissues sections is a sign of severe joint degeneration, and is believed to be a trigger 
for synovitis189,454. Tissue sections from donors receiving cell therapy showed less synovitis, 
compared to OA donors, which is likely indicative of their lack of severe joint degeneration. 
However, a larger sample size would be required to confirm the difference in the levels of 
synovitis when comparing OA and cell therapy donors. 
Macrophages are usually resident within both normal and diseased synovium183,187. 
Although the M1 and M2 subsets of macrophages have been well characterised in other 
tissues and diseases, their phenotype and role in the articular joint (more specifically the 
knee), following injury and in disease states has only recently attracted research 
interest201,204.  
The staining intensity for markers tested stronger in OA tissues compared to non-OA tissues, 
suggesting a higher prevalence of macrophages in OA tissues. CD68 is a lysosomal 
glycoprotein commonly used as a pan macrophage/monocyte marker in humans370. This 
predominantly intracellular marker is a member of the family of scavenger molecules which 
are essential to the function of phagocytic cells such as macrophages455,456. CD68 has also 
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been employed previously to confirm the presence of macrophages in the FP of OA donors 
with a similar staining pattern to the immunohistochemical stains shown in this results 
chapter204.  
The M1 marker CD86 is a cell surface transmembrane protein, found on antigen presenting 
cells, that is central to the activation of T cells during an immune response371. The presence 
of CD86 on macrophages has been confirmed in both the synovium and FP by 
immunohistochemistry201,204, however the function of this subset of cells in the joint has not 
yet been revealed. CD11c is a subunit of the integrin alpha X protein specific to leucocytes 
notably monocytes, macrophages and dendritic cells372,457. Although no CD11c positive cells 
were found in the FP samples examined, small populations were found near infiltrating 
lymphocytes in the sub-synovial stroma. This observation, although unexpected, is not 
entirely surprising as dendritic cells have been reported in lymphocyte-rich regions of 
lymphoid organs (such as the spleen), where they mediate the pro-inflammatory activity of 
T-helper and T-killer cells457. It remains unclear whether these CD11c dendritic cells are 
part of the resident population of macrophages in the synovial tissue and, importantly, 
whether they promote the infiltration of circulating lymphocytes from blood vessels. Recent 
publications also suggest that T-helper cells contribute to the differentiation of monocytes 
into dendritic cells by producing high levels of granulocyte macrophage colony-stimulating 
factor458.  
Arg-1, an intracellular M2 marker, is an enzyme that catalyses the hydrolysis of arginine 
into ornithine and urea374. This enzyme directly competes with the nitric oxide synthase 
(NOS), which converts arginine into NO and in turn facilitates cartilage damage459. There is 
a paucity of literature exploring the activity of Arg-1 in the OA joint and its presence on 
joint derived macrophages. Immunohistochemical results presented here show that Arg-1 is 
present in human synovium and to a lesser extent in the FP. The mannose receptor, CD206, 
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found on the surface of a number of phagocytic cells is involved in the recognition of 
microbial carbohydrates and the clearance of inflammation-induced enzymes in order to 
regulate an immune response373,460. Conditioned medium from FP explants was found to 
have anti-catabolic effect on cartilage in vitro; this was attributed to the high prevalence of 
CD206 positive macrophages in the FP204. The abundance of CD206 cells in the synovium 
and FP of OA patients reported here confirms recent studies201,204, in which no record of the 
presence of CD206 cells in normal (or less inflamed) synovium has been reported. In 
addition, this is the first investigation comparing the presence of cells with M1 and M2 
markers in donor matched synovium and FP. 
Correlation analyses showed an association in the macrophage ranks when comparing the 
synovium and sub-synovial stroma for all of the markers investigated, with the exception of 
CD86. The close proximity between the two tissues could possibly explain this association, 
that is, a high prevalence of macrophages in the synovium could induce an increase in 
macrophages within sub-stroma by secreted factors or by the free movement of cells between 
the two tissues. The lack of a significant association for CD86 remains unclear. When 
correlating macrophage ranks between the sub-synovial stroma and FP, only CD206 showed 
a significant association, which has not been demonstrated before.  Further, only Arg-1 
showed a significant association when correlating macrophage ranks between the synovium 
and the FP; here again this has not been demonstrated previously. These results present an 
interesting theory that although the synovium and FP function differently in terms of the 
general abundance of macrophages (CD68), a link could potentially exist when looking at 
various subsets of macrophages. 
In addition, strong positive correlations were found between the synovitis score and the 
macrophage rank in the synovium and stroma for all the markers tested (barring CD86 in the 
stroma). This suggests that the general increase in the number of macrophage as a result of 
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an inflamed synovium involves453 all the subsets of macrophages. Conversely, synovitis 
scores did not correlate with any of the macrophage ranks in the FP, which again points to 
the potential independence of FP and synovium with regards to their inflammatory status.  
Ideally, a larger sample size would be more appropriate for more robust results. It is 
important to note the limitations of immunohistochemical characterisation of macrophages 
using single markers. The CD markers used in this study, while highly expressed on 
subpopulations of macrophages, are not always specific to macrophages. For instance, CD68 
is known to be present in lymphocytes and fibroblasts, both of which are commonly found 
in synovial tissue461. Although this may not be a concern in the FP since macrophages often 
adopt a specific crown-like structure in adipose tissues, this could introduce bias when 
observing the synovium and the sub-synovial stroma where macrophages do not have a 
distinct morphology. Double staining methods which identify two indicative macrophage 
markers simultaneously in a cell have been developed to characterise macrophage subsets in 
other human tissues462 and the adoption of these techniques here would provide more 
confidence in the results obtained.  
Multicolour flow cytometry is another method that can be used to identify subsets of 
macrophages by targeting multiple indicative markers on cells following their extraction 
from tissues. CD14 was used in this chapter to identify the monocyte/macrophage population 
amongst all the cells extracted from the synovium and FP, from which the positivity of other 
markers can be determined. A low sample size limits the inferences that can be made from 
the data obtained in this results chapter, however it is perhaps safe to say that the macrophage 
content was comparable between the tissues. One other recent study (n=34 donors) which 
has utilised flow cytometry to compare freshly isolated macrophages in paired synovium 
and FP samples corroborates this finding448. Similarly this report used CD14 to identify 
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macrophages and found no significant difference between the synovium and FP, however 
no further experiments were conducted to characterise M1and M2 subsets. 
The evidence gathered in this chapter indicates that M1 and M2 macrophages co-exist within 
the synovium and FP of OA patients. Interestingly, an observation of the co-expression of 
surface markers revealed that macrophages from both tissues can simultaneously express 
M1 and M2 markers. A growing body of literature now confirms that macrophages not only 
exist in strict polarisation states, but can also be part of a polarisation spectrum that 
incorporates the cells that are between the M1 and M2 phenotypes197,198. In the synovial 
joint, the presence of multiple macrophage subsets could perhaps be accounted for by the 
plethora of different cytokines available. For instance, IFN-γ and TNF-α are known to induce 
the expression of CD80, while IL-4 and IL-10 induce the expression of CD163 and CD206 
in the differentiation process of naive peripheral blood derived monocytes463,464. All  of these 
cytokines are known to be present in the knee joint164, which would logically lead to the 
potential differentiation of freshly recruited monocytes along multiple macrophage lineages 
and could induce the expression of multiple M1 and M2 markers in the same cell. 
It is now believed that the M2 subset of macrophages is comprised of M2a M2b, and M2c 
categories representing parasite clearance, immunoregulatory and wound healing cells 
phenotypes, respectively198. The co-positivity of CD163 and CD206 shown in synovium and 
FP tissues suggests the presence of M2c cells465,466, while the co-positivity of CD86 and 
CD163 suggests the presence of M2b cells465. The panel of markers chosen here did not 
allow for the identification of M2a cells due to the absence of markers such as CD209466 and 
Fizz1465, amongst others.  
To determine whether the phenotype, or polarisation state, of joint derived macrophages 
could be modulated. The anti-inflammatory drug triamcinolone was applied to FP explant 
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cultures in an experiment using tissues derived from two donors. The results from these two 
donors were comparable but should be taken as preliminary data which will be discussed but 
will need further study (with increased donor size) before conclusions can be drawn. In this 
preliminary data set an increase in the number of cells that were positive for CD163 and 
CD206 after treatment with triamcinolone was observed, however, the M1 marker CD80 
(which has a similar co-stimulatory function to CD86) was only partially diminished. The 
increased co-expression of CD86 and CD163 could indicate a possible mechanism of action 
of triamcinolone within the joint, i.e., to induce a shift in macrophage polarisation towards 
the M2b immunoregulatory phenotype. One mouse study showed that the administration of 
triamcinolone prevented the formation of osteophytes which was linked to the induction of 
CD163 positive macrophages, however, this study did not mention a particular macrophage 
subset467. Techniques that are used to characterise the cellular component of tissues such as 
immunohistochemistry and flow cytometry capture a snapshot of macrophages at a particular 
time, which may not reflect the true transient phenotype of the cell if it is indeed between 
M1 and M2 on the polarisation spectrum. 
 
 In addition to surface markers, assessing the secretory profile and gene expression may be 
a more reliable characterisation method to determine macrophages polarisation states. To 
delineate M1 cells, secretory factors such as IL-1, IFN-γ, TNF-α and IL-6 should be assessed 
together with the signal transducer and activator of transcription 1 (STAT1) and surface 
markers CD80 and CD86198. For M2 cells, secreted antiinflammatory factors such as IL-10 
and IL-1 receptor antagonist (IL-1ra) can be measured together with the transcription factor 
STAT6 and surface markers CD163 and CD206377,468.  
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The obesity-related alterations that occur in adipose tissues away from the joint, such as 
increased adipocyte size469, are not well characterised in the FP.  The results in this chapter 
have shown that unlike subcutaneous adipose tissue adipocytes, the size of FP adipocytes 
was not associated with BMI. These observations in human tissues provide evidence that the 
FP adipocytes do not undergo the metabolic alterations that often engenders cellular 
hypertrophy449, and confirms a previous investigation that showed the absence of 
hypertrophic adipocytes in the FP of obese mice470. Subcutaneous adipose tissue is 
considered as both an energy storage and an endocrine organ that is susceptible to 
inflammatory macrophage infiltration during obesity 471,472. The FP is a potential contributor 
to local joint inflammation via the production of adipokines and cytokines473 that exacerbate 
joint degeneration. It has been shown that inflammation of the FP is associated with knee 
pain and disability in obese OA patients.474 Since the adipocytes of the FP itself are not 
altered, at least not in size as a result of obesity, it could be inferred that the FP derived 
adipocytes do not possess the same obesity induced pro-inflammatory phenotype as 
subcutaneous adipocytes. Hence, the findings presented here could highlight novel 
functional differences between the FP and subcutaneous adipose tissue in obesity, indicating 
perhaps that the inflammatory role of the FP in the pathogenesis of obesity related OA is 
separate to that of subcutaneous fat. The cellular, genetic or molecular mechanisms that 
cause this difference in sensitivity to obesity in the FP and other adipose tissues is not fully 
understood and warrants further investigation.  
It is noteworthy however, that recent MRI based studies have associated a large FP with a 
reduced number of bone marrow lesions, reduced walking pain and higher total cartilage 
volume in OA patients475. Furthermore, conditioned media of FP adipocytes from obese OA 
patients was found to have no effect on the secretion of TNF-α in lipopolysaccharide 
stimulated macrophages in vitro, but interestingly inhibited the production of IL-12p40 in 
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these stimulated macrophages.476 Other studies have also shown that there were no 
differences between the quantity of secreted factors in conditioned media derived from the 
FP from obese and non-obese OA donors205; conditioned media from OA FP explants had a 
chondroprotective effect on cartilage.204 In a rat model of ageing, the only OA feature which 
correlated with FP adipocyte size was synovial thickness and this correlation was 
independent of age. The secretion of the pro-inflammatory cytokine TNF-α from FP was 
associated with age, but no association between FP adipocyte size and cytokine release was 
reported477. The progressive age-dependant downregulation of genes related to anti-
inflammatory macrophages in FP explants from these rats suggests that a shift towards a pro-
inflammatory phenotype is likely to be mediated by immune cells rather than adipocytes. 
Taken together, it is clear that further investigations are required to clarify whether and how 
obesity influences the FP (particularly in humans), and if so, what the implications are for 
OA. 
The use of unmatched FP and subcutaneous fat is a limitation to the interpretation of the 
results presented in this chapter. Assessing a larger sample size with matched FP and 
subcutaneous fat would further confirm the differences in adipocyte size in the two tissues 
within a particular donor. A recent human study reported considerably larger adipocyte sizes 
for both FP (3708 ± 976 µm2) and subcutaneous fat (6082 ± 628 µm2) in normal donors 
compared to the average sizes observed in our study478. This difference in comparison to our 
results could be attributed to the difference in methods used to measure cell size.  
Analysis of the molecules secreted by individual adipocytes would also provide valuable 
insight into the inflammatory status of the FP in obese and non-obese patients. One 
investigation revealed that the secretory profile of FP explants and the presence of 
macrophages in the FP are not influenced by donor BMI205,473. This provides supporting 
evidence for our hypothesis that perhaps an increased BMI does not have a significant 
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influence on the adipocytes in the FP. Furthermore, we did not have samples from non-OA 
FP donors. Therefore, the possibility that OA could already have influenced the adipocyte 
size in the donors cannot be excluded. Further, the FP can also become fibrotic which could 
possibly limit the enlargement of adipocytes.  
5.6 Conclusion 
Figure 5.15 gives an illustration of the results obtained in this chapter regarding the 
phenotype and polarisation of macrophages. The characterisation of joint derived 
macrophages has significant implications in understanding their role in the progression of 
OA and in developing therapies to target macrophage related joint inflammation. The 
potential for modulating the phenotype of macrophages as a treatment option to inhibit, or 
even reverse, the molecular processes that promote cartilage degeneration is of particular 
interest and requires further study. A difference in the physiological roles of the FP and 
subcutaneous fat could possibly account for the difference in susceptibility of their 
adipocytes to hypertrophy. The data presented here adds novel insights into the physiological 
function of the FP and its role in the development OA. 
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Figure 5.15: Summary of key findings presented in Chapter 5. Monocyte/macrophages from 
OA joints (synovium and infrapatellar fatpad) express both M1 (CD80 and CD86), pro-
inflammatory, and M2 (CD206 and CD163), anti-inflammatory markers. Although the exact 
functional phenotype of these cells remains unknown, the results shown in this chapter 
suggest that these cells respond to anti-inflammatory stimuli (i.e. corticosteroids) by 
producing more M2 marker. The expression of M1 markers however, does not appear to be 
affected by this stimulus. The plasticity of polarised macrophages from the joint to revert to 
a previous or different phenotype warrants further studies. 
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Chapter 6:  
General Discussion 
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6.1 General Discussion 
Despite the numerous treatment modalities available, OA remains a major clinical challenge 
for clinicians, healthcare services and patients. Over the years, a tremendous amount of 
research has been conducted by scientists worldwide to find new ways of treating cartilage 
injury and OA and more specifically cartilage degeneration. The cell therapy ACI was 
developed to address the problem of cartilage damage, which is known to be a risk factor in 
the progression of OA479,480. Notwithstanding the advances that have been made to improve 
the procedure, many scientific questions remain unanswered. One of these questions is, 
which cell type is most appropriate for regenerating damaged cartilage: chondrocytes, stem 
cells (embryonic or adult), or combinations of more than one cell type? Furthermore, one of 
the limitations of ACI is the need to harvest healthy cartilage to obtain chondrocytes, which 
is a process of creating an injury capable of producing pro-inflammatory conditions in the 
joint164,481.  
The aim of this thesis was to evaluate the chondrogenic potency of multiple sources of MSCs 
in an attempt to determine the most appropriate for treating cartilage defects and OA. Donor 
matched BM-MSCs, FP-MSCs, SCF-MSCs and SF-MSCs were investigated in this thesis 
as alternative cells for cartilage regeneration, with BM-MSCs and FP-MSCs displaying the 
highest propensity for chondrogenic differentiation in vitro. Although BM-MSCs are often 
considered the “gold standard” adult stem cell for regenerative therapies, there is growing 
evidence (including clinical studies) to support the use of adipose derived stem cells, such 
as FP-MSCs, in cartilage repair. Fat tissues are more easily accessible than bone marrow and 
would thus be an ideal source of therapeutic cells. The results illustrating the 
immunomodulatory properties of FP-MSCs, together with the fact that obesity does not alter 
the inflammatory status of the FP are additional advantages of this tissue over other adipose 
tissues470. 
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Another current debate is centred on whether allogeneic therapies are more appropriate than 
autologous. While both methods are being trialled clinically, a single-step allogenic therapy 
has been suggested as perhaps the most cost effective and “patient friendly” approach482,483. 
More than 40 companies worldwide having already investigated ways of improving cartilage 
tissue engineering484. An allogeneic “off the shelf” source of cells would significantly 
simplify the clinical translation and commercial viability of cell therapies for cartilage injury 
and OA. The development of advanced cell culture platforms that allow a well-controlled 
environment (such as sustained oxygen tension) for optimal cell expansion is key to the 
translation of these procedures. 
Defining what are the key attributes of the ideal cell, as well as deciding upon the appropriate 
patients to treat and at what stage of the disease are also important factors to consider when 
developing cell therapies for cartilage repair. A number of markers, both cell surface and 
genetic, have been identified as indicative of chondrogenic potency, however these markers 
may not be consistent across chondrocytes and stem cells. As a result, it may be more 
appropriate to test and establish separate panels for chondrocytes and MSCs. Furthermore, 
distinct panels may even be required for subsets of MSCs depending on their tissue of origin. 
The lack of a clear definition of OA, particularly in its early phases, presents a challenge for 
applying a treatment since clinical symptoms often manifest when the disease is relatively 
advanced485. This poses a challenge for the screening process to identifying suitable patients 
to recruit in cell therapy trials. The significant progress made in OA and cartilage injury 
biomarkers studies ( including genomics, proteomics and metabolomics) have aided in the 
understanding of the molecular pathways involved in the pathogenesis of OA486,487 and are 
promising tools for the stratification of patients. In addition predictive, biomarker assessment 
will allow the identification of patients that are most likely (or least likely) to benefit from 
the therapy488. 
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A large body of research is now aimed at harnessing the immunomodulatory properties of 
MSCs to attenuate joint inflammation in OA. This holds great promise for treating some of 
the symptoms of OA although it has been shown that MSCs with enhanced 
immunoregulatory properties have a poor propensity to undergo chondrogenesis293. In this 
respect, a co-transplantation of MSCs with immunoregulatory properties together with 
chondrocytes may offer an interesting option. One such clinical study is currently being 
performed at the Robert Jones and Agnes Hunt Orthopaedic Hospital (Autologous Stem cells 
Chondrocytes or the Two (ASCOT trial)). Patients are recruited as part of a three-arm trial 
to receive one of the following autologous therapies to treat focal cartilage defects: 1) 
chondrocytes, 2) BM-MSCs from the iliac crest, or 3) a combination of chondrocytes and 
BM-MSCs. This unique study will permit the analysis of the immunomodulatory factors 
expressed and secreted by the cells as well as their chondrogenic potency, both of which will 
be related to clinical outcome and histological analysis of repair tissues.  
In the design of a cell therapy, the target may dictate the type of delivery system used to 
apply the cells into the injured joint: intra articular or into the defect itself. This delivery 
decision may be significantly influenced by the therapeutic target, ie for cartilage repair or 
the treatment of inflammation. The transplantation of cells into a defect, as is the case for 
traditional ACI, would be aimed at regenerating the damaged cartilage, whereas an intra-
articular injection of cells would treat the entire joint, including dampening joint 
inflammation.  Another option for cartilage injury or OA cell therapy development would 
be to trigger the endogenous cells into repairing damaged tissues or resolving 
inflammation489–491. For example, MSCs have been identified in the synovium, synovial 
fluid, cartilage, and fat inside the knee joint315,320,406,492, all of which could potentially serve 
endogenous as sources of s reparative cells. Finding the molecules that could target and 
initiate reparative processes in these cells remains an unmet research question worthy of 
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further study. The homing of reparative cells to an injury site was illustrated when labeled 
BM-MSCs intra articulally injected into a canine model of chondral defects, were able to 
migrating to cartilage defect sites to promote repair493. However, the mechanism by which 
this process occurred was not investigated, neither has the homing capability MSCs been 
demonstrated endogenously in humans.  
Addressing the challenge of joint inflammation has lead researchers to identify the cells that 
are actively involved in producing pro-inflammatory molecules in the OA joint, such as 
macrophages. While these are not the only cells that promote joint degeneration, 
macrophages have attracted research interest due to their plasticity and their ability to induce 
pro-inflammatory processes in other immune cells such as T cells. A clearer understanding 
of the phenotype (s) of macrophages and the molecular triggers that induce their activation 
during the pathogenesis of OA is needed. New treatment options, and perhaps diagnostics 
tools, could potentially be developed by manipulating how the various subsets of 
macrophages influence inflammatory state in the different stages of OA. For example, there 
is scope for the use of MSCs as macrophage immunoregulators in the treatment of OA, as 
MSCs conditioned media has been shown to induce induce an anti-inflammatory phenotype 
in macrophages (measured by the increase in positivity for CD206 and CD163 and synthesis 
of IL-10494). Thus, the use of MSC conditioned media, or the therapeutic molecules secreted 
by these cells, have been proposed as novel additional treatment modalities. 
Finally, the influence of low grade systemic inflammation in obesity-related OA is slowly 
coming to light227,495. While the adipocytes in fat depots in the knee joint may not undergo 
obesity induced hypertrophy to contribute to joint inflammation, infiltrating pro-
inflammatory cytokines produced by fat tissue around the body during obesity can damage 
the joint, and poses a significant scientific challenge to overcome. It is clear that 
consideration should also be given to educating individuals on the relatively simple lifestyle 
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changes that could help reduce the risk of OA, such as a healthy diet and frequent physical 
activity.  
 
6.2 Conclusions and future work 
Tremendous strides have been made in the research race to find new and innovative 
treatments for OA. The hope and excitement that has accompanied the field of regenerative 
medicine, should be balanced with less promissory discourses to reduce the often misleading 
hype and expectation in the general public. The overall findings in this thesis are summarised 
in Figure 6.1. This work adds to the current literature by shedding light on the chondrogenic 
and immunomodulatory nature of joint derived MSCs and elucidating the phenotypes of 
macrophages found in the synovium and FP of the knee. Of the stem cell populations 
examined, BM-MSCs and FP-MSCs displayed the highest chondrogenic potential; however, 
joint derived MSCs were inferior to chondrocytes in terms of chondrogenesis. Macrophages 
exist on a spectrum of different phenotypes and are more prevalent in the synovium of end 
stage OA patients than non-OA patients. Inevitably, as some questions were answered, other 
new research questions arose, which themselves warrant further investigation. For instance, 
it is still unknown whether MSCs be triggered to migrate from their respective niches in the 
joint to naturally repair an injury site. The difference in differentiation potential of FP and 
SCF-MSCs, two types of ASCs also remains unclear. Macrophages are important players in 
joint inflammation that require further study to understand how they can be targeted for 
intraarticular immunomodulation. Taken as a whole, the results presented here provides new 
insights into the biology of joint derived stem cells and inflammatory cells, and their 
potential implications in the development of cellular therapies for OA and cartilage 
regeneration.  
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Figure 6.1: Illustration of the overarching findings presented in this thesis. The human knee 
harbours multiple sources of MSCs. To determine which of these cell populations is most 
suited for cartilage repair, a series of characterisation experiments were performed. MSCs 
from the bone marrow (BM-MSCs) and infrapatellar fatpad (FP-MSCs) displayed the 
highest chondrogenic propensities, compared to synovial fluid (SF-MSCs) and subcutaneous 
fat (SCF-MSCs) derived cells that showed poor chondrogenic potential. All MSCS were 
inferior to chondrocytes in terms of chondrogenic ability. Macrophages are immune cells 
that actively contribute to joint inflammation and joint destruction. It was discovered that 
although macrophages from the synovium and fatpad expression both pro- and anti-
inflammatory markers, they can be stimulated to an M2 phenotype. Further investigations 
are needed to determine how the immunomodulatory properties of MSCs can help attenuate 
inflammation by “switching” the phenotype of macrophages from M1 to M2, and hence 
reduce joint degeneration.   
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Appendix 1: Image of an electrophoresis gel to detect the presence of mycoplasma in cell 
culture. Lane 1 is a negative control, lanes 2-9 are test samples and lane 11 is the positive 
control. In this example, samples 3 and 4 are infected with mycoplasma. 
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Name  SevenGo SG6-ELK HI-2040 
Type of probe Optical Electrode 
Range 0-600% 0-300% 
Accuracy  ±10.0% ±1.5% 
Resolution 0.10% 0.10% 
Temperature range 0-40°C 0-50°C 
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 GAPDH TBP HPRT1 B2M PPIA 
 15.974 25.046 23.392 17.177 20.133 
 16.862 24.958 23.002 17.954 20.393 
 15.971 24.852 23.859 16.776 21.357 
 15.231 24.048 22.326 15.817 19.461 
 15.708 23.953 22.256 15.221 19.479 
 14.528 22.713 20.592 15.337 18.649 
 14.495 24.187 22.194 14.729 19.886 
 15.253 24.518 22.576 15.109 20.032 
 15.826 25.564 22.724 15.109 20.881 
 15.230 25.299 20.826 15.165 19.315 
Ct mean 15.508 24.514 22.375 15.839 19.959 
SD 0.67916 0.787045 0.970744 1.026001 0.751196
CV 0.043794 0.032106 0.043385 0.064776 0.037638
 
Appendix 3: Ct values from preliminary tests conducted to determine the most stable 
reference genes across cell types. The two genes with the lowest coefficient of variation 
(CV), TBP and PPIA, were used for PCR experiments. 
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Appendix 4: Comparison of the chondrogenic differentiation of chondrocytes that were 
isolated and expanded in normoxia (top panel) or hypoxia (bottom panel). Pellets from cells 
grown in hypoxia produced more GAGs and type II collagen as shown by toluidine blue 
staining and immunohistochemistry respectively.  
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Characterisation of synovial fluid 
and infrapatellar fat pad derived 
mesenchymal stromal cells: The 
influence of tissue source and 
inflammatory stimulus
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The infrapatellar fat pad (FP) and synovial fluid (SF) in the knee serve as reservoirs of mesenchymal 
stromal cells (MSCs) with potential therapeutic benefit. We determined the influence of the donor 
on the phenotype of donor matched FP and SF derived MSCs and examined their immunogenic and 
immunomodulatory properties before and after stimulation with the pro-inflammatory cytokine 
interferon-gamma (IFN-γ). Both cell populations were positive for MSC markers CD73, CD90 and CD105, 
and displayed multipotency. FP-MSCs had a significantly faster proliferation rate than SF-MSCs. CD14 
positivity was seen in both FP-MSCs and SF-MSCs, and was positively correlated to donor age but only 
for SF-MSCs. Neither cell population was positive for the co-stimulatory markers CD40, CD80 and CD86, 
but both demonstrated increased levels of human leukocyte antigen-DR (HLA-DR) following IFN-γ 
stimulation. HLA-DR production was positively correlated with donor age for FP-MSCs but not SF-
MSCs. The immunomodulatory molecule, HLA-G, was constitutively produced by both cell populations, 
unlike indoleamine 2, 3-dioxygenase which was only produced following IFN-γ stimulation. FP and 
SF are accessible cell sources which could be utilised in the treatment of cartilage injuries, either by 
transplantation following ex-vivo expansion or endogenous targeting and mobilisation of cells close to 
the site of injury.
Regenerating joint tissues that have been damaged by trauma or degenerative diseases, such as osteoarthritis 
(OA), continues to present a challenge to scientists and clinicians world-wide. Autologous chondrocyte implan-
tation (ACI) is a two-stage procedure that involves harvesting healthy cartilage arthroscopically in the first stage, 
followed by implantation of culture expanded cells at the damaged site via open surgery in the second stage, in 
an attempt to induce repair of the damaged tissue1. Eighty one percent of patients treated at our centre showed 
improved joint function and pain reduction (assessed via Lysholm scores) over an average follow-up time of 5 
years2. However, ACI has some disadvantages relating to cost and possible donor site morbidity3–5, which limits 
its current use as a standard treatment for cartilage repair. Mesenchymal stromal cells (MSCs) have been iso-
lated from many different tissue sources, including bone marrow (BM-MSCs), adipose tissue (commonly called 
adipose stem cells, ASCs), synovium (SM-MSCs) and umbilical cord (UC-MSCs) and are promising candidates 
for use in regenerative cell-based therapies. The infrapatellar fat pad (FP) and synovial fluid (SF) also represent 
accessible sources of MSCs (FP-MSCs and SF-MSCs, respectively) which are often routinely removed as surgical 
waste during arthroscopy or open knee surgery. The precise origin of SF-MSCs is not known; reports propose 
that they come from different tissues within the knee such as cartilage, bone and synovium, with synovium often 
considered as the most likely6–8. In an in vitro model, one study has illustrated that the joint SF of OA patients 
enhances MSC migration from synovium explants, a process believed to be mediated by transforming growth 
factor beta-3 (TGF-β 3)9.
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Better characterisation of these cells is vital, not only to ensure their safety for in vivo use, but also to test 
their therapeutic efficacy. However, a number of parameters such as tissue source and donor specificity are often 
overlooked by researchers, despite the clear evidence indicating that these features influence the phenotype of 
MSCs. It has been demonstrated that both donor age and gender affect the differentiation of BM-MSCs and 
A-MSCs; male and young donors generally produce MSCs with a more enhanced osteogenic and chondrogenic 
potency10–12. Further, older donors are known to produce MSCs that are less proliferative compared to younger 
donors12. These findings collectively suggest a clear influence of the donor on the phenotype of MSCs, and sup-
port the need for more robust studies that consider tissue origin and donor features as important parameters for 
the development of cell therapies.
In addition to the minimum characterisation criteria of MSCs established by the International Society 
for Cell Therapy (ISCT)13 which assesses cell surface markers and multipotent ability, understanding the 
immunological properties of MSCs in response to a pro-inflammatory stimulus has also been proposed as 
an important part of their characterisation14. BM-MSCs have been shown to increase their production of the 
immunomodulatory molecule indoleamine 2, 3-dioxygenase (IDO)15 in response to stimulation with the 
pro-inflammatory cytokine interferon-gamma (IFN-γ ). IDO is an enzyme involved in the depletion of the 
essential amino acid, tryptophan, resulting in the inhibition of the proliferation of microbes and T cells16. Like 
IDO, the human leukocyte antigen-G (HLA-G) is another important immunomodulatory molecule which 
exerts its immunosuppressive effect on activated T cells17. It is produced by BM-MSC and by the trophoblast 
cells in the placenta where it plays a role in maternal tolerance to the foetus. The human leukocyte antigen-DR 
(HLA-DR), a major histocompatibility complex class II (MHCII) molecule, is found on antigen presenting 
cells (APCs) of the immune system and interacts with T cell receptors during an immune response. HLA-DR 
is not inherently expressed on BM-MSCs, but is known to be upregulated following a pro-inflammatory 
stimulus18. In contrast, the costimulatory markers CD40, CD80 and CD86, which are also produced by APCs 
involved in T cell mediated immune reactions19, are not produced on BM-MSCs even after inflammatory 
stimulation20. While FP-MSCs and SF-MSCs have been previously characterised in terms of their growth, 
multipotency and CD profile7,21, the immunological and immunomodulatory properties of these cells have 
not been thoroughly defined. The purpose of this investigation was to assess the influence of tissue source and 
donor on the properties of MSCs sourced from donor matched FP and SF isolated from human knees. We also 
investigated the previously unexplored response of FP- and SF-MSCs to a pro-inflammatory stimulus, such as 
that which may be found in an osteoarthritic joint.
Results
Macroscopic observations of FP, Histology, Cell culture and Growth kinetics. Donor variability 
was noted in the apparent level of inflammation observed by the surgeon (Table 1). The complex and hetero-
geneous features of the intact FP tissue were clearly visible in our histological preparations showing synovium 
and adipose regions (Fig. 1a). Blood vessels appeared scattered throughout the synovium (Fig. 1c) and deeper 
adipose tissue (Fig. 1b). For some samples a layer of synovial cells could be found on the superficial regions of the 
synovium along with mast cells, lymphocytes and numerous blood vessels (Fig. 1c). To avoid contamination of 
adipose derived cells with synoviocytes, only the deepest areas of the FP were used for digestion, as highlighted 
in Fig. 1d.
MSCs isolated from both FP and SF were plastic adherent and appeared to consistently have a 
fibroblastic-like morphology at early passage (P2) through to the last passage tested (P10) (Fig. 2a,b). The 
results of the hierarchical regression analysis (Table 2) show that the average doubling time (DT) of SF-MSCs 
was 8.3 days longer than the DT of FP-MSCs (P < 0.001) over the 10 passages tested, for all donors. The DT 
increased with passage number by 1.4 days per passage and this increase was significantly dependant on the 
donor (P < 0.001).
Immunoprofile of FP-MSCs and SF-MSCs. Flow cytometry analyses (Fig. 3a) revealed that both cell 
populations were over 95% positive for the MSC markers CD73 and CD105, but CD90 showed only 92.7% ± 11 
positivity in SF-MSCs but 98.3% ± 3.1 in FP-MSCs. Interestingly, some positivity was recorded for the cock-
tail of PE conjugated markers expected to be negative on MSC cultures i.e. CD11b, CD19, CD45, CD34 
and HLA-DR. FP-MSCs showed significantly (P = 0.046) greater positivity for the “negative” MSC markers 
(31.7% ± 24% of cells) compared to cells sourced from SF (7.8% ± 6.9% of cells). To explore this further, sin-
gle PE-conjugated antibodies for CD11b, CD19, CD45, CD34 and HLA-DR were used to analyse FP-MSCs. 
FP-MSCs were negative for all of these markers, with the exception of CD34 which was 30.1% ± 18.6% 
ID Gender Age (years) Condition Macroscopic observation of FP Procedure
Donor 1 Male 35 Chondral defect on lateral femoral condyle Mild inflammation ACI
Donor 2 Female 42 Chondral defect on patella Severe inflammation ACI
Donor 3 Female 49 Osteochondral defect on patella Hypertrophy ACI
Donor 4 Female 49 Chondral defect on patella Hypertrophy ACI
Donor 5 Male 53 OA degeneration of knee with chondral defect on trochlea General inflammation ACI
Donor 6 Male 79 End-stage OA General inflammation Total knee replacement
Table 1.  Demographics of donors from which samples were sourced.
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Figure 1. Example histology of a fat pad.  Samples were paraffin embedded and stained with H&E. (a) Low 
power view of the fat pad as received after a knee replacement showing synovium (blue arrow) and adipose 
tissue (red star). (b) The deep adipose tissue is indicated by a red star and the adjacent synovium is indicated by 
a blue arrow. (c) High magnification view of the synovium with a layer of synoviocytes (blue arrow), mast cells 
(black arrows), and a blood vessel surrounded by a cuff of lymphocytes (green arrow). (d) Representative region 
of deep-lying vascularised adipose tissue from which FP-MSCs are isolated. Scale bars represent 1 mm (a) and 
200 μm (b–d).
Figure 2. Microscopic photographs and growth kinetics of FP- and SF-MSCs. (a–d) Representative 
images were taken at passage 2 (a,b) and passage 10 (c,d). Scale bars represent 100 μm. (e) Growth kinetics 
data represents the mean doubling time ± standard error of the mean (SEM) for 6 donor-matched FP and 
SF samples. Over 10 passages, SF-MSCs show a significantly longer doubling time compared to FP-MSCs 
(P = 0.018). *P < 0.05, **P < 0.01.
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positive (Fig. 3b). The macrophage lineage and inflammation marker CD14 was present on both FP-MSCs 
(30.5% ± 30.3%) and SF-MSCs cells (7.4% ± 7.2%, P = 0.14), with some variability observed between donors 
(Fig. 3c). An increase in CD14 positive was associated with donor age for SF-MSCs (n = 5, r = 0.94, P = 0.016), 
but not FP-MSCs (n = 5, r = 0.66, P = 0.23)
Mesenchymal Trilineage Differential Potential. After 21 days of differentiation, all donor matched 
samples showed multipotent capability (Fig. 3d). FP-MSCs and SF-MSCs in adipogenic medium produced 
lipids which stained positively with oil red O, with those produced by FP-MSCs being more numerous and 
larger than those produced by SF-MSCs. Furthermore, they also showed stronger staining for alkaline phos-
phatase compared to SF-MSCs, which suggests greater osteogenic potential for the FP-MSCs. Histological 
staining for metachromasia using toluidine blue of chondrogenic cell pellets after differentiation revealed a 
similar level of GAG production by both cell populations, with no discernible difference in staining intensity 
between donors.
Immunogenic and immunomodulatory properties of FP-MSCs and SF-MSCs after IFN-γ stim-
ulation. After 48 h of treatment with the either 25 or 500 ng/ml of the pro-inflammatory cytokine, IFN-γ , 
analysis via flow cytometry showed that CD40, CD80 and CD86 were not present on FP-MSCs or SF-MSCs 
and were similar to the untreated controls (Fig. 4a,b). In contrast, a low concentration (25 ng/ml) of IFN-γ sig-
nificantly increased the positivity for HLA-DR in both cell populations compared to their respective controls 
Factor Fixed/Random effect Coefficient or SD (days) p-value
Cell source (SF) Fixed 8.3 (6.1–10.4) < 0.001
Passage number Fixed 1.4 (0.8–2.0) < 0.001
Passage by donor Random 0.54 (0.19–1.1) 0.004
Table 2. Results of the hierarchical regression analysis for the influence of cell source, passage number and 
donor on doubling time of matched FP- and SF-MSCs. Note: Coefficients and standard deviation (SD) based on 
a linear mixed effect model. P-values are from Wald tests (fixed effects) and likelihood ratio tests (random effects).
Figure 3. MSC immunoprofile (via flow cytometry) and trilineage differentiation of FP and SF-MSCs.  
(a) Both FP and SF-MSC populations were immunopositive for CD73 (98.8%), CD90 (98.3%), CD105 (99.6%); 
FP-MSCs showed significantly more cells which were positive for the cocktail of ISCT defined negative MSC 
selection markers compared to SF-MSCs (P = 0.046). (b) Single antibody cytometric analysis revealed a 
high positivity for CD34 in FP-MSCs (n = 3), but no positivity for CD11b, CD19, CD45 and HLA-DR. Error 
bars indicate SEM. (c) Cell positivity for CD14 was variable between donors and matched cell populations 
(n = 5). (d) The two MSC populations demonstrate differentiation potential when grown in different media; 
Chondrogenesis is shown by GAG production (purple metachromasia when stained with toluidine blue), 
adipogenesis is shown by the formation of lipid vesicles (oil red O) and osteogenesis is shown by the activity of 
alkaline phosphatase (red staining). Images are representative of the differentiation potential of all six donor 
matched samples. Scale bars represent 100 μm.
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(FP-MSCs = 39.8% ± 35.1%, SF-MSCs = 13.1% ± 11.7%). FP-MSCs also showed a significantly higher percentage 
of HLA-DR positive cells (46.9% ± 36.5) compared to SF-MSCs (10.0% ± 10.4) at 500 ng/ml IFN-γ (P = 0.04). 
Donor variability was noted with regards to the induction of HLA-DR by IFN-γ , however MSCs derived from 
both the FP and SF of donor number 2 consistently produced more HLA-DR in response to IFN-γ stimula-
tion compared to the other donors, at both doses tested (Fig. 4c,d). After stimulation with 25 ng/ml of IFN-γ , 
FP-MSCs showed more production for HLA-DR, which was positively correlated with an increase in donor age 
(n = 6, r = 0.82, P = 0.045); SF-MSCs showed no such trend (n = 6, r = 0.72, P = 0.105).
Both cell populations produced the immunomodulatory marker, HLA-G, regardless of inflammatory stimulus 
and with no significant difference observed between FP-MSCs and SF-MSCs (Fig. 5a). Western blots showed that 
the production of IDO in both cell populations was induced by IFN-γ stimulation but was absent in unstimulated 
controls (Fig. 5b).
Discussion
In this study, we have characterised the endogenous population of MSCs found in patient matched samples of 
infrapatellar FP and joint SF, and explored the possible influence of a pro-inflammatory stimulus on the immuno-
genic and immunomodulatory properties of these cells. Histology of the FP and synovium revealed the presence 
of immune cells, notably mast cells and lymphocytes, in the superficial regions of the tissues. Both of these cell 
types are known to be present in synovial tissues of arthritic patients and produce molecules that promote joint 
inflammation22–24. Macroscopic inspection of the FP during surgery in the present study revealed some degree of 
inflammation as indicated by the size of the FP itself and redness of the attached synovium. Our results show that 
both FP- and SF-MSCs are plastic adherent cells with similar fibroblast-like morphologies in vitro. We have noted 
a significant increase in the doubling times of SF-MSCs at late passages (compared to FP-MSCs), which suggests 
that SF-MSCs lose proliferative capacity earlier than FP-MSCs. Reports have indicated that both human BM-MSC 
and ASC doubling times increase with passage number25–27; a longer culture period may have been required in the 
current study in order to observe a similar reduction in FP-MSC proliferation. The consistent difference in growth 
rate observed between FP-MSCs and SF-MSCs, isolated from matched donors, highlights that these cells are bio-
logically different. Interestingly, an investigation observing patient-matched SM-MSCs and SF-MSCs revealed 
no significant difference in the proliferation rate of the two cell types between P0 and P228, perhaps providing 
supportive evidence that these cells share a common origin.
In agreement with previous studies6,29, we confirm the multipotency of both cell populations, with 
FP-MSCs showing enhanced differentiation towards adipogenic and osteogenic lineages compared to 
Figure 4. Immunogenic properties of FP and SF-MSCs after stimulation with IFN-γ (error bars indicate 
SEM). (a) The production of co-stimulatory markers (CD40, CD80, and CD86) and the class II MHC receptor 
HLA-DR for FP-MSCs is shown after 48 hours of stimulation with IFN-γ along with unstimulated controls. FP-
MSCs do not produce co-stimulatory molecules regardless of stimulation, but show greater HLA-DR positivity 
at 25 ng/ml (39.8% ± 14.3, p < 0.0001) and at 500 ng/mL (46.9% ± 14.9, p < 0.0001) stimulation with IFN-γ .  
(b) SF-MSCs show no positivity for co-stimulatory marker, even when stimulated, but produce significantly 
higher levels of HLA-DR at 25 ng/ml (13.1% ± 6.4, P = 0.0015) and at 500 ng/mL IFN-γ (9.8% ± 4.3, P = 0.025). 
(c–d) Donor variability in the levels of induced HLA-DR on FP-MSCs and SF-MSCs was observed at both 
25 ng/mL (C) and 500 ng/ml (D). However, donor number 2 (indicated by the square data points) had higher 
positivity for HLA-DR compared to other donors for both FP-MSCs and SF-MSCs and for both of the IFN-γ 
doses tested.
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SF-MSCs. Also, as previously described7,29 we have demonstrated that both FP-MSCs and SF-MSCs popu-
lations possess chondrogenic ability, but we have also shown that there was no discernible difference in the 
chondrogenic potential of FP-MSCs or SF-MSCs derived from the same donor. Our results show that these 
donor-matched SF-MSCs and FP-MSCs are positive for MSC cell surface markers CD73, CD90, CD105, as 
well as many of them being positive for the myeloid lineage marker CD1430. This observation indicates that 
joint SF and the stromal fraction of FP contain cells that in part meet the ISCT criteria for MSCs, but may also 
harbour a sub-population that do not i.e. those with CD14 positivity. CD14 positivity has previously been 
reported on BM-MSCs31, but not FP-MSCs or SF-MSCs to date. Macrophage-like synoviocytes, which are 
also positive for CD14, are a likely contaminant sub-population contributing to the heterogeneity of our cul-
tures32,33. SF is known to contain CD14 positive macrophages that secrete pro-inflammatory cytokines, such 
as IL-1 and TNF-α , that induce enzyme-mediated cartilage degradation34,35. Furthermore, there is increased 
detectable soluble CD14 in the SF of osteoarthritic patients36. Hence, the positive association of CD14 in 
SF-MSCs and advancing age could be indicative of an increase in pro-inflammatory conditions in the degen-
erative joints of older subjects37–39.
No single surface marker that we investigated allowed a clear distinction between FP-MSCs and SF-MSCs, 
which suggests that a broader panel of markers would be required in order to distinguish between these two cell 
types. Recent guidelines from the ISCT and the International Federation for Adipose Therapeutics and Science 
now accept CD34 as being positive on adipose stromal cells40. CD34 positive cells in FP-MSCs and other ASCs 
cultures41,42, are likely to represent subpopulations of either vascular endothelial lineages, pericytes or a mixture 
of the two, as found in cells isolated from subcutaneous lipoaspirate34. Further work would be required to isolate 
and phenotypically characterise these CD34 positive cells within adipose tissues to assess their function in native 
and transplanted tissues.
In addition to surface antigens and differentiation characterisation criteria, the need to understand the immu-
nological properties of MSCs is becoming crucial to the development of cell therapies14,43, particularly in the 
treatment of conditions which involve inflammatory elements as is the case for OA44,45. APCs interact with T cells 
via MHC class II molecules, such as HLA-DR, to trigger an alloresponse46. This reaction involves the activation, 
differentiation and proliferation of T cells but is not possible without the expression of costimulatory surface 
molecules47. The results we present here are the first to show an increased positivity of MHC class II and a lack 
of expression of costimulatory molecules on matched FP-MSCs and SF-MSCs in response to an in vitro inflam-
matory stimulus. BM-MSCs stimulated with IFN- γ have been shown to produce levels of HLA-DR that are 
comparable to our observations with FP-MSCs20. Conversely, the immunoprofile of IFN-γ induced HLA-DR on 
SF-MSCs was much lower, perhaps indicating that SF-MSCs are less immunogenic following inflammatory stim-
ulation and hence display a distinct immunological phenotype compared to FP-MSCs and also BM-MSCs. This is 
the first time, to our knowledge, that a difference in positivity for HLA-DR on stimulated MSCs derived from the 
same joint has been reported and requires further investigation. Inflammation of the knee, due to elevated levels 
of pro-inflammatory molecules, has been reported to increase with age39,48. Our results indicate an increasing 
trend with age in the production of HLA-DR by FP-MSCs after exposure to IFN-γ . It could be hypothesised that 
the inflammatory nature of the FP is increased with age and in turn pre-conditions the endogenous MSC niche 
to respond to IFN-γ by augmenting HLA-DR positivity. The reason why this correlation was not reproduced 
in the SF-MSCs derived from the same joints remains undetermined, but this observation highlights another 
biological difference between the two cell populations. In vivo investigations evaluating the general effects of 
natural aging and inflammation on MSC pools within the human knee joint could not only elucidate the cellular 
pathways involved in the pathogenesis of chronic joint diseases, but may also reveal potential therapeutic targets 
Figure 5. Immunomodulatory properties of FP and SF-MSCs after stimulation with IFN-γ (error bars 
indicate SEM). (a) Both FP and SF-MSCs (n = 3) inherently produce HLA-G in control conditions (82.7% ± 5.1 
and 64.0% ± 3.4 respectively), as well as following treatment with 25 ng/ml (73.8% ± 11.2 and 52.4% ± 12.5 
respectively) and 500 ng/ml IFN-γ (79.7% ± 8.3 and 5.2% ± 14.9 respectively). (b) Cropped image of a 
representative western blot indicating the production of IDO by FP-MSCs and SF-MSCs after stimulation with 
IFN-γ , but not in untreated controls, a full-length blot is presented in Supplementary Figure S1.
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(genetic, molecular or cellular) to counter the degenerative processes. Despite the presence of HLA-DR on FP- 
and SF-MSCs in this study, these cells cannot be considered as truly immunogenic without an accompanying 
increase in the production of costimulatory markers47,49.
It is perhaps also noteworthy that the only donor included in this study observed in surgery to have a ‘severely 
inflamed’ infrapatellar fat pad (donor 2) produced FP-MSCs and SF-MSCs which showed the most pronounced 
response to an inflammatory stimulus. We suggest that cells derived from such severely inflamed joints are 
‘primed’ to be more responsive to inflammatory stimuli, but we appreciate that a larger cohort of donors with 
better defined (macroscopic and histologically quantified) tissues would be required to confirm this hypothesis.
The immunosuppressive properties of SF-MSCs have been demonstrated in mixed lymphocyte reactions50, 
but the constitutive production of HLA-G in FP-MSCs and SF-MSCs has not been reported previously. A similar 
level of HLA-G production has, however, been observed in both BM-MSCs and UC-MSCs17,20. HLA-G positive 
UC-MSCs have been shown to inhibit the proliferation of pro-inflammatory T helper 1 cells, which are present in 
OA joints51, and promote the expansion of anti-inflammatory regulatory T cells. Further, we have demonstrated 
that the production of IDO can be induced in both cell populations by an inflammatory stimulus, comparable to 
BM-MSC and ASC cultures52,53. In a collagen induced arthritis mouse model, IDO deficiency was associated with 
a high incidence of arthritis and pronounced T cell infiltration54. The pro-inflammatory conditions within the 
OA joint could potentially activate the local MSC populations to dampen the influence of certain immune cells 
such as T cells and macrophages. The present study suggests that FP-MSCs and SF-MSCs may be considered as 
immunomodulatory cells but they would require more in depth in vitro functional testing alongside BM-MSCs 
to fully assess their therapeutic value in this respect. Others have shown that conditioned media derived from 
BM-MSCs that were stimulated with IFN-γ and TNF-α , reduced the gene expression of pro-inflammatory and 
cartilage degrading molecules in synovial and cartilage explants in vitro55. This trophic feature remains largely 
undefined in FP- and SF-MSCs but may provide insight into the possible mechanism of action that these cells 
might have in an arthritic joint.
The use of donor matched samples in our investigations has allowed us to better identify and analyse 
donor-specific variability. Tissue source appears to be more influential on the proliferative and differentiation 
properties of joint derived MSCs than the donors themselves or related factors. The reasons for this are still 
unclear. An increase in donor age, for example, is known to negatively affect the differentiation potential and 
growth rate of BM-MSCs56 and subcutaneous ASCs12,but this does not seem to apply for the FP- and SF-MSCs 
observed in our study.
Donors included in this study were predominantly patients with chondral defects and with early signs of OA. 
However, one donor was described as having end stage OA and was thus undergoing total joint replacement. 
This heterogeneity in samples may account for some of the variability observed, but also provides insight into the 
inherent biological differences in donors that should be considered in the development of new cartilage repair 
strategies.
Conclusion
We have characterised the phenotype and have identified biological distinctions between MSCs sourced from 
the FP and SF within the same articular joint. We have confirmed that there is obvious potential for the use of 
FP-MSCs or SF-MSCs in the treatment of cartilage defects following ex-vivo expansion. However, it may be more 
advantageous to find means of recruiting these resident MSCs with chondrogenic potency from their respective 
niches in vivo, as opposed to current methods of transplanting expanded cells. The advantage of this approach 
would be that the significant costs and regulatory hurdles involved with the in vitro manufacturing of cells may 
be circumvented.
Further, we have shown that the levels of CD14 on SF-MSCs and the inducibility of HLA-DR on FP-MSCs 
are possibly due to age-related inflammation. We confirm for the first time, an immunomodulatory capacity for 
FP- and SF-MSCs which confers further therapeutic value to these cells with regards to treating the inflammatory 
aspect of OA. This also highlights the need to understand the physiological inflammatory conditions into which 
transplanted cells are place and how this could affect the outcome of a cellular treatment. FP-MSCs and SF-MSCs 
may not realistically be suited for large-scale allogeneic therapies due to limited sample availability and low cell 
numbers, but certainly represent sources of autologous cells for cartilage regeneration in addition to sourcing 
chondrocytes from healthy cartilage, as is used currently. Further investigations will seek to understand how these 
MSCs can be directed to effect repair endogenously either by means of dampening down inflammatory processes 
or by producing repair cartilage themselves or even by encouraging reparative cellular recruitment.
Methods
Isolation and culture of FP-MSCs and SF-MSCs. All samples were obtained after patients had pro-
vided written informed consent; favourable ethical approval was given by the National Research Ethics Service 
(11/NW/0875) and all experiments were performed in accordance with relevant guidelines and regulations. FP 
and joint SF were obtained from 6 patients (3 males and 3 females, ages 35–79 years) undergoing either total knee 
replacement or ACI surgery. At the time of surgery a macroscopic observation of inflammatory state of the FP 
was made by the operating surgeon and is shown in Table 1, along with all other donor demographics. The FP was 
dissected from the deepest zone, to avoid contamination with synovium derived cells. To confirm clear dissection 
of the two tissues, portions of selected samples were fixed and processed for paraffin wax embedding and routine 
histological study via haematoxylin and eosin staining. FP tissue was washed in phosphate buffered saline (PBS, 
Life Technologies Paisley, UK), minced into 2–3 mm3 pieces and digested with 1 mg/ml collagenase type I (>125 
digesting units/mg, Sigma-Aldrich, Poole, UK) in Dulbecco’s Modified Eagle’s Medium/F-12 (DMEM/F-12, Life 
Technologies) with 1% (v/v) penicillin/streptomycin (P/S) (Life Technologies) for 1 h at 37 °C. The resulting cells 
were strained through a 40 μm nylon cell strainer and centrifuged (350g for 10 min). Cells were then seeded at a 
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density of 5000 cells/cm2 in the above media supplemented with 10% (v/v) foetal calf serum (Life Technologies). 
FP was prepared for histology via paraffin embedding and sectioned at 5 μm using a Shandon SME cryotome 
(Thermo Scientific Loughborough, UK) and tissue sections were collected onto adhesive slides (Leica Biosystems 
Surgipath, Nussloch, Germany). Haematoxylin and eosin (H and E) staining was conducted as per standard 
procedure.
SF was centrifuged (800g for 15 minutes) and the resulting pellet seeded into a T25cm2 culture flask. All 
cultures were maintained at 37 °C and 5% CO2 in a humidified atmosphere. Media was replaced every 2–3 
days. At 70% confluence, growth media was removed and the cells washed with PBS to remove residual serum 
and media. Cells were then detached with 0.05% (v/v) trypsin-EDTA (Life Technologies) and reseeded at 
5000 cells/cm2.
Growth Kinetics. The proliferation rate of the cells was evaluated by calculating their DT over ten passages 
(P). Cells were seeded into T25 cm2 flasks at a density of 5000 cells/cm2 and allowed to proliferate to 70–80% con-
fluence before trypsinisation and reseeding. The cell population DT was calculated using the following equation:
= − ×Doubling time t t
n n
( 2 1) ln(2)
ln( 2/ 1)
where t2-t1 is the number of days in culture, n2 is the number of cells recovered after passage and n1 is the total 
number of cells seeded.
Microscopy. Histological sections were viewed by light microscopy (Leitz, Wetzlar, Leica Microsystems 
GmbH, Germany) using × 6.3, × 25 and × 40 objective lenses and a DS-Fi1 camera (Nikon Corporation, Japan), 
images were analysed using NIS-Elements BR software version 3.2 (Nikon). Cells in monolayer culture were 
digitally imaged by phase contrast microscopy using a ×10 objective lens (Nikon Eclipse TS100) and a C4742-9S 
camera (Hamamatsu, Japan), images were analysed using IPLab v3 software (BD Biosciences).
Flow cytometry Immunoprofiling. Flow cytometry was used to assess the immunoprofile of MSCs 
derived from FP and SF. Cells at P3–4 were harvested, pelleted, and re-suspended in 2% bovine serum albu-
min (BSA, Sigma-Aldrich, Poole, UK) in PBS. FC receptors were blocked for 1 h at 4 °C using 10% (v/v) 
human IgG (Grifols, UK) with 2% BSA in PBS. The cells were then washed with 2% (v/v) BSA in PBS and 
centrifuged (350g for 8 minutes). Cells were stained for (30 minutes at 4 °C) with fluorochrome conjugated 
antibodies against CD90-phycoerythrin (PE) (clone 5E10), CD105-allophycocyanin (APC) (clone 266), 
and CD73-brilliant violet 421 (BV421) (clone AD2) (BD Biosciences, Oxford, UK). A commercially avail-
able pre-mixed cocktail of PE-conjugated antibodies was initially used for the detection of markers CD11b 
(clone ICRF44), CD19 (clone HIB19), CD34 (clone 581), CD45 (clone HI30) and HLA-DR (clone TU36) 
(BD Biosciences) on FP-MSCs and SF-MSCs. Further staining for individual markers was performed for 
FP-MSCs with fluorochrome conjugated antibodies against CD11b-PE, CD19-BV421, CD34-APC, CD45-PE 
and HLA-DR-APC (clones stated previously) (BD Biosciences). The expression of CD14 was assessed 
using a peridinin chlorophyll protein-cyanine5.5 (PercP-Cy5.5) conjugated antibody (clone Mφ P9) (BD 
Biosciences). Appropriate isotype-matched IgG controls were used throughout (BD Biosciences). Data from 
10,000 stained cells is presented which was collected using a FACSCanto II flow cytometer (BD Biosciences) 
and analysed using BD FACSDiva v.7.0.
Differentiation assays. The multipotency of FP-MSCs and SF-MSCs at P3 was assessed using osteo-
genic, adipogenic and chondrogenic differentiation protocols. The osteogenic, and adipogenic differentia-
tion of FP-MSCs and SF-MSCs was investigated using monolayer cultures. Cells were seeded at a density 
of 5 × 103/cm2 in 24 well plates (Sarstedt, Nümbrecht, Germany), and fed the appropriate differentiation 
medium, either osteogenic or adipogenic medium for 21 days. Osteogenic differentiation medium contained 
DMEM F12, FCS (10%), β -glycerophosphate (10 mM), dexamethasone (10 nM) and L-ascorbic-acid (50 μM). 
Adipogenic differentiation medium contained DMEM F12, FCS (10%), Insulin-transferrin-selenium-X (ITS) 
(1%) (Gibco UK), isobutylmethylxanthine (0.5 μM) (Sigma, UK), dexamethasone (1 μM) and indomethacin 
(100 μM). For control cultures, media containing DMEM F12, FCS (10%) and P/S was used. To evaluate the 
differentiation, cells were fixed with buffered formalin and stained with oil red-O for 1 h to assess lipid forma-
tion for adipogenesis or napthol-AS-BI phosphate and fast red for 1 h to assess alkaline phosphatase activity 
for osteogenesis.
A pellet culture system (2 × 105 cells/pellet) was used to assess chondrogenic differentiation potential. Cells 
(2 × 105) were centrifuged in sterile 1.5 ml microcentrifuge tubes with DMEM F12, FBS (10% v/v), P/S (1%) 
ITS (1%, v/v), ascorbic-acid (0.1 mM) (Sigma-Aldrich), dexamethasone (10nM) and transforming growth factor 
β -1 (TGF-β 1, PeproTech, London, UK) (10 ng/ml)57. After 21 days, cell pellets were snap frozen in liquid nitro-
gen and stored at − 80 °C prior to use. Pellets were cryosectioned (7 μM) onto poly-L-lysine coated slides (Cell 
Path, Newtown, UK) and stained for glycosaminoglycans (GAG) with toluidine blue (BDH) metachromatic stain. 
Sections were stained with toluidine blue for 30 seconds and then washed briefly in tap water. Slides were left to 
air dry before mounting in Pertex (Cell Path).
Interferon-γ stimulation. The immunogenic nature of FP-MSCs and SF-MSCs was investi-
gated by assessing the presence of the costimulatory markers CD40, CD80, CD86, and the class II Major 
Histocompatibility Complex (MHC), HLA-DR, after stimulation with the pro-inflammatory cytokine IFN-γ 
(20 units/ng, PeproTech). Cells at P3 were treated with culture medium containing either 25 ng/ml (low con-
centration) or 500 ng/ml (high concentration) of IFN-γ for 48 h. Untreated cells grown in standard culture 
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medium were used as controls for comparison. After 48 h, cells were prepared for flow cytometry as described 
previously with PE-conjugated antibodies against CD40, CD80, CD86 (BD Biosciences) and HLA-DR 
(Immunotools, Friesoythe, Germany). HLA-G was assessed via flow cytometry using antibodies against 
surface and intracellular antigens (Santa-cruz, Texas, USA), using a Cytofix/CytopermTM and Fixation/
Permeabilisation Kit (BD Biosciences) to the manufacturer’s recommendations.
Western blotting for IDO detection. The production of IDO in cells at P3 was evaluated before and 
after stimulation with IFN-γ using western blotting. Cells were lysed with cold lysis buffer (100 μl lysis buffer 
per 1 × 106 cells) containing 0.005% Tween 20, 0.5% Triton X-100 and protease inhibitors (Sigma-Aldrich, UK) 
at 4 °C, and kept at − 20 °C until further use. After quantification of total protein using the bicinchoninic acid 
(BCA) assay (Life Technologies), 20 μg of each sample was loaded into pre-cast NuPAGE® 4–12% Bis-Tris gels 
(Life Technologies). An iBlot and transfer stacks system (Life Technologies) was used to transfer proteins 
onto nitrocellulose membranes. Primary and secondary antibodies employed to detect IDO were used at 
dilutions of 1:250 and 1:125, respectively, in antibody diluent. The primary antibody (Abcam, Cambridge, 
UK), against IDO, was applied first to the membrane, then the secondary antibody (1:125, Life Technologies) 
which was conjugated to horseradish peroxidase. Membranes were washed three times with a wash solution 
(Life Technologies), then twice with autoclaved water. A chromogenic substrate solution, NovexR Alkaline 
Phosphatase (Life Technologies), was added to the membranes, after which colour development was allowed 
for no longer than an hour. Membranes were washed again in autoclaved water before being allowed to dry in 
the dark prior to imaging.
Statistical analyses. Statistical analyses were performed using GraphPad Prism (GraphPad Software, 
California, USA) and R (The R Foundation, Vienna, Austria). The Shapiro–Wilk test was used to assess the 
normal distribution of numerical data. The mean doubling times of FP-MSCs and SF-MSCs were compared 
using a two-way ANOVA with Bonferroni’s multiple comparisons tests, while a hierarchical regression analy-
sis was used to determine the effect of donor, cell source and passage number on DT. A paired Student’s t-test 
was used to compare means and a Pearson’s test was used to establish correlations where appropriate. Graphs 
are shown as means ± standard error of the mean (SEM). Statistical significance was considered at *p < 0.05, 
** p < 0.01 and ***p < 0.001.
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Autologous chondrocyte implantation (ACI) is a cell-based therapy that has been used clinically for over 20 years to treat cartilage
injuries more efficiently in order to negate or delay the need for joint replacement surgery. In this time, very little has changed
in the ACI procedure, but now many centres are considering or using alternative cell sources for cartilage repair, in particular
mesenchymal stem cells (MSCs). In this study, we have tested the chondrogenic potential of donor-matched MSCs derived from
bone marrow (BM), infrapatellar fat pad (FP), and subcutaneous fat (SCF), compared to chondrocytes. We have confirmed that
there is a chondrogenic potency hierarchy ranging across these cell types, with the most potent being chondrocytes, followed by
FP-MSCs, BM-MSCs, and lastly SCF-MSCs. We have also examined gene expression and surface marker profiles in a predictive
model to identify cells with enhanced chondrogenic potential. In doing so, we have shown that Sox-9, Alk-1, and Coll X expressions,
as well as immunopositivity for CD49c and CD39, have predictive value for all of the cell types tested in indicating chondrogenic
potency. The findings from this study have significant clinical implications for the refinement and development of novel cell-based
cartilage repair strategies.
1. Introduction
Autologous chondrocyte implantation (ACI) for the treat-
ment of focal chondral and/or osteochondral lesions has
changed very little since its inception [1], but there remains
scope for improvement. While we and others have reported a
significant level of improved joint function and a reduction
in pain following treatment with ACI [2–4], disadvantages
such as cost, potential donor-sitemorbidity, and the quality of
repair tissue formed remain. Althoughwe have shown donor-
site morbidity to be minimal [5], there is also the added risk
of chondrocyte dedifferentiation during culture expansion
[6, 7], the extent of which is likely to impact on the ability
of the chondrocytes to redifferentiate upon implantation into
the defect site.
Mesenchymal stem cells (MSCs) isolated from the bone
marrow (BM-MSCs) have been used in several clinical trials
as an alternative cell source for use in cell therapies to
treat cartilage injuries and osteoarthritis [8–10]. The process
of acquiring a sample of bone marrow, however, results
in an additional, painful procedure for the patient. The
infrapatellar fat pad (FP) is often routinely removed and
disposed of as surgical waste during arthroscopy or open knee
surgery and may provide an accessible alternative source of
MSCs (FP-MSCs) with demonstrable chondrogenic capacity
in vitro [11, 12]. Another accessible source of MSCs, although
studied to a lesser extent for their chondrogenic propensity,
is MSCs derived from subcutaneous fat (SCF-MSCs) [13, 14].
The ability to utilise these tissues for the treatment of cartilage
injuries has the potential to improve the way we currently
treat patients.
An important factor to consider when comparing and
contrasting the properties of different cell types is the “donor
impact” as donor demographics, such as age and gender, are
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Table 1: Donor demographics.
ID Gender Age (years) Pathology
Donor 1 Male 71 OA with extensive joint degeneration
Donor 2 Female 67 OA with loss of joint space
Donor 3 Female 75 Patellofemoral OA and loss of joint space in medial compartment
Donor 4 Female 81 OA
Donor 5 Male 74 OA with joint stiffness
factors which are known to affect cell proliferation and differ-
entiation capacity [15–17].The impact of donor is particularly
critical for autologous treatment regimes and in deciding
whether such a cell-based therapy represents the appropriate
treatment option for an individual patient. Unravelling the
impact of tissue and donor source and developing tools to
predict the efficacy of cell-based treatments will likely result
in the refinement of existing treatments and may provide
valuable additional information for consideration during
the decision making process of cost benefit versus clinical
efficacy.
In this study, we have examined 4 different cell types
(chondrocytes, BM-MSCs, FP-MSCs, and SCF-MSCs) and
tested the chondrogenic potential of each population of
cells. This study compares donor-matched cell types and was
designed to establish the impact of tissue source and donor
on chondrogenic differentiation capacity and to continue the
process of establishing a marker panel indicative of chon-
drogenic potency and likely clinical success. Such marker(s)
could be screened for and used in the selection of a partic-
ular cell type and/or subpopulation of cells with enhanced
chondrogenic capability prior to treatment. We envisage that
taken together this information could significantly improve
the success of cell-based therapies for cartilage injuries and
perhaps even lead to the development of novel individualised
treatments for cartilage repair.
2. Materials and Methods
2.1. Patients. All samples were obtained after patients had
provided written informed consent; favourable ethical ap-
proval was given by the National Research Ethics Ser-
vice (11/NW/0875) and all experiments were performed in
accordance with relevant guidelines and regulations. Donor-
matched samples of cartilage, BM, FP, and SCFwere obtained
from 5 patients (2 males and 3 females, ages 67–81 years)
undergoing total knee replacement (TKR) surgery (Table 1).
2.2. Isolation of Chondrocytes. Macroscopically normal artic-
ular cartilage was excised from the femoral condyles of
patients undergoing TKR. Cartilage tissue was weighed,
minced into small pieces with a sterile scalpel, and digested
in collagenase type II (250 IU/mg dry weight, Worthington,
New Jersey, USA) for 16 hours at 37∘C.The resulting suspen-
sionwas passed through a 40𝜇mcell strainer and centrifuged
(350×g for 10 minutes) to produce a cell pellet that was
resuspended in Dulbecco’s Modified Eagle’s Medium/F-12
(DMEM/F-12) with 1% (v/v) penicillin/streptomycin (P/S)
and 10% (v/v) foetal calf serum (FCS, all Life Technolo-
gies, Paisley, UK), hereafter referred to as complete culture
medium, at a seeding density of 5 × 103/cm2.
2.3. Isolation of MSCs from Bone Marrow. Bone marrow as-
pirates and bone chips were obtained from the tibial plateau
of patients undergoing TKR. Bone marrow was first diluted
with an equal volume of phosphate buffered saline (PBS, Life
Technologies) then split between two 50mL tubes, layered
onto 10mL of Lymphoprep (Alere Technologies AS, Oslo,
Norway), and centrifuged (900×g for 20 minutes). The buffy
coat, containing mononuclear cells, was aspirated and added
to complete culture medium and centrifuged (750×g for
10 minutes). The resulting cell pellet was resuspended in
complete culture medium and BM-MSCs were seeded at a
density of 20 million cells per 75 cm2 tissue culture flask.
Cells were left to adhere for 24 hours before the media were
changed and the nonadherent cells were removed. Bone chips
were placed in a 175 cm2 culture flask with 30mL of complete
media for 7 days to allow the plastic adherent cells to migrate
out of the bone chips.
2.4. Isolation of MSCs from Adipose Tissues. Human FP and
SCF tissue samples were obtained from patients and pro-
cessed within 2 hours of receipt from the operating theatre.
The FP was dissected from the innermost zone, to avoid
contamination with synovium derived cells as described
previously [12]. Dissected FP and SCF tissues were washed
in PBS, minced, and digested with 1mg/mL collagenase type
I (≥125 digesting units/mg, Sigma-Aldrich, Poole, UK) in
serum-free media for 1 h at 37∘C. The resulting cells were
strained through a 40𝜇m nylon cell strainer and centrifuged
(350×g for 10min). Cells were then seeded at a density of
5 × 10
3/cm2 in complete culture medium. All cultures were
maintained in a humidified incubator at 37∘C and 5% CO
2
.
2.5. RNA Extraction and Quantitative Real-Time Polymerase
Chain Reaction (qRT-PCR). After trypsinisation at passages
3-4, 2 × 105 monolayer cells were centrifuged (500×g
for 5 minutes), frozen in liquid N
2
, and stored at −80∘C
briefly prior to extraction. Cells were thawed on ice and
messenger RNA (mRNA) was extracted using an RNeasy
extraction kit (Qiagen, Hilden, Germany) according to the
manufacturer’s recommendations. RNA was converted to
cDNA using a High-Capacity cDNA Reverse Transcriptase
Kit (Applied Biosystems, Warrington, UK) according to the
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manufacturer’s instructions. qRT-PCR was used to evaluate
the expression of specific genes, indicative of chondrogenic
potency or hypertrophy [18]. RT-qPCR analysis was per-
formed on the Quant Studio 3 Real-Time Quantitative PCR
System (Applied Biosystems) using SYBR green QuantiTect
primer assays for the chondrogenic genes Sox-9, collagen
type II (Coll II), aggrecan (ACAN), frizzled-related protein
(FRZB), and the following genes indicative of hypertrophy:
activin receptor-like kinase 1 (Alk-1) and collagen type X
(Coll X). Peptidylprolyl isomerase A (PPIA) and TATA-
binding protein (TBP) were used as reference genes (Qiagen).
The relative expression of each genewas determined using the
comparative CT method [19].
2.6. Flow Cytometry. Flow cytometry was used to assess the
immunoprofile of chondrocytes andMSCs prior to chondro-
genic differentiation. Cells at passages 3-4 were harvested,
pelleted, and resuspended in 2%bovine serumalbumin (BSA,
Sigma-Aldrich) in PBS. FC receptors were blocked for 1 h at
4∘C using 10% (v/v) human IgG (Grifols, Barcelona, Spain)
in 2% (v/v) BSA in PBS (immunobuffer). The cells were
then washed with immunobuffer and centrifuged (350×g
for 8minutes). Cells were stained for 30minutes at 4∘C
with fluorochrome conjugated antibodies against cell surface
markers indicative of MSC according to the International
Society for Cellular Therapy (ISCT) [20]. Markers probed
for were CD90-phycoerythrin (PE) (clone 5E10), CD105-
allophycocyanin (APC) (clone 266), and CD73-brilliant vio-
let 421 (BV421) (clone AD2), CD19-BV421 (clone HIB19),
CD34-APC (clone 581), CD45-PE (clone HI30), HLA-DR-
APC (clone TU36), and CD14-PerCP-Cy5.5 (clone M𝜙P9).
CD markers which have been reported as putative chondro-
genic potency markers [21–28] were also probed for; these
included CD49c-PE (clone C3 II.1), CD166-BV421 (clone
3A6), CD39-APC (clone TU66), CD44-peridinin chloro-
phyll protein-cyanine 5.5 (PerCp-Cy5.5) (clone G44-26), and
CD271-BV421 (clone C40-1457) (BD Biosciences). Appro-
priate isotype-matched IgG controls were used throughout
(BD Biosciences). Data from at least 10,000 stained cells is
presented which was analysed using a FACSCanto II flow
cytometer (BDBiosciences) and BD FACSDiva v.7.0 software.
2.7. Chondrogenic Differentiation. The chondrogenic poten-
tial of all cultured cell populations was assessed at passage
4 using an established 3D pellet culture system [12, 29].
Briefly, 2 × 105 cells were centrifuged to produce a cell pellet
which was maintained in DMEM F12, FBS (10% v/v), P/S
(1%) ITS (1%, v/v), ascorbic acid (0.1mM) (Sigma-Aldrich),
dexamethasone (10 nM), and transforming growth factor 𝛽-1
(TGF-𝛽1, PeproTech, London,UK) (10 ng/mL). After 28 days,
cell pellets were frozen in liquid nitrogen and stored at −80∘C
prior to use. In total, 𝑛 = 6 pellets per donor were produced,
𝑛 = 3 for glycosaminoglycan (GAG)/DNA analysis and 𝑛 = 3
for histological analysis.
2.8. GAG/DNA Analysis of Chondrogenic Pellets. Pellets were
digested using papain to release GAGs and DNA. A digestion
buffer consisting of 50mM sodium phosphate (BDH), 2mM
EDTA (Sigma-Aldrich), and 20mMN-acetyl cysteine (BDH)
was prepared and the pH adjusted to 6. Papain (Sigma-
Aldrich) was added to the digestion buffer to reach a final
concentration of 125𝜇g/mL. Each chondrogenic pellet was
digested using 200𝜇L of papain digest solution and placed in
a 60∘C oven for 3 hours. The digest suspensions were mixed
vigorously every 30 minutes by vortexing the tubes. Samples
were then centrifuged at 1000×g for 5mins, aliquoted, and
stored at −20∘C until further use.
The dimethylmethylene blue (DMMB) assay was used
to quantitate GAGs [30, 31]. Standards were prepared by
dissolving chondroitin sulphate (Sigma-Aldrich) frombovine
trachea in PBS to create appropriate serial dilutions. Fifty
microlitres of sample or standard was added in triplicate to
a 96-well plate and 200𝜇L of the DMMB staining solution
was added to each well. The absorbance was immediately
read at 𝐴530 nm and 𝐴590 nm. A standard curve was plotted
(𝐴530 nm/𝐴590 nm) − (𝐴530 nmblank/𝐴590 nmblank), from which
the total GAG content in each sample was calculated using
the equation of the curve.
The PicoGreen fluorescence assay (Invitrogen) was used
to quantitate the amount of double stranded DNA in solution
and was conducted according to the manufacturer’s instruc-
tions. Fluorescence was read on a plate reader configured to
excitation = 480 nm and emission = 520 nm. The normalisa-
tion of GAG content in chondrogenic pellets was achieved by
dividing the total GAG content of a given pellet by the DNA
content of that same pellet.
2.9. Histological Analysis of Chondrogenic Pellets. Pellets were
cryosectioned (7 𝜇m) onto poly-L-lysine coated slides (Cell
Path, Newtown, UK) and stained for GAGs with toluidine
blue (BDH) metachromatic stain for 30 seconds and then
washed briefly in tap water. Slides were left to air dry before
mounting in Pertex (Cell Path). Chondrogenic pellets were
assessed following toluidine blue staining using a modified
version of the Bern score [32]. In brief, cells pellets were
assessed using the following criteria: uniformity and intensity
of toluidine blue staining and distance between cells/amount
of matrix produced and cell morphology. Each of these three
categories was scored from 0 to 3.
2.10. Statistical Analysis. TheShapiro-Wilk normality test was
used to assess the distribution of quantitative data. A one-
wayANOVAwith Bonferroni’smultiple comparisons test was
used to test for significant differences between cell types with
regard to gene expression, immunoprofile, GAG quantita-
tion, and histological scores for chondrogenic pellets. Pear-
son’s correlation coefficients were determined for gene-gene
expression analyses and chondrogenic assessments (GAG
quantitation and histological analyses). Multilevel modelling
was conducted to determinewhether gene expression and cell
surface marker positivity were predictors of chondrogenic
outcome asmeasured by GAG content of the pellet and histo-
logical scoring. In these models, cell source, gene expression,
and cell surface marker positivity were considered as fixed
effects, while the donor was considered as a random effect.
The donor effect was determined using Wald’s tests. Graphs
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Figure 1: The expression of chondrogenic and hypertrophic genes in monolayer cell populations prior to chondrogenesis. ((a)–(f))
Chondrocytes (Ch), bonemarrowMSC (BM), fat padMSC (FP), and subcutaneous fat MSC (SCF). Data shown are themeans ± the standard
deviation of triplicate runs and 5 donors for each cell population. One-way ANOVA and post hoc Bonferroni tests were used to test for
significant differences in gene expression levels between cell types. (g) Pearson’s correlation analysis matrix comparing genes which may be
predictive of chondrogenic potential; significant correlations are in bold. Gene expression is expressed relative to the reference genes PPIA
and TBP.
are shown as means ± standard deviation, with statistical
significance considered at ∗𝑝 < 0.05, ∗∗𝑝 < 0.01, and ∗∗∗𝑝 <
0.001. All statistical analyses were performed in GraphPad
Prism version 6 (GraphPad Software, California, USA) and
SPSS version 20 (IBM, New York, USA).
3. Results
3.1. Chondrogenic/Hypertrophic Gene Expression prior to
Chondrogenic Differentiation. Perhaps not too surprisingly,
of the cell types tested in this donor-matched study, the
chondrogenic potency genes (Sox-9, Coll II, aggrecan, and
FRZB)were consistently expressed at the highest levels in cul-
ture expanded chondrocytes. Further, chondrocytes demon-
strated the lowest expression profiles for the hypertrophic
genes tested (Alk-1 and Coll X). Of the MSC populations
that we have examined, BM-MSCs displayed chondrogenic
and hypertrophic profiles that most closely resembled those
of culture expanded chondrocytes. In contrast, the adipose
sources of MSCs investigated (FP-MSCs and SCF-MSCs)
were least like culture expanded chondrocytes and demon-
strated the lowest chondrogenic potency and the highest
hypertrophic gene expression profiles. SCF-MSCs expressed
Alk-1 at significantly higher levels than chondrocytes and
BM-MSCs (𝑝 = 0.044 and 𝑝 = 0.034, resp.) (Figures 1(a)–
1(f)).
Gene expression associations for all of the cell types
examined in this study were tested using Pearson’s correla-
tion coefficient analyses and are presented in a correlation
matrix (Figure 1(g)). Significant interactions noted between
the chondrogenic potency genes were as follows: aggrecan
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Percentage of positive cells (mean% ± SD)
Markers
Chondrocytes BM-MSCs FP-MSCs SCF-MSCs
CD73 91.2 (±17.7) 87.1 (±18.0) 99.9 (±0.1) 99.9 (±0.0)
CD90 98.0 (±3.8) 96.4 (±2.5) 99.9 (±0.0) 99.9 (±0.1)
CD105 99.4 (±0.7) 96.7 (±4.1) 98.1 (±4.1) 99.9 (±0.1)
CD34 9.5 (±8.0) 5.1 (±5.4) 74.5 (±15.6) 62.2 (±20.8)
CD45 1.5 (±0.6) 1.3 (±0.4) 2.4 (1.3) 1.6 (±0.6)
CD14 20.4 (±27.1) 14.8 (±12.0) 17.9 (±36.5) 21.4 (±39.3)
CD19 1.3 (±0.8) 2.0 (±1.2) 1.4 (±0.6) 1.6 (±0.5)
HLA-DR 1.4 (±0.6) 1.3 (±0.8) 1.7 (±0.7) 1.3 (±0.6)
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Figure 2: Immunoprofiles for MSC markers and putative chondrogenic potency markers of culture expanded cells prior to chondrogenesis.
(a) ISCTMSC immunoprofiles. Immunoprofiles for the putative chondrogenicmarkers CD49c (b), CD166 (c), and CD39 (d). Flow cytometry
was used to detect the percentage of positive cells for each marker on monolayer cell populations of chondrocytes (Ch), bone marrow MSC
(BM), fat pad MSC (FP), and subcutaneous fat MSC (SCF) prior to chondrogenesis. Data shown are the means ± the standard deviation of 5
donors for each cell population. One-way ANOVA and post hoc Bonferroni tests were used to test for significant differences in the positivity
of cell surface markers between cell types.
was positively associated with Sox-9, Coll II, and FRZB; in
addition, Sox-9 was positively associated with Coll II. There
was also a significant negative association observed between
Coll II and Alk-1 expression.
3.2. MSC/Chondrogenic Immunoprofiling. Flow cytometry
analyses revealed immunopositivity for the MSC markers
CD73, CD90, and CD105 for all of the populations of cells
examined, but to varying levels. FP and SCF derived MSCs
adhered to ISCT criteria (i.e., >95% positive); chondrocytes
and BM-MSCs also adhered to ISCT criteria for CD90 and
CD105 positivity but were <95% positive for CD73. All of the
cell populations tested were <2% positive for CD19, CD45,
and HLA-DR, in line with ISCT criteria. Some positivity
was recorded in all of the cell populations tested for CD34
with high levels (62.2–74.4% positivity) seen in the adipose
derived MSCs, which also adheres to ISCT [33]; in addition,
>2% of BM-MSCs were also CD34 positive, which does not
conform to recommendations by the ISCT [20]. CD14 was
present on all cell populations, ranging on average between
14.8 and 21.4% positivity for each cell type (Figure 2(a)).
Differences between cell types for putative chondrogenic
potency marker positivity were noted for CD49c, CD166,
and CD39 (Figures 2(b)–2(d)). Chondrocytes showed sig-
nificantly greater positivity for CD49c compared to SCF-
MSCs (𝑝 = 0.014), whereas the adipose derived MSCs
showed significantly higher positivity for CD166 compared
to chondrocytes or BM-MSCs (𝑝 = 0.0046 and 𝑝 = 0.0002,
resp., for FP-MSCs and 𝑝 = 0.021 and 𝑝 = 0.01, resp., for
SCF-MSCs). No differences were noted for CD44 or CD271,
in that all cell types were >95% positive for CD44 and <5%
positive for CD271 (data not shown).
3.3. Chondrogenic Differentiation. After 28 days of differ-
entiation, donors demonstrated variability in chondrogenic
capacity across the cell types tested. When results from
individual donors were examined, chondrocytes consistently
produced chondrogenic pellets in terms of GAG quan-
titation and histological analyses, but the propensity for
MSCs to undergo chondrogenic differentiation was variable
between individuals. GAG/DNA analyses appeared to match
the histological findings noted for each patient: that is,
larger pellets with prominent matrix metachromasia had
the highest levels of GAGs measured (Figure 3). Pearson’s
correlation analyses across donors confirmed that there was a
significant association between pellet GAG quantitation and
histological score (𝑝 = 0.01). When donors were grouped
and chondrogenic analyses were performed comparing dif-
ferentiation between cell types, chondrocytes consistently
demonstrated the most pronounced chondrogenic differ-
entiation in terms of GAG/DNA analyses; they produced
significantly more GAG than BM and SCF derived MSCs
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Figure 3: Chondrogenic assessments of pellet cultures between donors. (a) Production of GAG/DNA in pellet cultures from chondrocytes
(Ch), bonemarrowMSC (BM), fat padMSC (FP), and subcutaneous fatMSC (SCF). GAGs weremeasured after chondrogenic differentiation
using the DMMB assay and normalised to the DNA content of pellets; each donor is represented in individual graphs. Data shown are the
means ± the standard deviation of triplicate pellets. (b) Chondrogenic pellets from Ch, BM, FP, and SCF showing representative toluidine
blue staining for each donor. Scale bars represent 200 𝜇m.
(𝑝 = 0.032 and 𝑝 = 0.030, resp., Figure 4(a)). In terms of
histological quantitation and chondrogenic score SCF-MSC
scores were significantly lower than chondrocytes, BM, and
FP derived MSCs (𝑝 < 0.0001, 𝑝 = 0.0195, and 𝑝 =
0.0082, resp.) and chondrocytes scored significantly higher
than BM-MSCs (𝑝 = 0.013, Figure 4(b)). Chondrocytes also
produced the largest pellets (in terms of diameter) compared
to any of the MSCs tested (𝑝 < 0.0001) and FP-MSC pellets
were significantly larger than SCF-MSC pellets (𝑝 = 0.008,
Figure 4(c)).
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Figure 4: Chondrogenic assessments of pellet cultures across cell types. (a) Production of GAG/DNA in pellet cultures from chondrocytes
(Ch), bone marrow MSC (BM), fat pad MSC (FP), and subcutaneous fat MSC (SCF) for all donors combined. (b) Chondrogenic histology
scores for Ch, BM, FP, and SCF for all donors combined. (c) Mean chondrogenic pellet diameter (𝜇m) for Ch, BM, FP, and SCF for all donors
combined. Data shown are the means ± the standard deviation of triplicate pellets and 5 donors for each cell population. One-way ANOVA
and post hoc Bonferroni tests were used to test for significant differences between cell types.
3.4. Chondrogenic Potency Analyses. Multilevel modelling
analysis was performed in an effort to identify chondrogenic
potency predictors prior to chondrogenic differentiation.
This analysis demonstrated that Alk-1 expression and CD166
immunopositivity both negatively associated with GAG
quantitation in pellet cultures. However, CD49c and CD39
expression positively associated with GAG quantitation and
histological score, respectively. Sox-9 expression positively
associated with chondrogenic histological score, whereas
expressions of the hypertrophic genes Coll X and Alk-1 were
shown to negatively associate (Table 2).
Further multilevel model analysis showed that cell type
(but not donor source) had a significant impact on the pre-
dictive aspect of gene expression for both of the chondrogenic
assessments tested, that is, GAG quantitation (𝑝 < 0.001) and
histological outcome (𝑝 < 0.001). Similarly, cell type (but
not donor source) had a significant impact on the predictive
aspect of cell surface marker positivity with regard to both
GAG quantitation (𝑝 < 0.001) and histological outcome
(𝑝 < 0.001). Using an interaction term in a multilevel model
consisting only of the cell types and the variable in question,
results showed that the relationship between Sox-9/Alk-1
expression and the histological outcome varied significantly
across cell source (𝑝 = 0.03 and 𝑝 = 0.034, resp.), which was
not the case for Coll X (𝑝 = 0.07). The relationship between
Alk-1 expression and GAG quantitation also did not vary
across cell types (𝑝 = 0.43). In terms of immunopositivity,
the relationship between CD39 positive cells and histological
outcome varied significantly between cell types (𝑝 < 0.001) as
did the relationship between CD49c or CD166 positive cells
and GAG quantitation (𝑝 < 0.001 for both markers).
4. Discussion
In recent years MSCs isolated from BM, FP, and SCF have
been compared and contrasted extensively in in vitro studies
[12, 13, 34–38] as alternative cell sources to the chondrocytes
used in ACI. However, to our knowledge there are no studies
to date that have compared the in vitro chondrogenic potency
of these cell types together and from matched samples. In
the present study, we have tested known gene profiles and
immunoprofiles indicative of chondrogenic potential in a
predictive model comparing chondrocytes, BM, FP, and SCF
derived MSCs from 5 matched human donors. We have
determined the expression of the chondrogenic genes, Sox-
9, Coll II, ACAN, and FRZB, and the hypertrophy associated
genes, Coll X and Alk-1, in these cell populations prior to
chondrogenesis. In doing so, we have confirmed that across
all of the cell populations tested, the master regulator of
chondrogenesis, Sox-9, correlates with the expression of Coll
II and ACAN and that the hypertrophy associated marker
Alk-1 is negatively associated with Coll II expression. In
addition, we have shown that there is a positive association
between the expression of FRZB and ACAN, which has been
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Table 2: Multilevel modelling.
GAG/DNA Chondrogenic histology score
Coefficient 95% CI 𝑝 values Coefficient SE (95% CI) 𝑝 values
Sox-9 −5.6 −11.7, 0.5 0.07 1.01 0.18, 1.84 0.02
Coll II 22.3 −7.8, 52.4 0.14 3.96 −0.16, 8.08 0.06
Aggrecan −0.003 −0.2, 0.2 0.97 −0.019 −0.04, 0.004 0.10
FRZB 33.1 −27.4, 93.6 0.3 0.86 −7.46, 9.18 0.83
Coll X −0.01 −0.02, 0.003 0.12 −0.002 −0.004, −0.0002 0.03
Alk-1 −9.5 −12.2, 6.7 <0.001 −0.61 −0.99, −0.23 0.003
CD49c 0.2 −0.1, 0.5 0.018 −0.04 −0.02, −0.01 0.63
CD166 −0.3 −0.5, −0.04 0.03 0.01 −0.04, 0.034 0.16
CD39 −0.02 0.01, 0.4 0.78 0.024 0.01, 0.04 0.002
Significant associations are indicated in bold.
previously reported in the chondrogenic ATDC5 cell line
[39]. In terms of immunoprofile, the putative chondrogenic
markers CD44, CD105, and CD271 were excluded from
predictive analyses due to their uniform expression levels
across cell types. CD49c, CD166, and CD39 were present on
all of the cell populations examined to varying degrees and
as such were taken forward into our multilevel chondrogenic
potency analysis.
Following an established in vitro cell pellet chondrogenic
differentiation procedure [12, 29] our quantitative assessment
of GAG synthesis demonstrated that chondrocytes generate
significantly more GAGs compared to BM-MSCs and SCF-
MSCs but not FP-MSCs,with somenotable variation between
donors. Our findings are comparable to previous studies
which have shown that chondrocytes and FP-MSCs display
similar levels of GAG production and that FP-MSCs produce
more GAGs than BM-MSCs [37] and donor-matched SCF-
MSCs [38]. Further, our assessments for chondrogenic differ-
entiation status in terms ofGAGquantitation andhistological
score were significantly correlated. Chondrocyte-generated
pellets consistently produced the highest scores, which were
significantly greater than those formed by BM or SCF cell
populations, whereas SCF pellets produced the lowest scores
of all the cell populations examined. By simply measuring
the diameter of pellets we have also shown that chondrocytes
produced the largest pellets compared to BM and SCF
derived pellets. Taken together, our chondrogenic assess-
ments suggest that, not too surprisingly, culture expanded
chondrocytes have the greatest propensity for chondrogenic
differentiation in vitro, closely followed by FP-MSCs and
then BM-MSCs, whereas SCF-MSCs consistently produced
the worst chondrogenic outcome measures, regardless of the
assessment used. These findings are corroborated by other
studies that have reported paired comparisons between these
cell types [12, 13, 34–38]. However, this is the first time, to
our knowledge, that all four of these cell populations have
been examined in the same study, allowing for a hierarchical
chondrogenic potency comparison with the impact of donor
taken into account by donor matching the samples tested.
The multilevel modelling analyses performed in this
study have allowed us to explore the relationships between
putative chondrogenic potency markers (gene expression
and surface marker profiles) and chondrogenic outcome
based on combined data from each cell source tested, while
simultaneously examining the potential influence of donor
and cell type. However, we have not yet verified whether the
predictive factors for chondrogenesis that we have identified
for combined data are present if only individual cell types are
analysed as we believe that the small donor size precludes this
type of analysis in the present study. We should of course
be cautious when interpreting any analyses derived from
a small donor sample size and we acknowledge this as a
limitation of the study. Nonetheless, ourmultilevel modelling
has revealed that the expressions of Alk-1 and Coll X are
negatively associated with chondrogenic potential in terms
of histology scores and for Alk-1 expression, as well as the
GAG content of chondrogenically induced pellet cultures. In
contrast, Sox-9 expression prior to chondrogenesis positively
correlated with histological pellet scores. Some of these gene
associations match a previous report comparing FP-MSCs
and SCF-MSCs [38]. The novelty of our study is that some
of these chondrogenic potency gene associations hold true
across all of the cell types examined in the present study. The
poor correlation between the baseline (predifferentiation)
expressions of the chondrogenic genes Coll II and ACAN
is noteworthy and comparable to findings in other studies
[40, 41]. For example, Stenberg et al. (2014) have confirmed
that the transplanted chondrocyte expression levels of ACAN
and Coll II in ACI had no bearing on clinical outcome [40].
Further, Cote et al. (2016) demonstrated that the genome-
wide transcription profile of Coll II and ACAN (amongst
other genes) did not correlate with the production ofGAGs in
a single cell analysis of bovine MSCs and chondrocytes. The
authors attribute this finding to the heterogeneity in single
cell transcriptional profiles. It is extremely likely that the gene
analysis in the present study derived from heterogeneous cell
populations and four very different tissue sources will vary to
an even greater extent.
In addition, our multilevel analysis indicates that CD49c
and CD39 immunopositivity positively predicts GAG pro-
duction and histological score, respectively, in cell pellets,
with no significant difference observed between donors.
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Other studies have shown that CD49c positivity on chon-
drocytes and CD39 positivity on synovium derived MSCs
are associated with increased in vitro chondrogenic potential
[21, 27]; however, our results are the first to demonstrate
these relationships across matched chondrocytes, BM-MSCs,
and adipose derived MSCs. Perhaps surprisingly CD166
positivity did not indicate chondrogenic potential, as has
been previously shown [24, 26]; in fact immunopositivity
for this marker was negatively associated with chondrogenic
assessments. One potential explanation for this findingmight
be that CD166 was expressed at significantly greater levels
on SCF-MSCs compared to chondrocytes and BM-MSCs
and that in our hands SCF-MSCs have been shown to
consistently demonstrate a poor propensity for chondrogenic
differentiation. Interestingly, we have demonstrated through
this multicell type, donor-matched study that the source
of cells significantly influences both GAG production in
pellet culture and also the histological score of the pellet. In
contrast, the donor had no demonstrable impact on either
of the chondrogenic assessments tested, although as stated
previously we must be cautious with this finding as our
results are based on a small cohort of donors. Follow-up
studies should be geared towards understanding the molec-
ular mechanisms that account for the differences observed
between cell populations and in the development of methods
to select cells with enhanced chondrogenic potential.
5. Conclusions
We have demonstrated the chondrogenic predictive value
of high levels of Sox-9 and low levels of collagen type X
or Alk-1 expression as well as immunopositivity for CD49c
and CD39 in a combined data analysis of chondrocytes,
BM-MSCs, FP-MSCs, and SCF-MSCs. Further individual
analyses on larger donor cohorts will be required to validate
these findings for individual cell types before these predictive
factors could be used as selection criteria prior to the
transplantation or banking of each cell type in the treatment
of cartilage injuries. We have also shown, using donor-
matched samples, that cell type significantly influences the
chondrogenic potency of the MSC sources examined in this
study; we have demonstrated that MSCs sourced from the
infrapatellar fat pad of the knee or bone marrow provide the
“next best” alternative to chondrocytes, in terms of in vitro
chondrogenic differentiation capacity. Further, our results
have consistently shown that SCF derived MSCs have the
poorest propensity for chondrogenic differentiation. These
findings have important clinical implications, not only for the
understanding ofMSC chondrogenic differentiation capacity,
but also for the development of cell therapy strategies to
screen for and select potent cell types prior to application in
the treatment of cartilage injuries.
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